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Abstract 
Siderophores are non-ribosomally derived peptides, and are key components in bacterial 
virulence and in the bacterial endogenous secondary metabolome. Therefore, they provide a 
unique insight into bacterial infection and potential treatments. 
 
As such, we have isolated two bacterial siderophores, the first being produced by a novel 
Actinomadura species. We carried out a de novo structural determination, utilising NMR, 
HMRS and Marfey’s analysis, allowing us to identify the isolated siderophore as madurastatin 
C1. This work also allowed us to determine the absolute stereochemistry of madurastatin C1 
and ultimately reassigned the structures of the madurastatin family of siderophores. This 
culminated in a publication in the ACS Journal of Natural Products in early 2017. As a 
continuation of this work, the total synthesis of madurastatin C1 has been completed.  
 
A second novel bacterial strain yielded a novel siderophore like peptide, with structural 
similarities to the known siderophores; chlorocatechelins. Once again the structure was 
elucidated via NMR and HRMS with the stereochemistry assigned through Marfey’s analysis. 
The total synthesis of this novel siderophore was completed, and the synthetic material used 
in biological studies, confirming the efficacy of the originally isolated natural product.  
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Chapter 1 – Introduction  
 
1.1 Natural products  
1.1.1 Introduction to natural products  
Natural products are small molecules produced by a living organism whether it be a bacteria, 
fungi, plant or animal. Natural products have been shown to have diverse biological activities, 
acting as stimulants, depressants, hallucinogens, pain killers and antimicrobials. Due to their 
useful biological properties and production by readily available organisms, natural products 
have been useful to mankind for thousands of years, with records documenting the use of 
plant derived medicinal agents in ancient Egypt dating back to 2900 BC.1  
 
1.1.2 Natural products and chemical research 
Not unlike early man, both the pharmaceutical industry and research chemists have looked to 
investigate natural products as a source of novel bioactive molecules. This is due to the wide 
range of chemical structures produced in nature, which has given us molecules capable of 
reducing and controlling pain (morphine, 1)2, therapeutic molecules used as anticancer agents 
(paclitaxel, 2)3 and as antibiotics to fight infections (penicillin, 3)4. In addition to their utility, 
the synthesis of natural products is seen by many organic chemists as an intellectual challenge. 
The complexity of natural products gives chemists a great opportunity to push known 
chemical reactions to their limits, forcing new synthetic methodologies and new reagents to 
be developed to tackle these challenging substrates. 
An example of the total synthesis of a natural product utilising new methodological 
approaches can be seen in the total synthesis of tropinone (4). The first synthesis of tropinone 
was completed in 1901 in a 1% overall yield by Willstätter.5 This was then ultimately 
superseded by a synthesis carried out by Robert Robinson, in which he synthesised tropinone 
in a single step using what we would come to know as a biomimetic synthetic strategy, building 
a molecule using the route that nature has previously developed.6 
Furthermore the use of new reagents to synthesise challenging substrates can be exemplified 
by the Dicyclohexylcarbodiimide mediated total synthesis of penicillin V. Peptide (amide) 
bonds cannot be generated by the direct combination of an amine and a carboxylic acid, due 
to the protonation of the amine by the carboxylic acid, forming a stable salt.7 This inherent 
difficulty in generating an amide bond can be overcome by the generation of a reactive 
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carboxylic acid derivative such as an acid chloride. Unfortunately, the β-lactam ring found in 
penicillin V is susceptible to ring opening under the acidic conditions used to generate such 
reactive carboxylic acid derivatives, preventing the desired ring closure from taking place. The 
use of a reagent, that could assist in the rapid generation of an amide bond, ideally at neutral 
pH and room temperature, was desired. The use of DCC to facilitate ring closure generated 
penicillin V in an aqueous solution at room temperature and was the first reported total 
synthesis of penicillin V.8,9  
Recently there has been increased interest in natural products due to the emergence of multi-
drug resistant bacteria and the requirement for new anti-microbial agents with which to treat 
them.   
 
 
Figure 1. Chemical structures of morphine (1), paclitaxel (2), penicillin G (3) and tropinone (4) 
 
1.2 Bacteria and human health  
1.2.1 Introduction  
Many bacteria can act as pathogens, posing a serious risk to human health. For more than half 
a century mankind has been able to treat bacterial infections using chemotherapeutic agents. 
This began with the serendipitous discovery of penicillin in 1929 for the treatment of 
infections by Gram-positive bacteria4 and the subsequent treatment of tuberculosis some 14 
years later with the arrival of streptomycin.10 However bacteria are capable of evolving to 
become resistant to antibiotics. In fact, genes which encode for antibiotic resistance pre-date 
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the modern antibiotic era. Bacteria are known to produce antibiotics to provide a competitive 
advantage in the quest for resources they need to grow and thrive. As such other bacteria 
have evolved mechanisms to resist the action of these naturally occurring antibiotics.11 In a 
similar way, our own advances in antibiotic discovery have been shadowed by the rise of 
bacteria that are resistant to known antibiotic treatments. This continual evolution of 
antibiotic resistant bacteria is of grave concern, as in the future once easily treatable bacterial 
infections could once again become deadly.  
 
1.2.2 Antibiotic Resistance  
Antibiotic resistance is now known against the vast majority of antibiotics currently in use, a 
timeline of which can be seen in Figure 2. 
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Figure 2. A timeline of antibiotic introduction and the first reports of observed resistance to the 
named drug. PDR = pan-drug-resistant; R = resistant; XDR = extensively drug-resistant. Figure taken 
from Ventola Ref:  12. 
 
 Resistance is even known for “drugs of last resort”. For example, antibiotic resistant strains 
of Escherichia coli have been discovered with resistance to polymyxin (colistin), an antibiotic 
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used for the treatment of Gram-negative infections.13 The mcr-1 gene gives a plasmin-derived 
resistance against colistin. This is achieved by structurally altering lipid A, lowering its affinity 
toward colistin, and reducing the activity of this antibiotic agent.14 In addition, colistin 
resistance can be transferred between bacteria, including different species. This is achieved 
through a process known as horizontal gene transfer in which genes encoded on plasmid DNA 
are passed between bacterial cells. This has resulted in the rapid appearance of antibiotic 
resistant strains of Salmonella enterica, Klebsiella pneumoniae, Enterobacter aerogenes and 
Enterobacter cloacae against polymyxin all of which employ the mcr-1 gene.13  
Multiple resistance mechanisms in bacteria are now known, including alterations in the 
permeability of their cell membrane, alteration of the target site of an antibiotic, generation 
of enzymes capable of deactivating an antibiotic and the using of efflux mechanisms to pump 
drugs out of the bacterial cell.15,16 
 
 
Figure 3. A diagram showing the various methods used by bacteria to incur antibiotic resistance, 
taken from the Encyclopaedia Britannica Ref: 17. 
 
Whilst the prevalence of antibiotic resistant bacteria has increased, very few new antibiotics 
have been produced in recent years. 
 
6 
 
 
1.2.3 Bacterial natural products as antibiotics 
With an increasing need to develop novel antibiotics, many companies and research groups 
are now returning to investigating natural products as potential sources of new antibiotics. 
Traditionally plants provided the main source of natural products utilised by mankind, now 
however microorganisms are one of the key sources of bioactive natural products. Indeed, of 
the c. 50,000 known compounds produced by microbes, 46% are bioactive and 34% show 
antibiotic bioactivity.18 This greatly supersedes the percentages of bioactive natural products 
isolated from higher plants, with 16% of the total known number of plant derived natural 
products showing bioactivity and 2% showing antibiotic activity.18 As of 2005, up to 22,500 
bioactive natural products had been isolated from microbes, with 17% of these isolated from 
unicellular bacteria, 38% by fungi and finally 45% from the bacterial genus actinomycetes.19 It 
is of no surprise then that the most thoroughly researched genus of bacteria is the 
actinomycetes, which were the origin of 75-80% of all microbially sourced natural products 
discovered in the latter half of the 20th century.18 Actinomycetes are known to produce some 
of our most essential antimicrobial agents, including the tetracyclines, rifamycins and 
streptomycins to name but a few.20 The prevalence of antibiotic natural products from 
actinomycetes, coupled with the vast number of as yet unexplored bacterial species available 
(a single gram of soil can contain up to 5x104 species of bacteria, including many different 
actinomycete species),21 and the application of modern genomics and analytical techniques, 
has resulted in significant recent growth in the development of novel antibiotic natural 
products from bacteria.  
However, despite the vast number of potential new antibiotic natural products available from 
bacterial sources, the development of any new antibiotic molecule will undoubtedly lead, 
sooner or later, to the evolution of resistant bacterial strains. Therefore, alternative 
approaches are needed in which an increased understanding of the life cycle of the bacteria 
could either reduce the ability of a pathogenic bacteria to infect a host or modulate the 
pathogenicity of an infectious bacteria. 
 
1.2.4 Bacterial virulence  
Whilst the need to develop new antibacterial drugs has been recognised, investigation of the 
methods used by bacteria to colonise human hosts is also of interest. Pathogenicity is the 
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ability of a microbe to cause disease. When considered in terms of their pathogenicity, 
bacteria can be divided into three groups. Primary pathogens are agents of disease, infections 
by Vibrio cholerae being the causative agent of cholera being one example.22 Opportunistic 
pathogens are organisms that have taken advantage of a hosts lowered immune system 
response, such as patients on immunosuppressants after an organ transplant or people 
suffering from HIV induced AIDS. Finally the vast majority of bacteria are classified as 
nonpathogens as they rarely or never cause human disease.23 
Bacterial virulence is the measure of pathogenicity, or the ability of the bacteria to cause 
damage to the host. The degree of virulence is governed by various factors including the 
number of infecting bacteria, the route of entry to the human body, the hosts defence 
mechanisms and the virulence factors of the bacterium. These virulence factors produced by 
bacteria are used, broadly speaking, to actively fight against the hosts immune system, from 
toxins (e.g. the Botulinum neurotoxins (BoNTs)), to more subtle bacterial cell surface 
modifications to evade immune system responses (e.g. to inhibit phagocytosis).23 Ultimately, 
these virulence factors allow an invasive bacterium to colonise and replicate at the expense 
of the host. One class of bacterial virulence factors are known as siderophores, and interfering 
with the production, uptake and utilisation of siderophores by bacteria could suppress 
bacterial growth, reducing the rate of colonisation and allowing the immune system to tackle 
the bacterial infection without the need for the use of antibiotics. Due to their key role in 
bacterial virulence, we will now explore these natural products (bacterial siderophores) in 
more detail.  
 
1.3 Bacterial siderophores 
1.3.1 Introduction  
Iron is an essential element for almost all life forms on the planet due to its key roles within 
the cell. This applies to all microorganisms, including bacteria and fungi, as well as plants and 
animals. Due to the favourable redox properties of iron, allowing exchange between two 
oxidation states (Fe2+ and Fe3+), iron can partake in a large number of essential cellular 
processes including electron transport (e.g. cytochromes), oxygen transport (e.g. 
haemoglobin) and oxidative metabolism (e.g. P450s).24,25 However, despite the abundance of 
iron in the Earth’s crust, iron is usually one of the limiting factors for bacterial cell growth and 
replication. In the case of bacterial cells, an internal cellular concentration of 10-7 to 10-5 M 
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ferrous iron (Fe2+) is required.26–28 However, in aerobic environments Fe2+ is spontaneously 
oxidised to Fe3+, going on to form ferric hydroxide (Fe(OH)3) in the presence of water.24,29,30 
Ferric hydroxide is virtually insoluble in water and therefore the resulting free concentrations 
of Fe2+ (10-10 to 10-9 M) and Fe3+ (10-18 to 10-9 M) are very low in the environments in which 
many bacteria are normally found.26,27,31 Thus free Fe2+ and Fe3+ is effectively unavailable for 
utilisation by bacterial cells. 
This low concentration of free iron in the environment also extends to the human body. The 
human body strives to keep concentrations of free iron very low (< 10-24 M in human serum).32 
Iron is stored within the human body, bound in tightly coordinated complexes such as 
lactoferrin, transferrin and haem. Normally, only 25-40% of the transferrin present in human 
serum is chelated to iron, enabling any free iron to be rapidly scavenged.24 This low free iron 
concentration in human serum also helps to prevent colonisation of the human body by 
pathogenic bacteria. However, some pathogenic bacteria are capable of subverting the human 
iron storage systems to supply themselves with the iron they require. For example 
Actinobacillus pleuropneumoniae (the causative agent of porcine pleuropneumonia) 
expresses proteins that can uptake iron-containing transferrin for use by the bacteria.33,34 
Similarly proteins associated with the uptake of haem have been found in the bacterial 
pathogens Staphylococcus aureus, E. coli and Mycobacterium tuberculosis.35,36 
Outside of a mammalian host, in order to utilise the insoluble Fe3+ found in aerobic 
environments, most bacteria biosynthesise and release extracellular iron scavengers that can 
chelate Fe3+ and transport it into the bacterial cell. These iron scavengers are called 
siderophores (from the Greek sideros meaning “iron” and phores meaning “bearer”),31 are 
typically low molecular weight molecules (500 – 1500 daltons) and are highly selective for the 
chelation of Fe3+.24,37 Bacterial siderophores typically are hexa-dentate, employing three 
oxygen based bi-dentate chelating ligands, resulting in stable octahedral complexes with very 
high binding affinities for Fe3+ (Formation constant (Kf) values between 1022 to 1052 M-1).24,29 
 
1.3.2 Structures of siderophores 
Bacterial siderophores are structurally diverse with more than 500 different siderophores 
identified as of 2010, 270 of which had their chemical structures assigned, but this number 
continues to grow.24 The structures of four representative siderophores are shown in Figure 
4. Enterobactin (5) is one of the strongest iron chelators known, with a binding affinity 
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constant of Kf = 1052 M−1, and is known to be produced by two pathogenic bacteria E. coli and 
Salmonella typhimurium.38,39 Enterobactin comprises a cyclic ester back bone and three 
catecholate derived binding sites. Amychelin (6) is an example of a polypeptide siderophore, 
and one of the few siderophore-iron complexes to have been examined by X-ray 
crystallography.40 The chelation motif of amychelin contains two hydroxamic acids in 
combination with an unusual 2-hydroxybenzoyl-oxazoline group. Deferoxamine B (7) is a 
linear polyamide with the three chelating hydroxamic acid functionalities built into the 
backbone of the siderophore. Deferoxamine B is one of the simplest hydroxamate 
siderophores and was for a time was used for the treatment of patients suffering from 
hemochromatosis (elevated levels of iron in the blood), through the chelation of free Fe3+ 
allowing it be excreted. Finally ferrichrome (8) is a siderophore produced by fungi, but is 
utilised by bacteria to acquire Fe3+. Ferrichrome is a cyclic polypeptide with pendant 
hydroxamate groups used for iron chelation. 
 
 
Figure 4. Chemical structures of siderophores enterobactin (5), amychelin (6), deferoxamine B (7) and 
ferichrome (8). 
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As seen above, the chemical structures of bacterial siderophores are incredibly varied, and as 
such they are typically separated into three categories based on the chelating moieties they 
contain. These three categories are the catecholates (9), hydroxamates (10) and α-
hydroxycarboxylates (11), there are also miscellaneous cases containing unusual chelation 
motifs, such as in amychelin (16). Although some bacterial siderophores contain a single type 
of chelation group, there are many examples of siderophores in which a mixture of each 
category of chelating group are employed in the chelation of the Fe3+.  
 
 
Figure 5. The chemical structures of three of the most common siderophore chelating groups, the catecholate 
(9) hydroxamate (10) and α-hydroxycarboxylate (11). 
 
1.3.3 Biosynthesis of siderophores 
The biosynthesis of many bacterial siderophores is carried out by nonribosomal peptide 
synthetase (NRPS) enzyme clusters. NRPS enzyme clusters typically only produce the 
corresponding siderophore during times of stress induced by low iron concentrations. In a 
typical NRPS several domains responsible for a specific transformation are arranged into an 
“assembly line”, and the growing peptide chain is passed from one domain to the next, with 
each adding a new amino acid. In some cases specific epimerisation, methylation and 
cyclisation domains are also used to further modify the growing polypeptide. In the case of 
enterobactin, the biosynthetic process begins with the production of 2,3-dihydroxybenzoic 
acid and its loading into one of the biosynthesis domains. 2,3-Dihydroxybenzoic acid is then 
coupled to serine to give the corresponding amide bound to the NPRS. Three of these amide 
units are then sequentially combined to give the linear siderophore, before cyclisation leads 
to release of the completed enterobactin molecule from the NRPS cluster. 41 
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Figure 6. Biosynthesis of enterobactin. (A) Synthesis and activation of 2,3-dihydroxybenzoate by EntABCE. (B) 
Assembly of enterobactin by NRPS: EntF. IC – isochorismatase; C – condensation domain; A – adenylation 
domain; T – thiolation domain; Te – thioesterase domain. Taken from Reitz et al. Ref: 41. 
 
1.3.4 Bacterial-iron uptake processes. 
After chelation of Fe3+ by a siderophore, the producing bacteria then has to reabsorb the 
siderophore-iron complex from its environment. This uptake process differs between Gram-
positive and Gram-negative bacteria. The majority of siderophore uptake studies have been 
centred around pathogenic Gram-negative bacteria, such as E. coli and S. typhimurium. These 
Gram-negative bacteria have an internal cytoplasmic membrane which is shielded by a thicker 
outer membrane, with the area between dubbed the periplasmic space. The outer membrane 
is a lipid bilayer made up with lipopolysaccharides and phospholipids, and contains a number 
of different proteins.42,43 Proteins specially used for the uptake of molecules can be passive, 
as in the case of porins which are permanently open channels that let low molecular weight 
compounds into the periplasmic space, or active, such as energy dependant active 
transporters.24  
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Figure 7. The Fe3+transport system of E. coli and related Enterobacteriaceae. Taken from Hider et al. Ref: 24. 
 
As can be seen in Figure 7, there are multiple outer membrane proteins that are used to 
actively transport siderophores across the outer membrane. Once an external siderophore 
binds to one of these transport proteins, (FepA for example) a conformational change in the 
protein occurs. This change then allows the TonB protein to bind to the periplasmic side of the 
siderophore/transport protein complex, opening a channel and allowing the siderophore into 
the periplasmic space.24 Some of these siderophore binding proteins like ferric-enterobactin 
permease (FepA) are highly selective and only allow a specific siderophore-iron conjugate to 
pass through them.44 Meanwhile others such as the Ferrichrome outer membrane transporter 
(FhuA, Figure 8) are non-selective and allow uptake of many different siderophore-iron 
complexes.  
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Figure 8. Crystal structure of the FhuA transport protein with ferrichrome bound. Resolution 2.7 Å. Taken from 
Braun et al. Ref: 45. 
 
Once the siderophore-iron complex is inside the periplasmic space, it is transported to a 
periplasmic siderophore binding protein (FepB in the case of Fe-enterobactin) which delivers 
the siderophore across the periplasmic space to the cytoplasmic membrane (Figure 7).46 Once 
here, ATP mediated transport across the cytoplasmic membrane carries the siderophore into 
the bacterial cell cytoplasm.47 
The siderophore-iron complex uptake pathway of Gram-positive bacteria is not as well 
studied. However, it is believed to be a similar process to the way in which a siderophore-iron 
complex moves from the cytoplasmic membrane into the cytoplasm in a Gram-negative 
bacterium. More specially, in Gram-positive bacteria, siderophore binding proteins are 
tethered to the outside of the cytoplasmic membrane and are able to catch and bind 
siderophore-iron complexes. Once bound, the siderophore-iron complex is then imported by 
siderophore permeases that span the cytoplasmic membrane through an ATP mediated 
process.47 It has also been suggested that some of these siderophore binding proteins 
tethered to the outside of the cytoplasmic membrane contain an apo-siderophore (a 
siderophore without a chelated iron atom). Upon capture of an extracellular siderophore-iron 
complex by the siderophore binding protein, the iron atom is transferred from the 
extracellular siderophore to the apo-siderophore and it is this, now iron chelated, apo-
siderophore that is transferred into the bacterial cell cytoplasm.47,48  
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Once inside the cytoplasm of either a Gram-positive or Gram-negative bacterium, release of 
siderophore bound iron is proposed to occur almost exclusively via reduction of Fe3+ to Fe2+. 
Bacterial siderophores have low binding affinity for Fe2+, hence iron in the reduced Fe2+ form 
can then be more easily released form the complex.49,50 This method is common for  both the 
hydroxamate and α-hydroxy carboxylate siderophores, with the siderophore then being re-
excreted for reuse in iron uptake. However, catecholate siderophores, such as enterobactin, 
are unable to undergo redox based iron release processes. In this case, it is proposed that the 
cyclic ester backbone of enterobactin is hydrolysed by an esterase, to convert the hexa-
dentate siderophore into three independent bi-dentate ligands. The resulting complex is more 
easily reduced to release Fe2+ into the cell.51 
 
1.4 Uses of siderophores 
Bacterial siderophores have found applications in a number of areas of science and medicine. 
This includes their use as growth factors for unculturable bacteria, the detection of microbial 
pathogens, treatment of iron overload and their use as antibiotics, these are discussed below. 
 
1.4.1 Siderophores as growth factors 
1.4.1.1 Introduction 
Metagenomics sequencing of environmental samples (e.g. soils or marine sediments) 
supports the postulate that less than 1% of the prokaryotes present can be easily grown in 
isolation in the laboratory using current methodologys.52 New methods for the isolation and 
growth of these “unculturable” bacteria would be of significant benefit, not only aiding in the 
general study of the bacterial world, but also potentially resulting in the discovery of many 
new natural products arising from these previously unstudied bacteria. 
 
1.4.1.2 Natural products from “unculturable” bacteria  
Some approaches to cultivating these “unculturable” bacteria involve growing the bacteria in 
an alternative medium to agar, for example in sand, in an agar-marine sediment mix 
sandwiched between semi-permeable membranes, and so on.52 Some research groups have 
focused on the growth of these “unculturable” bacteria alongside other species from the same 
environment, postulating that signalling molecules released by the growing bacterial species 
can induce growth of the “unculturable” bacterial neighbours.53,54 It has also been found that 
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siderophores from these neighbouring bacterial species can also induce growth of 
“unculturable” bacteria.52,55 Indeed some of the first bacterial siderophores to be isolated; 
mycobactin and ferrichrome were identified as bacterial growth factors.56,57 It is possible that 
many of these “unculturable” bacteria do not actively produce their own siderophores, 
instead they elect to steal the iron they need from siderophore-iron complexes produced by 
other bacteria.52 In 2015 the use of iChip technology allowed the cultivation of an 
“unculturable” bacteria (Eleftheria terraes), resulting in the isolation of a novel Gram-positive 
antibiotic teixobactin (12). Experiments showed that teixobactin had antibiotic activity against 
methicillin-resistant S. aureus and vancomycin-resistant Enteococci. Furthermore no 
detectable resistance to teixobactin (12) was observed during these studies. Finally, Ling and 
Schneider showed that teixobactin (12) could be effective in an MRSA animal infection model 
(mice) with no observable toxicity.58 
 
 
Figure 9. Molecular structure of teixobactin (12) 
 
With such a promising novel antibiotic isolated from an “unculturable” bacterium, it is hoped 
that other approaches, such as the use of siderophores as growth factors for “unculturable” 
bacteria, could be used to enable access to the bioactive natural products produced from the 
99% of bacteria currently considered “unculturable”. 
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1.4.2 Siderophores as pathogen detectors  
1.4.2.1 Introduction 
Due to the high affinity and selectivity of siderophore receptors found on the bacterial cell 
outer membrane to siderophore-iron complexes, research has been conducted on the 
immobilisation of siderophore-iron complexes as a way of capturing and identifying 
potentially pathogenic bacteria.59 This approach has the potential for the production of a rapid 
diagnostic method for identifying the bacteria present in the blood or urine sample of a 
patient with a bacterial infection.  
 
1.4.2.2 Bacterial identification via immobilised siderophores  
A proof of concept study was carried out using a surface immobilised siderophore pyoverdine 
(13) to capture Pseudomonas aeruginosa, an opportunistic pathogen.60 In this study, 
specificity for P. aeruginosa was shown by treating the surface immobilised siderophore with 
E. coli and Yersinia enterocolitica, neither of which express a receptor for pyoverdine. In this 
experiment P. aeruginosa was captured onto the surface, whilst only minimal retention of E. 
coli or Y. enterocolitica was observed. 
 
 
Figure 10. Chemical structure of Pyoverdine (13). 
 
Research in this area has continued, with a recent publication showing the immobilisation of 
deferoxamine B (7) could be used to detect E. coli, with FTIR spectroscopy being used to 
monitor the binding of live E. coli cells whilst dead cells were not bound.61 With the limited 
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range of siderophores trialled in these studies described to date, it is difficult to say if the use 
of immobilised siderophores could be applied clinically for rapid bacteria detection. 
Optimisation of these techniques will therefore be required before the use of such systems 
could be applied in a clinical setting. 
 
1.4.3 Siderophores as clinical iron chelators 
1.4.3.1 Introduction  
Iron is an essential element in the human body, and its concentration is tightly regulated.62 
Iron overload disorder is caused by the presence of excess iron in the body, in particular in the 
organs and serum, and can be caused by frequent blood transfusions, chronic hepatitis, or 
through genetic disorders such as hemochromatosis.31,62 The excess iron accumulates in vital 
organs such as the liver and brain, where free radical production causes severe organ damage 
which can be fatal to the patient.62  
1.4.3.2 Siderophores in the treatment of iron overload  
Deferoxamine was used clinically as a treatment for iron overload disorder for several years 
and was approved by the FDA in 1969. Due to the non-toxic nature of this siderophore it 
proved to be an effective method for the treatment of iron overload disorder. It could be 
administered as an oral, intramuscular or continuous intravenous infusion and allowed excess 
iron to be excreted through the urine and faeces. Unfortunately, the physiological side effects 
of using this siderophore and the requirement for continuous doses caused a decline in its 
use. In addition to the direct health risks of using deferoxamine as an iron chelator in patients, 
it was also shown that the presence of deferoxamine in the blood could lead to increased risk 
of bacterial infection due to the availability of siderophore bound iron. Currently non-
siderophore based iron chelators such as deferiprone and deferasirox are used as an effective 
method of treatment for iron overload disorder.63 
 
1.4.4 Siderophores as “Trojan Horse” antibiotics  
1.4.4.1 Introduction 
Since the uptake of Fe3+ is essential for bacterial growth, then the targeting of this pathway is 
a potential route for the development of novel antibiotic molecules. Furthermore these active 
uptake pathways can be highly selective for a specific bacterial species. This then presents an 
opportunity for the development of highly selective antibiotics. If the siderophore uptake 
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process could be subverted as a means to carry an antibiotic payload into the bacterial cell. 
Thus a “Trojan Horse” approach in which the modification of a siderophore to incorporate an 
antibiotic molecule (Figure 11) that is released upon uptake into a bacterial cell, via a cleavable 
linker, could prove to be a viable method for the selective treatment of bacterial infections. 
 
 
Figure 11. Schematic representation of a siderophore-linked antibiotic “Trojan Horse” 
 
Looking to nature, it appears that this “Trojan Horse” approach of using a siderophore as a 
vector to transport a chemically bound antibiotic into a bacterial cell, which is then released 
to cause an antibiotic effect, is already used in the form of the natural product sideromycins.64  
 
1.4.4.2 Sideromycins  
The sideromycins are a class of natural products that include the antibiotic siderophore 
families the albomycins and salmycins (Figure 12). The siderophore component of the 
albomycins is structurally similar to ferrichrome (8) and is bound through a serine moiety to a 
thioribosyl pyrimidine, which acts as the antibiotic warhead.64 Similarly the siderophore 
component of the salmycins is structurally similar to deferoxamine B (7) and linked through 
an ester to an aminodisaccharide, which also acts as the active antibiotic in this case.64  
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Figure 12. Chemical structures of the albomycins (14+15) and salmycins (16-19). (Red - siderophore component, 
black – linker, blue – antibiotic compound) 
 
Due to the ability of the albomycins and the salmycins to chelate Fe3+ and to mimic the 
naturally occurring ferrichrome (8) and deferoxamine B (7) respectively, it is postulated that 
they are transported into bacterial cells via the same proteins used in the native siderophore 
uptake process. In E. coli, ferrichrome is actively transported into the cell via the outer 
membrane transport protein FhuA. In the case of the albomycins, it has been shown via X-ray 
crystallography that albomycin can complex with the outer membrane transport protein 
FhuA, suggesting that this protein can actively uptake the albomycins into the bacterial cell 
alongside its native siderophore.65  
 
In the case of albomycin δ2 (15), once transported into E. coli cells via FhuA, peptidase N 
cleaves the siderophore-serine amide bond, releasing the thioribosyl pyrimidine antibiotic 
warhead and leading to cell death (Figure 13). Mutant E. coli strains that were devoid of 
peptidase N activity were shown to be resistant to albomycin, and instead albomycin simply 
acted as a siderophore, delivering iron into the bacterial cell.66,67  
 
 
20 
 
 
Figure 13. Proposed method of antibiotic release in the albomycins. (Red - siderophore component, black – 
linker, blue – antibiotic compound) 
 
The combination of a siderophore and antibiotic has been shown to be considerably more 
effective than the antibiotic alone. For example albomycin δ2 (15) is 30,000 times more 
effective as an antibiotic against S. aureus and E. coli than the isolated thioribosyl pyrimidine 
antibiotic.64 Inspired by these antibiotic siderophores, much research has gone into the 
synthesis and development of both natural and unnatural siderophore-antibiotic conjugates, 
an overview of which will now be given.  
 
There are of course a number of ongoing challenges within the field of siderophore-antibiotic 
conjugates. For a successful siderophore-antibiotic conjugate, the molecule must: 
1) be recognised by the native siderophore uptake machinery, e.g. surface receptor proteins, 
in order to be actively transported across the cell membrane.  
2) be cleaved from the linker, once inside the periplasmic space or cell cytoplasm, by an 
enzyme that can release the antibiotic component. 
2) be bioactive once released from the linker within the cell.68  
 
1.4.4.3 Man made sideromycin analogues  
With the discovery of the sideromycins, much research has been undertaken to generate 
novel siderophore-antibiotic conjugates as potential antibiotic therapeutics. The use of a 
siderophore-antibiotic conjugate over a classical antibiotic has several potential advantages: 
1) Increased potency. One of the limiting factors for the efficacy of antibiotic drugs is the 
rate of uptake of the antibiotic into the bacterial cell. Usually this is governed by the 
concentration gradient leading to passive diffusion of the drug through the cell 
membrane.69 This uptake rate is countered by the bacteria through the use of efflux 
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pumps which are used to remove toxic substrates (such as antibiotics) from the 
bacterial cell. This means that very high doses of antibiotics are often required to give 
a sufficient concentration of the antibiotic inside the bacterial cell to induce cell death. 
Siderophore-antibiotic conjugates have the potential to greatly increase the rate of 
uptake of the antibiotic component into the bacterial cell, due to their hijacking of the 
bacterial active transport systems. As a consequence lower overall doses of the 
antibiotic component would be required for the same therapeutic effect, reducing off-
target toxicity. 
2) Selective targeting of pathogenic bacteria. Due to the presence of selective 
siderophore receptors on the surface of the bacterial cell, one could imagine the use 
of a specific siderophore-antibiotic conjugate to target a specific pathogenic bacteria. 
This would result in a very narrow spectrum antibiotic capable of killing the unwanted 
pathogenic bacteria in a patient, whilst leaving the naturally occurring “friendly” 
bacteria of the human microbiome unscathed.  
 
1.4.4.4 Broadening the activity of Gram-positive antibiotics 
Gram-negative bacteria are usually less sensitive to antibiotics due to their thicker cell walls, 
slowing the rate of diffusion of antibiotics into the bacterial cell.70 However if antibiotic 
molecules could be helped across the cell wall of a Gram-negative bacteria this could allow 
the use of molecules previously only used for Gram-positive infections to be re-tasked for the 
treatment of Gram-negative infections. Daptomycin is a Gram-positive antibiotic that, due to 
its large size, has difficulty in diffusing through the outer membrane of a Gram-negative 
bacteria.71 Indeed when Acinetobacter baumannii is treated with daptomycin, no antibiotic 
effect is observed at the maximum tested concentrations of 100 μM. However, when bound 
to a synthetic siderophore, the siderophore-daptomycin conjugate (20) showed much 
improved antibiotic activity against A. baumannii with a MiC value of 0.5 μM, suggesting that 
the siderophore component had been recognized by the siderophore transport proteins, 
successfully carrying the antibiotic into the cell. Thus an antibiotic commonly reported to only 
be active against Gram-positive bacteria can show antibiotic activity against Gram-negative 
bacterial species through the incorporation into a siderophore-antibiotic conjugate.71 
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Figure 14. Chemical structure of 20, a siderophore - daptomycin conjugate 
 
1.4.4.5 Increasing the potency of known antibiotics  
Siderophore-antibiotic conjugates of β-lactam antibiotics have also been prepared, including 
an enterobactin-ampicillin (21) and an enterobactin-amoxicillin (22) conjugate. Against 
uropathogenic E. coli CFT073 the siderophore-antibiotic conjugates were 1000 fold more 
potent than the parent antibiotics ampicillin and amoxicillin, with MIC values of 10 nM.72 The 
siderophore-antibiotic conjugate was selective for E. coli with a general lack of activity shown 
against Gram-negative strains K. pneumoniae ATCC 13883 and P. aeruginosa PAO1, and Gram-
positive strains Bacillus cereus ATCC 14579 and S. aureus ATCC 25923.  
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Figure 15. Chemical structures of 21 and 22, siderophore - β-lactam conjugates 
 
The role of the siderophore component in facilitating uptake into the bacterial cell was 
highlighted by the decrease in effectiveness of the siderophore-antibiotic conjugate in the 
presence of high concentrations of Fe3+ or when an excess of parent siderophore was used in 
growth inhibition studies.  
Unfortunately, bacteria which have already developed resistance to β-lactam antibiotics 
through the generation of β-lactamase enzymes also show resistance against these 
siderophore-β-lactam conjugates. For example, the treatment of the bacterial strain A. 
baumannii ATCC 17978 using a siderophore like-β-lactam antibiotic (23) was successful with 
MIC values of 0.4 μM, whilst the treatment of the β-lactamase producing A. baumannii. 
mutant (ATCC 17978 pNT255: ADC-1) was not (MIC >50 μM).73 As such, alternative antibiotics 
have been utilised to generate novel siderophore like-antibiotic conjugates.73  
 
 
Figure 16. Chemical structure of the siderophore - cephalosporin conjugate (23).  
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This resulted in the development of the siderophore like-antibiotic conjugate 24, wherein the 
antibiotic component was an oxazolidinone and the linker was a cephalosporin. Ultimately the 
resistance mechanism of the A. baumannii. mutant (ATCC 17978 pNT255: ADC-1), the 
production of β-lactamase enzymes, was used against it. By incorporating a cephalosporin as 
the linker, the β-lactamase enzymes targeted and ring opened the β-lactam ring, triggering 
the release of the antibiotic oxazolidinone and killing the bacteria at MIC values as low as 6 
μM (Figure 17). In this case the β-lactamase resistance process was used against the bacteria, 
resulting in the development of an actively transported, selectively released antibiotic in the 
treatment of β-lactamase producing A. baumannii.73  
 
 
Figure 17. The structure of the siderophore-cephalosporin-oxazolidinone conjugate (24) and the proposed 
method of oxazolidione release in the presence of a β-lactamase enzyme. 
 
1.5 Conclusions 
Natural products are an important source of bioactive molecules, with natural products from 
bacterial sources (actinomycetes) being a key source of novel antibiotics. Despite the current 
interest in isolating antibiotics from natural products, the ability of bacteria to develop 
24 
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mutations will ultimately render many of these new antibiotic agents ineffective for the 
treatment of bacterial infections.  
The ability of bacteria to acquire iron is essential to bacterial growth and therefore virulence. 
In order to obtain the concentrations of iron required for bacterial growth and replication, 
bacteria have developed specialist natural products for the chelation of Fe3+. These chelating 
agents are called siderophores and are used by bacteria to solubilize and transport Fe3+ to the 
bacterial cell surface. Once here, specialist proteins transport the siderophore-iron complex 
across the cell membrane and into the bacterial cell. 
Siderophores have found use in a variety of applications from the treatment of iron overload 
disorder and pathogen detectors, to assisting in the growth of “unculturable” bacteria and the 
development of sideromycin like “Trojan horse” antibiotics. Due to the essential role that iron 
uptake processes and siderophores play in the growth of bacterial cells, we have developed 
an interest in this area of research. The isolation of novel siderophores, their structural 
determination and their total synthesis is therefore a valuable addition to the growing body 
of research focused around bacterial siderophores.  
 
1.6 Project aims 
Therefore, the overall aims of this project are to investigate the siderophores produced by 
two bacterial species, Actinomadura sp. (DEM31376) and Streptomyces sp. (DEM30616). 
These investigations will include the isolation of the siderophores produced by these two 
bacterial strains. After isolation, a de-novo structural determination will be carried out to 
assign the chemical structure and absolute stereochemistry of the isolated natural products. 
Finally, the total synthesis of both of these siderophores will be carried out. The total synthesis 
should allow access to large quantities of siderophore and potentially modified derivatives of 
these siderophores, with which to carry out further experimentation. 
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Chapter 2 - Isolation and Structural Determination of Madurastatin C1 (DEM31376/A) 
 
2.1 Introduction  
In this chapter we will start by discussing the bacteria DEM31376, which is responsible for 
producing the siderophore madurastatin C1 (DEM31376/A), including attempts to identify the 
bacteria via 16S rRNA analysis. We will then discuss the isolation and structural determination 
of the siderophore madurastatin C1 (DEM31376/A). Finally, we will discuss our investigation 
of the stereochemistry of DEM31376/A and the correction of the literature structure for 
madurastatin C1.  
   
2.2 Demuris Ltd. 
The MJH research group work closely with the microbiology and antibiotic discovery company 
Demuris Ltd. based in the medical school at Newcastle University. They maintain a collection 
of bacterial strains from extreme and/or unusual environments, with the intention that these 
unusual strains of bacteria might produce novel antibiotics with unusual or unique modes of 
action. The prefix DEM followed by the identification number is assigned to each bacterial 
strain in Demuris’ catalogue.   
 
2.3 Actinomadura sp. DEM31376 
Actinomadura sp. DEM31376 was isolated from a deep sea marine sediment found at Canary 
Basin in the Atlantic Ocean.74 16S rRNA analysis of DEM31376 was carried out by Dr. Hamed 
Mosaei Sejzi and revealed that DEM31376 was a novel member of the Actinomadura genus, 
most closely related to Actinomadura mexicana A290T and Actinomadura citrea IFP 14678T.  
 
2.4 DEM31376/A 
The original rationale for investigating Actinomadura sp. DEM31376 was to identify and isolate 
novel antibiotic molecules. Preliminary work on DEM31376 was carried out at Demuris by Dr. 
Hamed Mosaei Sejzi, resulting in the isolation of a compound, assigned as DEM31376/A, 
through a bioassay guided fractionation approach. Initial testing of DEM31376/A suggested 
that this molecule had antibiotic activity. However, subsequent work revealed that 
DEM31376/A was not in fact bioactive, the observed bioactivity arising from a minor 
contamination of the sample with a co-eluting natural product GE23077 (a known and highly 
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active RNAP inhibitor, also produced by DEM31376). Due to this misleading bioactivity we had 
already began to examine DEM31376/A to gain understanding of its structure and biological 
role, prior to our identification of the presence of GE23077. However due to our interest in 
the structure and biology of bacterial siderophores, we decided to continue our investigations 
into this bacterial natural product. 
 
2.5 Isolation of DEM31376/A 
Early in our investigations into DEM31376/A we required the production of large (>100mg) 
quantities of the molecule in order to undertake structural elucidation. To achieve this I 
worked with Dr. Hamed Mosaei Sejzi at Demuris Ltd. to grow Actinomadura sp. DEM31376 on 
large scale, followed by isolation of DEM31376/A. Therefore DEM31376 was grown in liquid 
ISP2 media on a 20 L scale over seven days. After this time the fermentation broth was 
decanted from the bioreactor, Amberlite XAD16N beads were added to the broth and the 
mixture left overnight to absorb any organic compounds present. After 12 hours the Amberlite 
XAD16N beads were collected by filtration, washed with methanol and the resulting filtrate 
evaporated under reduced pressure. The concentrated filtrate was then fractionated on C8 
SPE cartridges through stepwise elution with 25%, 50% and 75% methanol in water with a final 
elution with 100% methanol. HPLC-MS revealed two related compounds in the 75% and 100% 
methanol fractions. The major compound, with a retention time of 12 minutes, gave a signal 
in MS with m/z = 592 (M+H)+ whilst the minor compound, at 9 minutes, gave m/z = 610 
(M+H)+. The minor compound gave an m/z of 18 more than that for the major compound, thus 
we postulated that they may be related through hydrolysis. The 75% methanol in water and 
100% methanol fractions were combined and further purified via reverse phase C18 column 
chromatography, with the major compound eluting between 4.5 and 6 minutes to give 283 
mg of DEM31376/A. From here, we sought to determine the chemical structure of 
DEM31376/A via a combination of high resolution mass spectrometry and NMR spectroscopy.  
 
2.6 Initial structural studies of DEM31376/A 
2.6.1 Mass spectrometry of DEM31376/A 
High-resolution mass-spectrometry of DEM31376/A gave m/z = 592.27315 for the proposed 
[M+H]+ ion, resulting in a calculated molecular formula of C26H37O9N7. MSn experiments also 
revealed major fragmentation ions with m/z values of 462.19, 434.20, 403.16, 349.15 and 
318.11, more discussion of which will be given later in section 2.7.9. 
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2.6.2 Calculation of double bond equivalents 
Based on the proposed molecular formula of DEM31376/A, we established that there were 
twelve double bond equivalents (DBE) present in DEM31376/A. 
 
DBE = 𝐶 − (
𝐻
2
) + (
𝑁
2
) + 1 = 26 − 18.5 + 3.5 + 1 = 12. 
Equation 1. Calculation of the number of double bond equivalents in DEM31376/A (C26H37O9N7) 
 
2.7 Structural determination of DEM31376/A via 1H, 13C and 15N NMR 
2.7.1 Introduction 
In this section, we will discuss the structural elucidation of DEM31376/A. At this stage we 
suspected that DEM31376/A was a polypeptide due to the presence of several nitrogen atoms 
and the ease of fragmentation during HRMS. This therefore allowed us to attempt to solve the 
structure of DEM31376/A as a number of discrete sections corresponding to each amino acid. 
To begin, we started our assignment by comparing our NMR data to our HRMS and DBE 
calculations. Initial examination of the 1H NMR spectrum (Figure 18) revealed a total of 23 
hydrogen atoms via integration, suggesting that 3 hydrogen atoms had undergone deuterium 
exchange. The 13C NMR spectra showed 26 carbon environments, matching the proposed 
chemical formula. Further to this, we were able to assign 10 of the 12 calculated DBE with the 
combined NMR data through the presence of a 6 membered aromatic ring (4 DBE) and 6 
carbonyl like carbons (6 DBE). Due to the high number of heteroatoms in DEM31376/A, long 
range 15N-1H correlation experiments were also performed. 15N NMR experiment gave signals 
corresponding to 7 nitrogen atoms, which is consistent with our assigned chemical structure. 
These 7 nitrogen atoms were found in four discreet chemical shift ranges: 20-40, 110-120, 
170-180 and 200-220 ppm suggesting four different nitrogen environments. With the initial 
NMR data corroborating our HRMS and DBE calculations, we next moved on to detailed 
examination of both 1D and 2D NMR spectra to conclusively assign the chemical structure of 
DEM31376/A.    
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2.7.2 Fragment 1  
Inspection of the 1H NMR showed a four proton spin system (assigned via COSY) with signals 
at 7.65, 7.47, 7.01 and 6.95 ppm. The splitting pattern was indicative of a 1,2-disubstituted 
aromatic ring, with the two quaternary carbons identifiable by 13C and HMBC experiments 
(position 1 and position 6). HMBC experiments showed that an additional deshielded carbon 
atom at 165.9 ppm (P-7) was connected to the aromatic ring at position 6. The chemical shift 
of the carbon signal at position 1 was higher than normal for a benzene derived aromatic ring 
at 159.1 ppm. We concluded that the carbon at position 1 was therefore substituted with an 
electron withdrawing hydroxyl group, explaining the high chemical shift. This assignment was 
supported by a lack of any additional HMBC correlations from the hydrogen at position 2. In 
summary, fragment 1 consists of a 1,2-disubstituted benzene ring, with a hydroxyl group at 
position 1 and a carbonyl group position 6 (Figure 19).  
 
 
Figure 19. Proposed structural assignment for fragment 1 of DEM31376/A (COSY = red, selected HMBC = blue) 
 
Table 1. 1H and 13C signals associated with fragment 1  
Position δ1H multiplicity, (J in Hz) δ13C HMBC  
1 - 159.1 - 
2 7.01 dd (J = 8.4, 1.1 Hz, 1H) 116.6 H to C6, 4, 1, 7 
3 7.47 ddd (J = 8.7, 7.2, 1.8 Hz, 1H) 134.1 H to C6, 5, 1 
4 6.97 – 6.93 (m, 1H) 119.1 H to C6, 2, 5, 3, 1 
5 7.65 dd (J = 7.9, 1.8 Hz, 1H) 128.1 H to C2, 3, 1, 7 
6 - 109.9 - 
7 - 165.9 - 
 
2.7.3 Fragment 2  
For fragment 2, a three-proton spin system was observed in the 1H NMR spectrum with signals 
at 5.01 (P-9), 4.65 and 4.52 ppm (P-10). The two signals at 4.65 and 4.52 ppm showed J values 
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of 10.5 Hz, suggesting a geminal coupling between two diastereotopic protons, which was 
confirmed through an HSQC experiment (Figure 20).  
 
 
Figure 20. HSQC correlation between the diastereotopic methylene signals 4.65 & 4.52 ppm (P-10) and carbon 
69.4 ppm (P-9). 
 
HMBC data revealed that all three proton signals were coupled to a new de shielded carbon 
at 170.2 ppm (P-11) and to the previously described deshielded carbon at position 7 in 
fragment 1. Long range 15N-1H experiments showed correlations between all three protons to 
a deshielded tertiary nitrogen atom at 208.2 ppm which, combined with the lack of an amide 
proton signal, suggested that this tertiary amine may be incorporated into some sort of 
heterocycle. The presence of a geminal methylene adjacent to an apparent alpha proton, a 
carbonyl like carbon and a nitrogen atom lead us to assign fragment 2 as a cyclised serine. This 
assignment would also count toward one of the two rings we anticipated from our DBE 
calculations. However, we were unable to conclusively assign this ring as either a five 
membered oxazoline ring, or a three membered aziridine – amide. At this stage, both of these 
could be assigned from the data (Figure 21).  
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Figure 21. The two possible structural configurations of fragment 2. Oxazoline left and aziridine right. (COSY = 
red, selected HMBC = blue) 
 
Upon investigation of literature structures, we found several examples of salicylic acid – 
oxazoline containing natural products. All of these had 13C chemical shifts matching that of 
our natural product (see Table 2). We therefore preliminarily assigned fragment 2 as an 
oxazoline ring. 
 
Table 2. 13C NMR signals at positions 7, 9 and 10 of DEM31376/A and several oxazoline containing natural 
products 
   13C chemical shift (ppm) for positions: 
Name Assignment Solvent 7 9 10 
DEM31376/A oxazoline d6-DMSO 165.9 67.4 69.4 
amychelin oxazoline d6-DMSO 168.7 64.9 72.2 
transvalecin Z oxazoline d6-DMSO 168.6 67.4 69.7 
nocardichelin A oxazoline d6-DMSO 165.6 67.2 69.0 
 
  
Figure 22. Proposed structural assignment for fragment 2 of DEM31376/A (COSY = red, selected HMBC = blue) 
 
Table 3. 1H, 13C and 15N signals associated with fragment 2 
Position δ1H multiplicity, (J  in Hz) δ13C δ15N HMBC  
7 - 165.9 - - 
8 - - 208.2 N to H9, 10 
9 5.01 dd, (J = 10.4, 7.7 Hz, 1H) 67.4 - H to C10, 6, 7, 11 
10 4.65 dd (J = 10.5, 8.4 Hz, 1H) 
4.52 t (J = 8.0 Hz, 1H) 
69.4 - 
- 
H to C9, 7, 11, 10 
H to C9, 7, 11, 10 
11 - 170.2 - - 
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2.7.4 Fragment 3  
In the 1H NMR spectrum, two distinctive double doublets were observed at 3.75 and 3.67 ppm 
(P-13) with J values of 16.5 Hz, again indicating geminal coupling. COSY experiments showed 
coupling between this geminal methylene and an amide proton signal at 8.52 ppm (P-12), with 
the corresponding nitrogen atom at 109.2 ppm in the 15N-1H spectrum. With no further 
coupling, we assigned this fragment as a glycine derived unit. HMBC data showed correlations 
between the geminal methylene and a new deshielded carbon at 168.4 ppm (P-14) and to the 
deshielded carbon previously reported at position 11 in fragment 2 (Figure 23). 
 
 
Figure 23. Proposed structural assignment for fragment 3 of DEM31376/A. (COSY = red, selected HMBC = blue) 
 
Table 4. 1H, 13C and 15N signals associated with fragment 3  
 
2.7.5 Fragment 4  
In the 1H NMR spectrum a second suspected amide signal can be seen at 7.93 ppm (P-15). 
COSY correlation spectra showed coupling between this amide proton and a two proton 
methylene signal at 3.25 ppm (P-16). This methylene group (P-16) showed coupling through a 
COSY experiment to a second methylene signal at 2.52 ppm (P-17). Both methylene groups 
showed HMBC correlations to a new deshielded quaternary carbon at 170.9 ppm (P-18), whilst 
the methylene at position 16 and the amide signal at position 15 showed a correlation to the 
previously reported carbonyl carbon at position 14 in fragment 3. We therefore assigned 
fragment 4 as a β-alanine unit (Figure 24). 
Position δ1H multiplicity, (J  in Hz) δ13C δ15N HMBC  
11 - 170.2 - - 
12 8.52 t (J = 5.9 Hz, 1H) -  109.2  H to C13, 14, 11 
N to H13 
13 3.75 dd (J = 16.5, 6.1 Hz, 1H) 
3.67 dd (J = 16.5, 5.7 Hz, 1H) 
42.2 
- 
- 
- 
H to C14, 11 
H to C14, 11 
14 - 168.4 - - 
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Figure 24. Proposed structural assignment for fragment 4 of DEM31376/A (COSY = red, selected HMBC = blue)  
R = fragments 1 - 3 
 
Table 5. 1H, 13C and 15N signals associated with fragment 4  
 
2.7.6 Fragment 5  
A distinctive singlet with an integration of 3 was observed at 2.21 ppm (P-25) in the 1H NMR 
spectrum, indicating the presence of a methyl group. A correlation was observed in the 15N-
1H NMR spectrum between this methyl group and a nitrogen atom with a chemical shift of 
29.1 ppm (P-24). This lead us to assign the signal as an N-methyl group, with the lack of 
coupling and therefore splitting of the methyl signal attributed to deuterium exchange of the 
amine hydrogen. This methyl group showed a correlation via a HMBC experiment to a one 
proton triplet at 2.87 ppm (P-23). This in turn showed a HMBC signal to a new deshielded 
quaternary carbon at 173.5 ppm (P-26). The COSY correlation spectrum showed that this 
triplet (P-23) was the first of 5 proton-proton coupled 1H signals, with the first correlation from 
the triplet at 2.87 ppm (P-23) to a diastereotopic methylene group split into two signals at 
1.40 and 1.48 ppm (P-22). Both signals attributed to position 22 showed proton-proton 
coupling to a second methylene group at 1.58 ppm (P-21). This penultimate methylene signal 
(P-21) was coupled to a broad multiplet signal with an integration of four between 3.49-3.42 
ppm (P-20). Thorough inspection of this signal via HMBC experiments showed that it was in 
fact two overlapping methylene signals (Figure 25), only one of which was part of the coupled 
spin system we were interested in. This terminal methylene group (P-20) showed correlations 
Position δ1H multiplicity, (J  in Hz) δ13C δ15N HMBC  
14 - 168.4 - - 
15 7.93 t (J = 5.8 Hz, 1H) 
- 
- 
- 
112.5 
- 
H to C16, 14 
N to H13, 17 
16 3.28 – 3.22 (m, 2H) 34.6 - H to C17, 14, 18 
17 2.53 – 2.51 (m, 2H)  32.0 - H to C16, 18 
18 - 170.9 - - 
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to the previously reported carbonyl carbon at position 18 in fragment 4 and to a nitrogen atom 
at 175.9 ppm (P-19). However, no amide proton was observed as anticipated, whilst the 
chemical shift of the nitrogen atom was significantly higher than our previously assigned 
amide nitrogen’s, at 175.9 ppm vs c.110 ppm.  
 
  
Figure 25. A HMBC experiment showing correlations of the two overlapping methylene groups between 3.49-
3.42 ppm to fragments 5 and 6.  
 
In summary for fragment 5, we identified an N-methyl group, as well as a spin system 
consisting of an α-proton at 2.87 ppm (P-23) and 3 methylene groups at 3.49-3.42, 1.58 and 
1.40/1.48 ppm (P’s 20-22). The lack of the expected amide proton was unsettling, as a HMBC 
correlation between the methylene at position 20 and the previously assigned carbonyl at 
position 18 (fragment 4) was observed. The chemical shift of the nitrogen at position 19 was 
higher than that previously observed for amide nitrogen signals, so we deferred the 
assignment of this nitrogen atom until more data was available. 
 
HMBC signals associated with: 
 Fragment 5 
 Fragment 6 
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Figure 26. Proposed structural assignment for fragment 5 of DEM31376/A (COSY = red, selected HMBC = blue)
 R = Fragments 1 – 4 
 
Table 6. 1H, 13C and 15N signals associated with fragment 5  
 
2.7.7 Fragment 6  
The final amide signal in the 1H NMR spectrum was observed at 8.11 ppm (P-27) and showed 
COSY coupling to an apparent α-proton signal at 4.32 ppm (P-28). This α-proton at position 28 
showed HMBC correlations to a new deshielded carbon at 165.0 ppm (P-33). In a similar 
fashion to fragment 6, a spin system containing an α-proton and an additional three 
methylene groups was observed (via COSY). To expand, the α-proton (P-28) was coupled to a 
diastereotopic methylene group (P-29) which was split into two signals at 1.67 ppm and 1.96-
1.82 ppm. The signal at 1.96-1.82 ppm was a multiplet with an integration of 3 (Figure 27), 
with HSQC confirming that the additional two hydrogens were a result of an additional 
methylene group (P-30). 
 
Position δ1H multiplicity, (J  in Hz) δ13C δ15N HMBC  
18 - 170.9 - - 
19 - - 175.9 N to H20, 21 
20 3.49 – 3.42 (m, 4H)(2H) 47.0 - H to C21, 22, 18 
21 1.58 tt (J = 16.5, 6.7 Hz, 2H) 22.8 - H to C22, 20, 23 
22 1.40 ddd (J = 15.9, 13.1, 6.8 Hz, 1H)  
1.48 ddt, (J = 11.7, 9.8, 5.9 Hz, 1H) 
30.2  - 
- 
H to C20, 23, 26 
H to C20, 23, 26 
23 2.87 t (J = 6.6 Hz, 1H) 63.7 - H to C21, 22, 25, 26 
24 - - 29.1 N to H25, 22 
25 2.21 (s, 3H) 34.2 - H to C23 
26 - 173.5 - - 
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Figure 27 HSQC showing that the multiplet at 1.89 ppm is a mixture of one and a half methylene groups found 
on carbons 27.8 ppm (a, P-29) and 20.4 ppm (b, P-30) 
 
The methylene group at position 30 (b in Figure 27) was shown via COSY and HMBC 
experiments to couple to the final methylene group in the chain at 3.49-4.42 ppm (P-31). This 
is the overlapping signal in the 1H NMR that we previously discussed in fragment 5 (Figure 25). 
This methylene group (P-31) correlated to a nitrogen at 171.8 ppm (P-32), allowing us to 
provisionally construct fragment 6 as shown in Figure 28 below.  
 
 
Figure 28. Preliminary assignment of NMR data for fragment 6 (COSY = red, selected HMBC = blue) R = 
Fragments 1 – 5 
  
The chemical shift of the nitrogen at position 32 (171.8 ppm) is similar to that of the partially 
assigned tertiary nitrogen at position 19 in fragment 5 (175.9 ppm) and as such it is probably 
also tertiary in nature. In addition, HMBC data showed a correlation between the protons at 
(a) 
(b) 
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position 31 and the carbonyl like carbon at position 33. This suggested that the fragment is 
cyclic, and as such would satisfy the final DBE calculated for the molecule. As such a cyclic 
ornithine amino acid can be assigned for fragment 6.  
 
 
Figure 29. Proposed structural assignment for fragment 6 of DEM31376/A as a cyclic ornithine (COSY = red, 
selected HMBC = blue) R = Fragments 1 – 5 
 
Table 7. 1H, 13C and 15N signals associated with fragment 6 
 
2.7.8 Final assignments 
Comparison of the calculated chemical formula for DEM31376/A against the atoms assigned 
for fragments 1-6 reveals that all seven nitrogen and twenty-six carbon atoms have been 
assigned. However, two oxygen and two hydrogen atoms are yet to be assigned. We know 
that the two nitrogen atoms at 171.8 and 175.9 ppm (positions 19+32) do not have a proton 
attached to them, and the high nitrogen chemical shifts suggest an electronegative atom is 
attached to these nitrogen atoms instead. As such a hydroxamic acid functionality can be 
assigned to these two nitrogen atoms. This assignment not only satisfies our molecular 
formula, but also satisfies the four different 15N chemical shift ranges observed: 29.1 ppm for 
the methyl amine, 110-120 ppm for the amides, 170-180 ppm for the hydroxamic acids and 
Position δ1H multiplicity, (J  in Hz) δ13C δ15N HMBC  
26 - 173.5   
27 8.11 d (J = 8.3 Hz, 1H) - 118.8 H to C28, 33, 26 
N to H27, 28, 23, 29 
28 4.32 ddd (J =10.9, 8.2, 5.3 Hz, 1H) 49.4  H to C30, 29, 33, 26 
29 1.96 – 1.82 (m, 3H) (1H) 
1.67 qd (J =12.5, 4.3, 1H) 
27.8  H to C30, 29, 33 
 
30 1.96 – 1.82 (m, 3H) (2H) 20.4   
31 3.49 – 3.42 (m, 4H) (2H) 51.2  H to C30, 29, 33 
32 - - 171.8 N to H31, 29 
33 - 165.0 
 
 
 
39 
 
208.2 ppm for the oxazoline nitrogen. The hydroxamic acid group is a common structural 
feature in siderophores.24 Whilst siderophores are specific Fe3+ chelators they are also well 
documented to chelate Ga3+.75–78 This is due to the similar ionic radii of Ga3+ (0.62 Å) and Fe3+ 
(0.65 Å).75 The role of DEM31376/A as a siderophore was confirmed by metal chelation 
studies, with the mixing of DEM31376/A in methanol with both Fe(acac)3 and Ga(acac)3 to 
form two 1:1 metal to ligand complexes. These complexes were then subjected to HPLC-MS, 
resulting in the appearance of both an [M-3H++Fe3++H]+ signal at m/z = 645 and a [M-
3H++Ga3++H]+ signal at m/z = 658 corresponding to the respective 1:1 molecule:metal chelates, 
confirming the biological role of DEM31376/A as a siderophore. 
 
2.7.9 Conclusions for the structural assignment of DEM31376/A 
The combination of each individual fragment via the HMBC data allows us to propose the full 
structure for DEM31376/A (25, Figure 30). This is a pentapeptide siderophore, constructed 
from the amino acids serine (which has been capped with a salicylic acid), glycine, β-alanine, 
Nα-methyl-ornithine and ornithine. This assignment fulfils the twelve double bond 
equivalents (DBEs) calculated for DEM31376/A via the three rings (one aromatic) and 6 double 
bonds. In addition, the three “OH” groups (two hydroxamic acid and one phenolic) and 
methylamine proton account for the four exchangeable protons that were not observed in the 
1H NMR spectrum.  
 
 
Figure 30. Structural assignment of DEM31376/A (25) (COSY = red, selected HMBC = blue) 
 
This assignment is also supported by the original MS and HRMS fragmentation data. Ring 
opening of the oxazoline under acidic conditions explains the [M+H2O+H]+ peak observed in 
our original HPLC and mass spectrometry data.  Whilst fragmentation of DEM31376/A at the 
amide bonds, as this is a common feature in mass spectrometry of peptides,79 yields the 
daughter ions we observed and detailed previously (Figure 31). 
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Figure 31. Proposed assignment of the fragmentation ions of DEM31376/A (25) 
 
With the chemical structure of DEM31376/A successfully assigned, we next decided to assign 
the stereochemistry of DEM31376/A using Marfey’s analysis.  
 
2.8 Marfey’s analysis 
2.8.1 Introduction to Marfey’s analysis 
Marfey’s analysis is a technique used for the determination of the absolute stereochemistry 
of amino acids.80 This is done via functionalization of the amino acid in question with Marfey’s 
reagent and comparing the HPLC retention time of the resulting diastereomer against 
Marfey’s functionalised L and D amino acid standards. 
 
 
Figure 32. Marfey’s reagent 
 
Marfey’s reagent (Nα-(2,4-dinitro-5-fluorophenyl)-L-alaninamide) (25) has an electron 
deficient aromatic ring which serves two purposes. First, it allows for nucleophilic aromatic 
substitution to occur via attack by the amino acid nitrogen. Second, the aromatic ring provides 
a chromophore to allow detection via UV-Vis absorption at 340 nm. Synthesis of standards of 
both L and D amino acids with Marfey’s reagent will give diastereomers with different HPLC 
retention times, without the need to use a chiral HPLC column (Figure 33).  
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Figure 33. Graphical representation of the separation of L and D Alanine via Marfey’s analysis 
 
Comparing the retention time of the Marfey’s functionalised amino acid standards against the 
functionalised, unknown-chirality, amino acid under investigation allows assignment of the 
absolute stereochemistry of that amino acid (Figure 34).  
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Figure 34 Graphical representation of the assignment of the absolute stereochemistry of alanine via Marfey’s 
analysis 
2.8.2 Advanced Marfey’s method 
Marfey’s method was improved by Harada and co-workers and coined the “Advanced 
Marfey’s Method”.81 In the original technique, the Marfey’s reagent always bore the same 
chirality (L-alanine) and the two standards were synthesised via reaction of this L-Marfey’s 
reagent (LM) with L and D amino acids (Laa or Daa) to give an LM-Laa diastereomer and an LM-Daa 
diastereomer. The insight of Harada and co-workers was that the relationship between an LM-
Laa derivative and a DM-Daa derivative would be enantiomeric, giving one class of Marfey’s 
derivatives with identical retention times. Likewise, the relationship between an LM-Daa 
derivative and a DM-Laa derivative would be enantiomeric as well. However, these two groups 
of enantiomeric Marfey’s derivatives would be diastereomers in relation to each other and 
therefore have different retention times (Figure 35).  
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Figure 35. Graphical representation of the separation of L and D Alanine via advanced Marfey’s analysis. 
 
This means that Marfey’s standards can be produced by changing the chirality of the Marfey’s 
reagent whilst using the same chiral amino acid. This is incredibly useful if the amino acid to 
be analysed has been functionalised or modified in some way, making access to both chiral 
enantiomers (either commercially or synthetically) difficult or prohibitively expensive. 
 
2.9 Advanced Marfey’s analysis of DEM31376/A 
2.9.1 Introduction 
There are three chiral amino acids in DEM31376/A that need to be assigned: serine (blue), Nα-
methyl-ornithine (red) and ornithine (green).  
 
 
Figure 36. Strutcure of DEM30616/A (25) showing the three chiral amino acids: serine (blue), Nα-methyl-
ornithine (red) and ornithine (green), chiral centres are marked with an asterix. 
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In order to determine the absolute stereochemistry of DEM31376/A, we will first needed to 
generate a series of L and D Marfey’s amino acid standards for L-serine, L-ornithine and L-Nα-
methyl-ornithine and record their HPLC retention times. After this, DEM31376/A could then be 
hydrolysed and reacted with L-Marfey’s reagent and the HPLC retention times obtained could 
then be compared to those of the amino acid standards, in order to determine the chirality of 
the amino acids in DEM31376/A.  
 
2.9.2 Preparation of Marfey’s standards for DEM31376/A 
To prepare our Marfey’s amino acid standards, we functionalised L-serine, L-ornithine and L-
Nα-methyl-ornithine with both Nα-(5-fluoro-2,4-dinitrophenyl)-L-leucinamide and Nα-(5-
fluoro-2,4-dinitrophenyl)-D-leucinamide in water and in the presence of base. Due to the 
presence of the two nitrogen atoms in the ornithine derived amino acids, the functionalisation 
reaction generated three products. These were the mono-α-functionalised, the mono-δ-
functionalised, and the bi-α,δ-functionalised products. After the synthesis of our standards, 
they were each subjected to HLPC-MS and their retention times recorded.   
 
2.9.3 Marfey’s analysis of DEM31376/A 
With the synthesis and HPLC retention times of the required amino acid standards completed, 
hydrolysis of the natural product was carried out.  
 
 
Figure 37. Graphical representation of the hydrolysable bonds in 25 in the presence of concentrated HI. 
 
For the hydrolysis we elected to react DEM31376/A in concentrated hydroiodic acid. The use 
of concentrated hydroiodic acid causes first the hydrolysis of the amide bond to the 
hydroxylamine, followed by the reduction of said hydroxylamine to the free amine.25,82 This 
allowed commercially available ornithine and Nα-methyl-ornithine to be used for the 
synthesis of the Marfey’s standards.  
Complete hydrolysis of DEM31376/A was achieved in concentrated hydroiodic acid, and the 
residue was functionalised with Nα-(5-fluoro-2,4-dinitrophenyl)-L-leucinamide. Analysis by 
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HPLC-MS gave a multitude of peaks via detection with UV-Vis, scanning between 190-640 nm. 
This was due to the presence of all 5 functionalised amino acid residues as well as hydrolysed 
Marfey’s reagent and other side-products. The chromatogram was simplified by searching for 
the exact masses of the Marfey’s functionalised amino acids we were interested in. The 
masses selected were 400.14 for serine, 427.19 (mono) and 721.28 (bi) for ornithine and 
441.20 (mono) and 735.30 (bi) for N-methyl-ornithine, generating the extracted ion 
chromatogram overleaf (Figure 38). 
 
 
Figure 38. Extracted ion chromatogram of hydroysed DEM31376/A functioanlosed with Nα-(5-fluoro-2,4-
dinitrophenyl)-L-leucinamide showing the ions with m/z values of 400.14, 427.19, 721.28, 441.20 and 735.30.  
 
Graphical comparison of the retention times of the Marfeys functionalised amino acids 
standards with Marfeys functioanlaised DEM31376/A (Figure 39), as well as direct comparison 
of the retention times in Table 8 showed that DEM31376/A is comprised of D-serine (R), L-
ornithine (S) and L-Nα-methyl-ornithine (S).  
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Figure 39. Extracted ion chromatograms from Marfey's analysis of DEM31376/A showing the experimental 
peaks (black), and amino acid standards: serine (blue), ornithine (green) and Nα-methyl-ornithine (red).   
 
  
L-serine standard 
D-serine standard 
EIC m/z = 400.14 
EIC m/z = 427.19 (mono)  
721.28 (bi) 
 
D-ornithine standard 
L-ornithine standard 
 
EIC m/z = 441.20 (mono)  
735.30 (bi) 
D-Nα-methyl-ornithine standard 
 
 
L-Nα-methyl-ornithine standard 
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Table 8. Retention times of Marfeys functioanlised amino acid standards and hydrolysed DEM31376/A 
Amino acid 
 
Marfey’s 
Chirality 
Retention Time 
(mins) 
Separation  
(mins) 
L-Serine L 11.6 
0.2 
L-Serine D 11.8 
L-Ornithine α L 9.9 
0.3 
L-Ornithine α D 9.6 
L-Ornithine δ L 10.2 
0 
L-Ornithine δ D 10.2 
L-Ornithine α+δ L 15.1 
0.4 
L-Ornithine α+δ D 14.7 
L-Nα-methyl-ornithine α L 9.6 
0.1 
L-Nα-methyl-ornithine α D 9.5 
L-Nα-methyl-ornithine δ L 10.4 
0 
L-Nα-methyl-ornithine δ D 10.4 
L-Nα-methyl-ornithine α+δ L 14.9 
0.4 
L-Nα-methyl-ornithine α+δ D 15.3 
DEM31376/A Serine D 11.8 - 
DEM31376/A Ornithine α L 9.9 - 
DEM31376/A Ornithine δ L 10.2 - 
DEM31376/A Ornithine α+δ L 15.1 - 
DEM31376/A Nα-methyl-ornithine α L 9.6 - 
DEM31376/A Nα-methyl-ornithine δ L 10.4 - 
DEM31376/A Nα-methyl-ornithine α+δ L 14.9 - 
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2.10 Resolution of the structure of madurastatin C1 
2.10.1 Introduction 
Upon completion of our structural assignment of DEM31376/A, we discovered the family of 
structurally similar siderophores named ‘madurastatins’ all of which had been isolated from 
the culture broths of Actinomadura sp. bacteria. This family of molecules also included 
madurastatin C1 (30), which bore a near identical structure to DEM31376/A (25).83,84 Indeed 
the only difference in structure between DEM31376/A (25) and madurastatin C1 (30) was in 
the structural assignment of the serine moiety. We had assigned this serine derived 
component as an oxazoline ring, which conflicted with the published structures of 
madurastatins A1, B1, B3 and C1, which had all been assigned with an aziridine ring. 83,84,85 
 
 
Figure 40. Published structures of madurastatins A1, B1, B3 and C1 and our proposed structure for 
madurastatin C1 (24) 
 
Correctly assigning the structure at this position is important, as madurastatins A1, B1 and C1 
showed mild antibiotic activity via inhibition of the growth of M. luteus (and S. aureus in the 
case of madurastatin C1) whilst madurastatin B3 (29) showed toxicity against Bacillus subtilis, 
E. coli, Mycobacterium tuberculosis and methicillin resistant S. aureus. Conversely, hydrolysed 
(ring-opened) madurastatins showed little to no antimicrobial activity at all. This lead the 
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authors to conclude that the aziridine ring played an important role in the antimicrobrial 
activity of the madurastatins, and as such the chemical structures of the madurastatins should 
be reviewed and re-assigned if necessary.83–85 
 
2.10.2 Assignment of DEM31376/A 
To this end, we went back to our assignment, wherein we had elected to classify the cyclised 
serine as an oxazoline ring. This was due to the 13C chemical shifts of the α and β carbons being 
67 and 69 ppm respectively. These chemical shifts were in line with other oxazoline containing 
siderophores including amychelin,40  gobichelin A,86 nocardichelin A,87 transvalecin Z88. The 
assignment of an oxazoline ring was further supported in the case of amychelin, through 
resolution of the structure via single crystal X-ray crystallography.40 Conversely to oxazoline 
rings, aziridine rings typically have lower 13C chemical shifts, in the range of 25-45 ppm. With 
these published structures lending support to our assignment of an oxazoline ring, we decided 
to finally prove through synthesis that the oxazoline assignment was correct.  
In order to confirm our assignment, we decided to synthesise two salicylate capped serine 
models, as both the oxazoline (31 or 32) and aziridine (33 or 34) and compare their NMR data 
against the isolated natural products.  
 
 
Figure 41. Structures of the target oxazoline models (31 + 32) and aziridine models (33 + 34). 
 
2.10.3 Synthesis of model oxazoline 
As the model we wished to construct was derived from the amino acid serine, we decided to 
utilise this amino acid in the form of serine methyl ester 35. This would be coupled via reaction 
with a protected derivative of salicylic acid to generate an amide bond, through either an acid 
chloride or peptide coupling.7 Cyclisation could then be carried out using thionyl chloride.89   
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Scheme 1. Proposed general synthetic route to the model oxazoline precursors 42 and 33. 
 
2.10.4 Synthesis of model oxazoline 31 
Our first synthetic attempts to generate the oxazoline model involved the reaction of O-
acetylsalicyloyl chloride (37) with L-serine methyl ester hydrochloride (35) at room 
temperature in the presence of base. We elected to use an acetyl group to protect the 
phenolic alcohol as it would enable easy removal at a later stage via base mediated hydrolysis, 
the same conditions used to remove the methyl ester, to generate oxazoline model 31 
(Scheme 2).  
 
 
Scheme 2. Proposed synthetic route to oxazoline 30 
 
Interestingly, the amide generated from the reaction of serine methyl ester 35 and acid 
chloride 37 failed to undergo ring cyclisation to generate oxazoline 42. As a result, 2D NMR 
experiments were carried out on amide 40 revealing that the attempted amide bond 
formation had in fact produced ester 43 as an unexpected product. Thus explaining the failure 
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of the attempted ring-cyclisation reactions. We therefore chose to utilise a new protecting 
group for the aromatic-hydroxyl group to circumvent this issue. 
 
 
Figure 42. Resulting product from the reaction of serine methyl ester 35 and salicylic acid derivative 37 
 
2.10.5 Alternative synthesis to generate model oxazoline (32) 
Due to the difficulty in generating amide 40 We therefore chose to use a benzyl protecting 
group in our second synthetic attempt, to generate target amide 41. Amide 41 was 
synthesised by reacting serine methyl ester 35 with either acid chloride 39 or through a DCC 
mediated peptide coupling with acid 38.89 Whilst DCC mediated peptide coupling between 
serine methyl ester 35 and acid 38 resulted a high yield of amide 41 (70%), the product 
required several rounds of purification to remove the DCU by-product. Conversely, reaction 
of serine methyl ester 35 and acid chloride 39 successfully gave higher yields of amide 41 (c. 
90%) and was significantly easier to purify.  
  
Scheme 3. Alternative synthetic route to generate model oxazoline 32 
 
With the synthesis of amide 41 completed we next looked to complete the required 
intramolecular ring closure to generate oxazoline 32 using thionyl chloride.89 Initial attempts 
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in both dry THF and DCM gave exclusively an unwanted alkyl chloride by-product 44.90 By 
monitoring the reaction via TLC we observed the formation of oxazoline 32 was being 
mirrored by the generation of alkyl chloride 44. We therefore elected to quench the reaction 
after one hour by the addition of water, enabling us to isolate oxazoline 32 in 34% yield. Whilst 
this result was promising  we looked to improve the yield of oxazoline by using DAST to 
accomplish the desired ring cyclisation.91 Using DAST in dry DCM afforded exclusively 
oxazoline 32 in 79% yield with no observable by-products generated. 
 
Table 9. Reaction conditions and results for the reaction of amide 41 with SOCl2 to generate 32 and 44 
Reagent Temperature (°C) Solvent Time 
(hours) 
Yield (%) 
oxazoline (32) 
Yield (%) 
chloride (44) 
SOCl2  -78 THF 18 0 95 
SOCl2 -78 DCM 18 0 84 
SOCl2 -78 DCM 1 34 45 
DAST -78 DCM 2 79 0 
 
The quantity of oxazoline produced was enough to allow us to fully characterise 32 via NMR, 
HRMS and X-ray crystal analysis. With the synthesis of oxazoline 32 completed, we next turned 
our attention to the synthesis of the aziridine model (34). 
 
2.10.6 Synthesis of model aziridine (34) 
To allow direct NMR comparison between the oxazoline and aziridine models, we elected to 
synthesise model aziridine 34. To synthesise 34, we first had to construct an aziridine ring 
followed by reaction with benzyl protected acid chloride 39. We therefore began with an N-
trityl (Tr) protected L-serine (45) which was reacted with mesyl chloride in order to activate 
the alcohol, making it a better leaving group (46). This mesylate was not isolated, but 
evaporated to dryness and dissolved in THF and heated in the presence of Et3N. This resulted 
in the mesylate being displaced via an intramolecular SN2 reaction to give the required 
aziridine (47) in 70% yield over two steps after isolation via trituration (Scheme 4).92–95 
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Scheme 4. Synthetic route to generate aziridine 47 
The next step was the removal of the trityl protecting group. This is usually achieved via the 
use of TFA in chloroform/methanol 1:1,93,96,97 however, in our hands this reaction proved 
unsuccessful with exclusively unreacted starting material observed by TLC. Modification of 
this procedure to include the use of triethysilane in the presence of TFA cleanly cleaved off 
the trityl protecting group, yielding the free amine (48).92,98 With our freshly deprotected 
amine in hand we reacted this, without purification, with freshly prepared acid chloride (39) 
to form oxazoline model (34) in a 20% yield from aziridine (47).  
 
 
Scheme 5. Synthetic route to generate aziridine 34 
 
2.10.7 Structural confirmation of DEM31376/A and the madurastatins  
With the synthesis of the oxazoline (32) and aziridine (34) model systems completed, NMR 
studies of both of these compounds were carried out. We then compared this data against 
the NMR data obtained for DEM31376/A and the literature values for madurastatin C1 (Table 
10). The 13C chemical shifts for the synthesised aziridine ring come at 37.5 ppm (P-2) and 33.1 
ppm (P-3), far lower than the corresponding signals observed for DEM31376/A and 
madurastatin C1. Meanwhile the 13C chemical shift for the quaternary carbon (P-1) is at 178.1 
ppm and thus too deshielded in comparison to the isolated natural products. Happily, the 13C 
signals for the synthesised oxazoline ring were found to be at 70.8 ppm (P-2), 69.3 ppm (P-3) 
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and 168.1 ppm (P-1), all of which are near perfect matches to the shifts seen in the natural 
products (Table 10) 
 
 
 
 
Table 10 13C NMR data for model systems (32) and (34) versus madurastatin  C1 and DEM31376/A 
 
 Carbon chemical shift (ppm) 
Name Solvent 1 2 3 
Synthesised Oxazoline (32) CD3OD 168.1 70.8 69.3 
Synthesized Aziridine (34) CD3OD 178.1 37.5 33.1 
DEM31376/A (25) CD3OD 165.9 69.4 67.4 
Madurastatin C1 (30) CD3OD 167.0 69.3 67.9 
 
As a result of our studies, we propose that DEM31376/A (25) and madurastatin C1 (30) are 
the same molecule. In addition, we have proven that madurastatin C1 (30) contains an 
oxazoline ring, not the previously reported aziridine. Similarly, the chemical structures of 
madurastatin A1 (27), B1 (28) and MBJ-0035 (49) are also incorrect and each has had its 
structures revised to contain an oxazoline ring in our publication from early 2017.99 We also 
propose that the reported isolation and antibacterial studies of madurastatin B3 (29) are in 
fact the isolation and bacterial studies of spoxazomicin C (see Figure 43).  
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Figure 43. Original structures of madurastatins A1, B1, B3, C1 and MBJ-0035 left, red and their new proposed 
structural assignments right, green 
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2.11 Conclusions for chapter 2 
In this chapter, we have highlighted our work to isolate and identify the potentially bioactive 
bacterial siderophore DEM31376/A from a novel Actinomadura sp. itself isolated from deep 
sea marine sediment found at Canary Basin in the Atlantic Ocean. After initial investigation it 
was realised that the antibiotic nature of samples of DEM31376/A arose from a co-eluting 
natural product GE23077. However, due to our interest in the structure and biology of 
bacterial siderophores, we decided to continue our investigations into this bacterial natural 
product. Investigations therefore began with a large scale fermentation of the bacterial strain 
DEM31376 and isolation of the bioactive compound through solid phase capture with 
Amberlite XAD16N beads and elution with methanol. This was followed by fractionation via 
solid phase extraction (C8 cartridge) and a final reverse phase chromatography step to yield 
283 mg of DEM31376/A. After Isolation we determined the chemical structure of 
DEM31616/A via a de novo structural determination utilising a series of techniques including 
HRMS, 1D and 2D NMR and Marfey’s analysis. This allowed us to assign DEM31376/A as a 
pentapeptide siderophore with three chiral centres (D-Serine, L-N-α-Methyl-Ornithine and L-
Ornithine). Comparison of this natural product to known siderophores informed us that we 
had in fact re-isolated the known siderophore madurastatin C1. However, our structural 
assignment differed slightly to that of madurastatin C1, with our assignment containing an 
oxazoline ring as opposed to an aziridine-amide. Synthesis of model compounds 32 + 34 and 
comparison of their carbon chemical shift data allowed us to prove that our assignment was 
indeed correct. With that we propose that the chemical structures of madurastatins A1, B1, 
C1 and B3 be changed to incorporate an oxazoline ring instead of an aziridine-amide 
functionality.  
 
With the chemical structure fully assigned, we next turned our attention to the total synthesis 
of madurastatin C1 which as of yet has not been reported in the literature. 
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Chapter 3. Total Synthesis of Madurastatin C1 
 
3.1 Introduction 
With the chemical structure and stereochemistry of madurastatin C1 (25) assigned by 
ourselves in Chapter 2, we next sought to complete the total synthesis of this natural product. 
The total synthesis of madurastatin C1 was deemed rewarding for several reasons. Primarily, 
at the time of writing the total synthesis of madurastatin C1 has not yet been reported in the 
literature. As organic chemists this represented an exciting opportunity to be the first to 
synthesise a natural product. In addition to this, total synthesis would allow us to access pure 
siderophore without the dependency on fermentation of bacterial strain DEM31376. This 
would remove the potential for contamination from the natural product GE23077 (described 
in Chapter 2) in any bioassay or feeding experiments we may wish to carry out in future. 
Furthermore, total synthesis would allow us to easily generate structural derivatives of 
madurastatin C1 by modification of the constituent amino acids either prior to their utilisation 
in the total synthesis, or via post synthetic modification. With this rational for the total 
synthesis of madurastatin C1, we looked to the literature for the synthesis of other similar 
natural products.  
 
3.2 Relevant literature  
3.2.1 Total synthesis of Exochelin MN (50). 
Exochelin MN (50) is an extracellular siderophore produced by Mycobacterium neoaurum and 
has been shown to facilitate iron uptake in Mycobacterium leprae, the causative agent of 
leprosy.100,101 Chelation of Fe3+ occurs at the hydroxamic acid groups (red) and either the 
threo-β-hydroxy-L-histidine or hydroxyl/amine positions (blue) depending on pH.102  
 
 
Figure 44. Chemical structure of Exochelin MN (50) 
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The reported total synthesis of exochelin MN (50) was completed in 2002 by Dong and Miller 
in an excellent overall yield of 4.7% and there are several structural similarities between 
exochelin MN and madurastatin C1.103 These include the cyclised hydroxamic acid derived 
from ornithine (blue) and the N-α-methyl functionalised ornithine with a hydroxamic acid 
functionality at the δ position (red) (Figure 45). Due to these similarities, the total synthesis of 
exochelin MN (50) will provide a valuable resource in the total synthesis of madurastatin C1. 
 
 
Figure 45. The structure of exochelin MN with the structurally similar amino acid components found in 
madurastatin C1 highlighted (cyclised ornithine blue, N-α-methyl ornithine red). 
 
In the total synthesis of exochelin MN a key intermediate was used to access both the 
methylated and cyclised ornithine components. This intermediate, nitrone 51 is an oxidised 
amino acid synthesised from Nα-Cbz-L-ornithine, and was developed from the indirect 
oxidation chemistry used in the synthesis of D-ferrichrome by Naegeli and Keller-Schierlein.104 
 
 
Figure 46. The key intermediate “nitrone” 51 used in the synthesis of exochelin MN. 
 
The synthesis of this key intermediate was completed via conversion of the primary amine in 
N-α-Cbz-L-ornithine to an imine, followed by oxidation of said imine to the corresponding 
oxaziridine using m-CPBA and finally acid catalysed hydrolysis to the nitrone 51.105 Using this 
route, Miller and co-workers synthesized nitrone 51 in 80% yield from L-N-α-methyl-ornithine 
on a 30 g scale. In addition to the large scale, this key intermediate was isolated over three 
steps without the use of column chromatography. This significantly sped up the synthetic 
process, allowing for large scale preparation and kept losses due to purification steps to a 
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minimum. This therefore seemed like an ideal candidate for use in the synthesis of 
madurastatin C1 (25).  
 
3.3 Project aims 
The aim of this part of the project was to carry out retrosynthetic analysis of madurastatin C1 
(25) to give synthetic targets that could be obtained by simple chemical reactions, that could 
also be scaled up to enable access to madurastatin C1 (25) in gram scale quantitates if needed. 
Once this is achieved we would synthesise our required modified amino acids. These 
modifications include the synthesis of hydroxamic acids, a mono-N-methylation and 
cyclisation reactions. Upon generation of our modified amino acids, we could then carry out 
the total synthesis of madurastatin C1 (25).  
 
3.4 Retrosynthetic Analysis 
Initial retrosynthetic analysis of madurastatin C1 shows that the disconnections should be 
relatively routine, owing to its poly-peptide nature. Disconnection at the amide and 
hydroxamic acid bonds leads us to basic amino acids and the key nitrone intermediate (51) 
already discussed. In order to maximise yields we elected to use a convergent synthetic route 
(Figure 47).  
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Figure 47. Retrosynthetic analysis of madurastatin C1 (25). 
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3.5 Results and discussion 
3.5.1 Introduction 
Due to the assembly line nature of polypeptide synthesis, the total synthesis of madurastatin 
C1 will revolve around the synthesis of modified amino acids and the coupling of these amino 
acids through amide bonds, as is shown in our retrosynthesis. We have already discussed the 
synthesis of a similar natural product, exochelin MN (50), utilising a similar process of amino 
acid synthesis followed by amide coupling. To this end, we will begin by synthesising the 
required modified amino acids derived from a salicylic acid capped serine (56), a glycine and 
β-alanine dipeptide (57) and the methylated (54) and cyclised (55) ornithines, produced from 
the key nitrone intermediate 51 (Figure 47). The generation of intermediates 56 and 57 
required amide bond coupling reactions to be carried out and as such the serine, glycine and 
β-alanine amino acids had their carboxylic acid functionality protected through a methyl ester 
group. Methyl esters are common protecting groups in amide/peptide chemistry, as they are 
stable to mild acids, bases and the reaction conditions required for amide bond coupling. 
These protecting groups prevent unwanted amide coupling reactions occurring at the 
carboxylic acid, preventing polymerisation. In addition, methyl esters are relatively easy to 
remove, utilising either strong acid or strong base catalysed cleavage of the methyl ester. 
Saponification, reaction with a base such as sodium hydroxide, is among the most common 
methods for cleavage of methyl esters. However, reaction with a strong base for extended 
periods of time can result in partial or total racemisation of a chiral amino acid, owing to the 
acidic nature of the α-proton. This will not be a problem in the synthesis of dipeptide 57 as it 
utilises two non-chiral amino acids. Whereas the synthesis of 56 and 52 include the chiral 
amino acid serine, and as such will need to be monitored to ensure racemisation has not 
occurred. With these points in mind, we began with the synthesis of the left hand side of 
madurastatin C1 (52). 
 
3.6 Synthesis of the left-hand half of madurastatin C1 (52) 
3.6.1 Synthesis of salicylic acid capped serine (56) 
The synthesis of 56 required that a carboxyl-protected D-Serine be coupled to a suitably 
protected derivative of salicylic acid via an amide bond. Due to our previous experience in the 
synthesis of amide 41 (all be it with the opposite stereochemistry, see Chapter 2), we elected 
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to use the same methods in the synthesis of 56, specifically the utilisation of an acid chloride 
and base to generate salicylic acid capped serine 56.  
 
 
Scheme 6. Synthetic route to generate salicylic acid capped serine methyl ester 56 
 
To this end acid chloride 39 was generated via refluxing 2-benzyloxybenzoic acid (38) in 
toluene in the presence of a slight excess of thionyl chloride for 3 h. This was then stirred with 
D-serine methyl ester hydrochloride (58) in the presence of Et3N, yielding the desired amide 
after column chromatography with an average yield of 74%. This yield is slightly lower than 
we anticipated and we attributed this to hydrolysis of acid chloride 39 back to the 
corresponding carboxylic acid (38) prior to reaction with D-serine methyl ester hydrochloride 
(58). Retention of the chirality at the α-proton was confirmed via optical rotation 
measurements (-21.6 °) and single crystal X-ray crystallography of the purified material. 
Confirmation of the stereochemistry of a molecule using X-ray crystal analysis is completed 
via calculation of the Flack parameter. The Flack parameter is used to estimate the absolute 
configuration of a molecule from the data obtained via X-ray crystal analysis. “A crystal of 
enantiomerically pure compound in the correct absolute configuration has a value of the Flack 
parameter of zero.”106 A calculated Flack parameter of 0 means that the absolute 
stereochemistry of the drawn structure is almost certainly correct, whist a Flack parameter of 
1 means that the assigned absolute stereochemistry is almost certainly inverted. As the flack 
parameter value of (56) was 0.08(±5), and therefore very close to 0, we were confident that 
the stereochemistry of 56 was in the R (D) configuration. 
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Figure 48. X-ray crystal structure of 56. 
 
3.6.2 Deprotection of 56 
Our next step was the conversion of methyl ester 56 to its corresponding carboxylic acid.  
 
 
Scheme 7. Synthetic route to generate salicylic acid capped serine 61. 
 
We elected to saponify methyl ester 56 via base mediated hydrolysis, generating the 
carboxylate, followed by acidification during work up to yield the carboxylic acid. Due to the 
presence of a chiral centre in D-serine we wished to limit the degree of racemisation by using 
the lowest possible reaction time. As such the reaction mix was monitored via TLC every 10 
minutes over the course of an hour. After one hour the TLC showed a complete loss of starting 
material with a new spot stuck to the baseline, corresponding to the generation of the 
carboxylate. Carboxylic acid 61 was then isolated in a quantitative conversion from 56 after 
acid/base extraction. Carboxylic acid 61 showed the clear loss of the methyl ester peak found 
at 3.69 ppm in the 1H NMR spectrum of methyl ester 56 and gave an optical rotation 
measurement of -22.4 °. This is very close to that of the starting methyl ester (-21.6 °) and we 
were therefore satisfied that we had not racemised the chiral centre via the base mediated 
hydrolysis of 56. 
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3.6.3 Synthesis of glycine-β-alanine di-peptide 57 
With carboxylic acid 61 synthesised, we now proceeded with the synthesis of dipeptide 57 
consisting of glycine and β-alanine. 
 
 
Scheme 8. Synthetic route to generate di-peptide 57 
 
The synthesis began with the protection of the primary amine of glycine methyl ester 
hydrochloride with a Cbz group by mixing 62 with benzyl chloroformate in water in the 
presence of sodium hydrogen carbonate. The appearance of a new UV visualised spot on TLC 
indicated formation of our product, which was then isolated in a 99% yield via column 
chromatography. Carboxylic acid 59 was then generated in the same manner as for 61, via 
hydrolysis of methyl ester 63 with aqueous sodium hydroxide and monitoring via TLC over 1 
hour. Carboxylic acid 59 was then subjected to peptide coupling conditions in the presence of 
β-alanine methyl ester hydrochloride (60). Initially EDC hydrochloride was used as our amide 
coupling reagent with Et3N as base, giving average yields of 63%. Changing from EDC to HATU 
allowed access to methyl ester 57 in 84% after isolation via silica gel column chromatography.  
 
3.6.4 Deprotection of 57 
With the synthesis of di-peptide 57 completed, we next had to remove the Cbz protecting 
group. Removing the Cbz group would allow us to couple carboxylic acid 61 to the newly 
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generated amine (64/65). Removal of a Cbz group is commonly achieved via acidic 
deprotection with HBr in acetic acid or through hydrogenation.107 
 
 
Scheme 9. Synthetic route to generate salicylic acid capped serine 64 and 65 
 
Both of these methods were experimented with, and reaction with HBr in acetic acid was 
easier to carry out, owing to the use of liquid reagents instead of gaseous hydrogen. The 
reaction of 57 with 33% HBr in acetic acid with DCM as solvent afforded the corresponding 
HBr salt as a red solid (65). This solid was hygroscopic however, which lead to difficulties in 
handling and characterisation. We therefore also attempted the deprotection of 57 via 
hydrogenation which consistently gave near quantitative yields. Hydrogenation was carried 
out using hydrogen gas (1 atm) in methanol with palladium on carbon as catalyst for 6 hours 
and gave a quantitative conversion to the free amine (64). Both 64 and 65 were used in future 
reactions in the synthesis of madurastatin C1. 
 
3.6.5 Synthesis of the left-hand half of madurastatin C1 (52) 
With the synthesis of both carboxylic acid 61 and amines 64/65 completed, we could now 
carry out the peptide coupling reaction to generate tripeptide 52 and finish the synthesis of 
the left-hand half of madurastatin C1.  
 
 
Scheme 10. Synthetic route to (52). 
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For the synthesis of tri-peptide 52, HATU was used as the peptide coupling reagent, with DMF 
as solvent and DIPEA as base. DMF was chosen due to the hydrobromide salt 65 being 
insoluble in DCM. These reaction conditions generated the corresponding amide in 67% yield 
after isolation via silica gel column chromatography. The optical rotation of 52 was -34.6 °, 
showing that we had retained R (D) stereochemisrty at the serine. With the left hand half of 
madurastatin C1 completed we next moved on to the synthesis of key nitrone 51. 
 
3.7 Synthesis of the right-hand half of madurastatin C1 (53) 
3.7.1 Synthesis of key nitrone intermediate 51 
In order to generate our oxidised ornithine amino acids, we looked to the oxidation chemistry 
that we discussed in the introduction of this chapter in section 3.2.1. This chemistry involves 
converting N-α-Cbz-L-ornithine into imine (67), followed by oxidation to the corresponding 
oxaziridine using mCPBA 68. This oxidation to an oxaziridine inserts the desired nitrogen-
oxygen bond, with acid catalysed rearrangement of the oxaziridine affording the desired 
nitrone 51 (Scheme 11). 
 
 
Scheme 11. Synthetic route to generate the key intermediate nitrone 51. 
 
3.7.2 Synthesis of imine 67 
We therefore began the synthesis with N-α-Cbz-L-ornithine 66 as it contained a suitable 
protecting group for the α amine whilst also being commercially available. This was reacted 
with benzaldehyde in the presence of potassium hydroxide. During the reaction, water is 
generated as a by-product and we therefore included 3 Å molecular sieves in the reaction mix. 
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These remove the generated water and help to push the reaction equilibrium toward the 
generation of products, rather than returning from the hemiaminal intermediate to 
benzaldehyde and N-α-Cbz-L-ornithine starting materials (66). After the reaction had 
completed, the pulverised molecular sieves were removed via filtration. We discovered that 
filtration through celite, a commonly used technique for the capture of molecular sieves, leads 
to decomposition of imine 67. Filtration of the molecular sieves through a sinter funnel and 
evaporation of the methanol yielded imine 67 as a hygroscopic white foam with quantitative 
conversion from ornithine starting material 66. 
 
3.7.3 Synthesis of nitrone 51 
With imine 67 generated we moved on to the oxidation step followed by the immediate 
conversion to the nitrone (51), owing to the unstable nature of the oxaziridine intermediate. 
Oxidation of the imine was accomplished via reaction of 67 with mCPBA in methanol. After 
removal of the solvent and extraction to remove the benzoic acid by-product the crude 
material was then stirred in the presence of TFA in DCM. Initial attempts at this reaction gave 
very low yields of the desired nitrone. After repeating the experiment several times, we 
realised that commercially available mCPBA contains both m-chlorobenzoic acid and water as 
stabilisers to reduce the danger of this potentially explosive material. We therefore purified 
the mCPBA via extraction with diethyl ether and washing with buffered basic solution to 
remove the m-chlorobenzoic acid and water impurities and generate higher purity mCPBA. 
Repeating the oxidation step with this batch of mCPBA and reaction of the crude mixture with 
TFA gave the corresponding nitrone (51) in significantly higher yields (76%), which was isolated 
via trituration from EtOAc and hexane as a white precipitate. Retention of the chirality at the 
α-proton was again confirmed via optical rotation measurements (-4.4 °). Whilst the optical 
rotation value appears to be close to zero, suggesting racemisation of the sample, a Flack 
parameter of -0.05(±10) was obtained from single crystal X-ray crystallography of the purified 
material, suggesting that the crystal had S (L) chirality. 
With significant quantities of our key intermediate nitrone (51) available, we next looked to 
synthesise the required methylated ornithine 54 and cyclised ornithine 55  
 
3.7.4 Synthesis of methylated ornithine 54  
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Scheme 12. Synthetic route to generate methylated ornithine 54. 
 
For the synthesis of methylated ornithine 54, we reacted nitrone 51 with methyl iodide in the 
presence of sodium hydride as base. Once again, owing to the product being a zwitterion, 54 
was isolated via trituration in 62% yield. Despite the use of a strong base in the form of sodium 
hydride, optical rotation measurements showed that the sample sill retained mostly D chirality 
(-13.2 °). The original 1H NMR of this material revealed a new peak at 2.83 ppm corresponding 
to the new methyl group. However, this and many other 1H and 13C NMR signals were 
duplicated due to the methyl group causing hindered rotation of the nitrogen-carbon bonds 
at the α position. This was overcome by heating the NMR sample to 70 °C, causing the peaks 
to coalesce and giving a clear spectrum (Figure 49).  
 
 
Figure 49. 1H NMR of 54 at 298 K top, and 343 K bottom (D-6 DMSO, 700 MHz) showing the coalescence of the 
duplicated 1H NMR signals at higher temperature. 
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3.7.5 Synthesis of cyclised ornithine 55  
For the synthesis of cyclised ornithine 55, a one pot deprotection, cyclisation and benzylation 
was carried out (Scheme 13).  
 
 
Scheme 13. Proposed generalised synthetic route to cyclised ornithine 55. 
 
Benzyl protection of the hydroxylamine oxygen is required as the hydroxylamine generated 
by cyclisation of 51 is very polar and also capable of chelating metal ions, significantly 
hindering its purification. Protecting the hydroxyl component of the hydroxamic acid with a 
benzyl group will prevent metal chelation whilst also decreasing polarity therefore allowing 
for isolation via silica gel column chromatography.  
To begin, nitrone (51) was dissolved in methanol and refluxed in the presence of 
hydroxylamine hydrochloride, generating hydroxylamine 69. This was then followed by 
addition of Et3N and 3 Å molecular sieves with the mixture continuing under reflux. After an 
hour the cyclised hydroxamic acid (70) was isolated via extraction and washing of the reaction 
mix, after which the crude material was stirred in the presence of benzyl bromide in DMF using 
K2CO3 as catalyst, yielding fully protected cyclised ornithine (55) in 57% yield from 51 (Scheme 
14).  
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Scheme 14. Synthetic route to cyclised ornithine 55 via a one pot deprotection, cyclisation and benzylation 
reaction. 
 
Upon measuring the optical rotation of cyclised ornithine 55 (+23.2 °), we noted that our 
experimental value was opposite to that found in the literature.103 Indeed further inspection 
of the literature for the synthesis of 55 gave both positive and negative optical rotation values 
for each of the R and S enantiomers.103,108,109 As we could not therefore confidently assign the 
stereochemistry of cyclised ornithine 55 using optical rotation, we elected to try and confirm 
the stereochemistry via X-ray crystallography. To this end, after the optical rotation of 54 was 
recorded the sample was allowed to slowly evaporate, yielding crystals suitable for single 
crystal X-ray analysis. Unfortunately, the Flack parameter for this crystal was not close to zero 
and had a large margin of error (Flack parameter = 0.35(±12)). As a result we could not 
confidently show that the chiral centre in 55 was in the expected S configuration. 
  
3.7.6 Deprotection of cyclised ornithine 55 
With the fully protected cyclised ornithine now completed, we had to remove the Cbz 
protecting group and generate the corresponding amine (Scheme 15).  
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Scheme 15. Synthetic route to deprotected cyclised ornithine 71. 
 
As discussed for the deprotonation of 57, it is well documented that the removal of a Cbz 
group can be completed via hydrogenation or with a solution of HBr in acetic acid.107As O-
Benzyl groups can be removed via hydrogenation but are resistant to strongly acidic 
conditions, the use of HBr in acetic acid was employed to selectively remove the Cbz group 
whilst leaving the benzyl group intact. To this end we reacted cyclised ornithine 55 with 33% 
HBr in acetic acid for 2 hours, yielding 71, which was isolated via trituration from ether and 
chloroform in 86% yield.103 The optical rotation of 71 was +43 ° and the structure was also 
resolved via X-ray crystallography (Figure 50). This time, the Flack parameter was much more 
acceptable at -0.030(±9), supporting the assignment of the stereocentre in an S configuration 
as we had anticipated.  
 
Figure 50. X-ray crystal structure of 71. 
 
With the required free amine now available, we could proceed to the amide coupling of 54 
and 71 to generate the right hand half of madurastatin C1. 
 
Synthesis of dipeptide 53. 
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With our two modified ornithine amino acids 54 and 71 now completed, we could now carry 
out the peptide coupling required to synthesise dipeptide 53.  
 
 
Scheme 16. Synthetic route to dipeptide 53. 
 
To begin, methylated ornithine 54 was stirred in the presence of the peptide coupling agent 
HATU in DMF. This was followed by the addition of cyclised ornithine 71 and DIPEA, generating 
the desired di-peptide. The structure was confirmed by HRMS and NMR studies, but in a 
similar fashion to the characterisation of methylated ornithine 54, numerous peaks were 
duplicated presumably due to hindered rotation. 1H and 13C NMR studies at a variety of 
temperatures showed some signal coalescence (as shown in Figure 51), leading to easier to 
interpret spectra. However, even at high temperatures the 13C NMR data still showed 
duplicated peaks whilst other appeared to broaden and disappear into the baseline.  
 
 
Figure 51. 1H NMR of 53 at 298 K top, and 348 K bottom (D-6 DMSO, 700 MHz) showing the coalescence of the 
duplicated 1H NMR signals at higher temperature. 
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3.7.8 Deprotection to generate hydroxylamine (72) 
With the fully protected dipeptide (53) in hand, we now had to remove the aromatic-imine 
group to give a hydroxylamine. This could then be used to couple the two halves of 
madurastatin C1 together via a hydroxamic acid group.  
 
 
Scheme 17. Synthetic route to dipeptide 72. 
 
In a similar fashion to the synthesis of ornithine hydroxylaime 69, generation of hydroxylamine 
72 was completed via stirring dipeptide 53 in the presence of hydroxylamine hydrochloride. 
This afforded the corresponding hydroxylamine 72 as the hydrochloride salt that could be 
easily isolated via trituration and filtration. Due to the instability of this intermediate, no 
further purification was carried out and instead the material was carried through and used 
immediately in the next coupling reaction.   
 
3.7.9 Deprotection of 52 
Prior to the coupling of both half’s of madurastatin C1, tripeptide 52 had to be converted from 
the methyl ester to the corresponding carboxylic acid 73.  
 
 
Scheme 18. Synthetic route to generate carboxylic acid 73. 
 
To synthesise carboxylic acid 73, methyl ester 52 was dissolved in THF and hydrolysis of the 
methyl ester was carried out using aqueous sodium hydroxide. TLC monitoring every 10 
minutes showed that the hydrolysis was complete after 30 minutes. Acid/base extraction 
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afforded the carboxylic acid as a clear oil, with 1H NMR analysis showing that the methyl group 
had been removed through loss of the singlet at 3.65 ppm from the starting material (52). 
Retention of the predominantly D enantiomer was again shown via optical rotation, with an 
[α]D value of -18.4 °. 
 
3.8 Final reactions to generate madurastatin C1 
3.8.1 Synthesis of pentapeptide 74 
With the synthesis of both of our target carboxylic acid 73 and hydroxylamine 72, we were 
now ready to move on to the amide coupling to generate pentapeptide 74 through a central 
hydroxamic acid.  
 
 
Scheme 19. Synthetic route to pentapeptide 74 via HATU mediated peptide coupling of 73 and 72. 
 
We therefore began with dissolving carboxylic acid 73 in DMF and stirring in the presence of 
the peptide coupling reagent HATU. This was then followed by the addition of hydroxylamine 
72 with DIPEA used as base. Unfortunately, TLC showed that several by-products were made 
over the course of the reaction with a similar Rf to that of our desired product 74, leading us 
to believe that we had synthesised diastereomers. This mixture of diastereomers proved 
difficult to separate via silica gel column chromatography, due to their highly polar nature and 
the similar Rf to that of our product. After two rounds of silica gel column chromatography we 
managed to partially isolate pentapeptide 74 in a 35% yield. This yield was disappointing 
considering that our previous HATU mediated amide coupling reactions had typically 
proceeded on average in 80% yields. The low yield could be attributed to the multiple 
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diastereomer by-products formed as well as the multiple rounds of silica gel column 
chromatography used to isolate 74. In addition to the suspected diastereomers produced, an 
additional by-product yielded crystals that were suitable for X-Ray single crystal analysis. 
Resolution of the crystal structure showed that we had generated the intramolecular cyclised 
ester 75 over the course of the reaction. The molecular ion of 75 was also observed via HRMS 
but due to the similar Rf of 75 to the other by-products generated in the reaction we were not 
able to isolate 75 for full characterisation by NMR.  
 
 
Figure 52. Chemical structure of cyclised tripeptide 75 formed via intramolecular cyclisation of HATU activated 
carboxylic acid 73. 
 
We propose that the cyclisation occurred via nucleophilic attack by the serine hydroxyl group 
at the HATU activated carboxylic acid, generating the corresponding eleven membered ring. 
Whilst it is unfortunate to lose material at this late stage of the synthesis, this could be 
prevented in future via protecting the serine alcohol with a selective and easily removable 
oxygen protecting group, such as a TBDMS. With the synthesis and isolation of pentapeptide 
74 complete, we could now complete the oxazoline ring cyclisation to generate fully protected 
madurastatin C1.  
 
3.8.2 Synthesis of oxazoline pentapeptide (76) 
Drawing on our experience of the synthesis of oxazoline model 32, we felt confident that we 
could complete the ring closure of 74 with DAST. Using DAST gave the highest yields of 
oxazoline during the synthesis of model oxazoline 32 without the formation of by-products 
such as alkyl chloride 44, generated when thionyl chloride was used.  
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Scheme 20. Synthetic route to oxazoline pentapeptide 76 via DAST mediated oxazoline formation from 74. 
 
Due to the low yield of pentapeptide 74 from the previous reaction, we had no choice but to 
carry out the oxazoline ring cyclisation reaction on a small scale. Unfortunately, half of starting 
pentapeptide 74 was lost due to experimental error. Despite this, oxazoline pentapeptide 76 
was successfully synthesised via reaction of 74 with DAST and the molecular ion of 76 was 
observed via HRMS (m/z value of 906.4036 for the proposed [M+H]+ ion). Due to the low 
quantity of material and its high polarity we elected not to purify via column chromatography, 
instead immediately moving on to the final reaction, the global deprotection of oxazoline 
pentapeptide 76. 
 
3.8.3 Global deprotection to generate synthetic madurastatin C1 (25). 
With our oxazoline ring now in place, we looked to carry out a global deprotection using 
gaseous hydrogen with Pd/C as catalyst. We anticipated this would remove both the N-Cbz 
and the two O-benzyl protecting groups in a single step.  
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Scheme 21. Global deprotection of 76 via hydrogenation over Pd/C to generate synthetic madurastatin C1 25 
 
The deprotection reaction was carried out in methanol under 1 atmosphere of hydrogen gas 
and 20 mg of palladium on carbon. With the desire to remove all three protecting groups at 
once we left the sample overnight, with the catalyst removed via filtration through celite. The 
initial crude NMR showed complete removal of the protecting groups, with only four aromatic 
1H signals present. These aromatic signals had an identical splitting pattern to that of the 
natural product madurastatin C1.  
With our global deprotection completed we sought to purify synthetic madurastatin C1 (25), 
however the sample appeared to change colour inside the NMR tube, from clear to yellow. A 
second NMR experiment was carried out, showing that the sample had begun to degrade, 
with the ratios of 1H NMR signals changing between both NMR experiments. This degradation 
was attributed to the presence of celite in the sample which, despite our best efforts, had 
passed through to our sample during the filtration process used to remove the palladium 
catalyst.  
With no additional pentapeptide staring material to hand, we were unable to complete a 
second synthesis of madurastatin C1 within the project timeline.  
 
3.9 Conclusions and future work 
In this chapter we aimed to develop a synthetic route to generate madurastatin C1 that was 
high yielding and scalable. We then aimed to synthesise the required modified amino acids 
and ultimately complete the total synthesis of madurastatin C1. Retrosynthetic analysis 
provided a viable convergent synthetic route to madurastatin C1 based around amide 
coupling chemistry and utilisation of amino acid oxidation chemistry. The synthesis of the 
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required modified amino acids was successful and coupling reactions were completed in high 
yields via utilisation of HATU as our amide coupling reagent of choice. Whilst we tentatively 
believe that we had completed the total synthesis of madurastatin C1 on a test scale, we were 
unsuccessful in the isolation or characterisation of any pure material due to the degradation 
of synthetic madurastatin C1. In future we would look to improve our reaction yields to allow 
access to larger volumes of synthetic material. In particular we would look to utilise a 
protecting group, such as TBDMS, for the serine hydroxyl. This would prevent the 
intramolecular cyclisation reaction we observed in the synthesis of pentapeptide 72. Finally, 
after the global deprotection reaction to yield madurastatin C1 we would look to utilise either 
size exclusion chromatography or HPLC to isolate pure material and to remove any celite or 
palladium catalyst that may have contaminated the sample.  
For the final part of this project, we look to a new bioactive bacterial natural product 
DEM30616/A. 
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  Chapter 4. Bioactivity, Structural Determination and Total Synthesis of DEM30616/A 
 
4.1 Introduction 
Lipoteichoic acid (LTA) is an important component of the cell wall of Gram positive bacteria 
and plays an essential role in bacterial growth and therefore virulence. One of the key enzymes 
responsible for the synthesis of lipoteichoic acid is known as LTA synthase (LtaS).110 LtaS is 
located on the cell membrane of Gram-positive bacteria and can be divided into two parts, 
the trans membrane domain and the extracellular domain (eLtaS). The eLtaS domain is 
responsible for the enzymatic activity of LtaS, and the X-ray crystal structure of eLtaS was 
resolved in 2008 (Figure 53).111 Due to the role of LtaS in bacterial growth, compounds that 
could inhibit eLtaS are interesting as potential novel antibiotics, as blocking the activity of 
eLtaS would prevent the production of the essential lipoteichoic acid, limiting bacterial growth 
and could therefore lead to new treatments of bacterial infections.    
 
 
Figure 53. X-ray crystal structure of the eLtaS enzyme in a ribbon representation taken from Freemont et al. Ref: 
111 
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4.2 Current inhibitors of eLtaS  
Current inhibitors of eLtaS include the poly aromatic compound 1771 (77) and the azo dye 
Congo red (78).112,113 When incubated with S. aureus, compound 1771 (77) showed the ability 
to reduce the abundance of LTA and also inhibited growth, however the binding site of 77 was 
not identified.112 A dual-drug approach of using LtaS inhibitor 1771 (77) in combination with 
known antibiotics has been shown to abrogate the growth of multi-drug resistant 
Enterococcus faecium.114 The azo dye Congo red (78) has been shown to exhibit a dose-
dependent decrease in LTA production with inhibition of LtaS demonstrated both in vitro and 
in cellulo, however the exact mode of action is unclear.113  
 
 
Figure 54. Chemical structures of eLtaS inhibitors 1771 (77) and Congo red (78). 
 
Despite these two examples and the potential for computer aided drug design due to the 
availability of the X-ray crystal structure of eLtaS, no commercial drug is currently available 
based on a small molecule inhibitor of LtaS.  
 
4.3 Screening for LtaS inhibitors 
Our collaborators (Dr. Bernhard Kepplinger, Prof. Jeff Errington) at the Centre for Bacterial 
Cell Biology have developed a novel screening approach for the detection of potential LtaS 
inhibitors. It was observed that a Bacillus subtilis mutant with a deleted mbl gene (Δmbl) 
yielded cells that failed to grow in their correct shape and had poor viability (C-Figure 55).115,116 
Normal growth of these cells could be restored when grown in the presence of a high 
concentrations of Mg2+ (D-Figure 55).  
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Figure 55. Bacillus subtilis Δmbl mutant showing abnormal growth (C) and the same Δmbl mutant grown with 
an additional 20 mM Mg2+(D). 
 
A second mutation of the Δmbl mutant resulted in the restoration of normal growth of the 
bacterial cells without the requirement for additional Mg2+. This second mutation being the 
deletion of the genes encoding for the LtaS enzyme. As the deletion of LtaS genes appeared 
to restore the normal growth and viability of these cells, it was postulated that the Δmbl 
mutant could serve as a useful test to screen for inhibitors of the LtaS enzyme. Any compound 
that inhibits LtaS in the Δmbl mutant should mimic the deletion of the LtaS gene, restoring 
normal growth and viability of these cells without the requirement for additional Mg2+.  
To this end the Δmbl mutant was used in a high throughput screen to identify novel natural 
product inhibitors of LtaS. Extracts from approximately two thousand bacterial strains were 
screened by Dr. Kepplinger, to see if they caused recovery of the Δmbl mutant in the absence 
of additional Mg2+. This would mean that these extracts may contain a compound or 
compounds that inhibit LtaS. Three of these two thousand extracts showed reproducible 
activity, with one (the extract from bacterial strain DEM30616) being selected for further 
study. After isolation of the bioactive compound (assigned as DEM30616/A), samples were 
sent to Fundación Medina for preliminary structural assignment. Based on mass spectrometry 
data in conjunction with the known literature, the structure was putatively assigned as a di-
peptide formed from two ornithine amino acids, one of which contained a hydroxamic acid 
and the other capped with a 2,3-dihydroxybenzoic acid moiety (79, Figure 56).  
 
 
Figure 56. Preliminarily assigned structure of DEM30616/A. 
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Upon inspection of the preliminarily assigned structure, DEM30616/A appeared to be a 
structural derivative of chlorocatechelins A (80) and B (81) and mirubactin (82) (Figure 57).117–
119 Chlorocatechelin A and mirubactin are both hexadentate siderophores and are produced 
from a Streptomyces sp. and Actinosynnema mirum respectively. 
 
 
Figure 57. Chemical structures of chlorocatechelins A (80) and B (81) and mirubactin (82). Structural differences 
vs DEM30616/A are highlighted in red. 
 
4.4 Project aims 
Our first priority was to carry out a detailed de novo structural elucidation of DEM30616/A, 
including the determination of the absolute stereochemistry. Our proposed structural 
assignment would then be compared to the preliminarily assigned structure provided by 
Fundación Medina. Second, due to the structural similarity to known siderophores, and our 
previous experiences, we were concerned that the observed activity of DEM30616/A may 
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have been due to the presence of minor quantities of other bioactive compounds in the tested 
samples. To address this, we decided to undertake the total synthesis of DEM30616/A. This 
would allow a comparison of our synthetic material against the natural isolate. If the same 
activity is observed between the natural product and synthetic DEM30616/A then we will have 
proven the efficacy of DEM30616/A. 
 
4.5 Structural determination of DEM30616/A.  
4.5.1 Mass Spectrometry of DEM30616/A  
Our first task in the structural elucidation of DEM30316/A was to validate the MS data 
provided by Fundación Medina. Therefore, we subjected DEM30616/A to High Resolution 
Mass Spectrometry studies. HRMS of DEM30616/A gave m/z = 427.1805 for the proposed 
[M+H]+ ion, resulting in a calculated molecular formula of C18H25O8N4. This result was in 
keeping with the proposed molecular formula of 79. 
 
4.5.2 Calculation of double bond equivalents 
Based on the proposed molecular formula of DEM30616/A, we established that there were 
eight double bond equivalents present in DEM30616/A. Again this result was in keeping with 
the preliminarily assigned structure for DEM30616/A (79). 
 
DBE = 𝐶 − (
𝐻
2
) + (
𝑁
2
) + 1 = 18 − 13 + 4 + 1 = 8. 
Equation 2. Calculation of the number of double bond equivalents in DEM30616/A (C18H25O8N4). 
 
4.6 Structural determination of DEM30616/A via 1H, 13C and 15N NMR 
4.6.1 Introduction 
In this section, we will discuss the structural elucidation of DEM30616/A. To begin, we started 
our assignment by comparing our NMR data to our HRMS data. Initial examination of the 1H 
NMR spectrum in D2O revealed a total of 18 hydrogen atoms via integration, suggesting that 
7 hydrogen atoms had undergone deuterium exchange (Figure 58). The use of D2O as NMR 
solvent also meant that there were no amide proton signals present in the 1H NMR spectrum 
to help in the assignment of the chemical structure. The 13C NMR spectra showed multiple 
duplicated carbon signals, making interpretation difficult, however a combination of HMBC 
and HSQC experiments allowed us to identify the main 13C signals associated with 
 
84 
 
DEM30616/A, totalling 18 carbon atoms which was consistent with the proposed chemical 
formula. With this initial examination completed, we next looked to assign the chemical 
structure of DEM30616/A via 2D NMR analysis, as a series of individual fragments. 
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4.6.2 Fragment 1  
Inspection of the 1H NMR showed a three proton spin system (assigned via COSY) with signals 
at 7.18, 6.98, and 6.76 ppm. The splitting pattern was indicative of a 1,2,3-trisubstituted 
aromatic ring, with the three quaternary carbons identifiable by 13C and HMBC experiments 
(P-1 to P-3). HMBC experiments showed that an additional deshielded carbon atom at 169.8 
ppm (P-7) was connected to the aromatic ring at position 1. The chemical shifts of the carbon 
signals at positions 2 and 3 were in line with what we would expect for an aromatic ring 
substituted with a hydroxyl group, however we were not able to conclusively assign which 13C 
signal corresponded to positions 2 and 3. In summary, fragment 1 consists of a 1,2,3-
trisubstituted benzene ring, with two hydroxyl groups at positions 2 and 3 and a carbonyl 
group position 7 (Figure 59).  
 
 
Figure 59. Proposed structural assignment for fragment 1 of DEM30616 (COSY = red, selected HMBC = blue). 
 
Table 11. 1H and 13C signals associated with fragment 1.  
Position δ1H multiplicity, (J in Hz) δ13C HMBC  
1 - 116.4  
2 - 146.3 or 
144.4 
 
3 -  
4 6.98 (dd, J = 7.9, 1.5 Hz, 1H) 119.5 H to C1, 2, 3, 5, 6 
5 6.76 (t, J = 8.0 Hz, 1H) 119.6 H to C1, 2, 3, 4, 6, 7 
6 7.18 (dd, J = 8.1, 1.6 Hz, 1H) 119.2 H to C 1, 2, 3, 4, 5, 7 
7 - 169.8  
 
 
4.6.3 Fragment 2  
An apparent α-proton was observed at 4.53 ppm in the 1H NMR spectrum (P-9). This showed 
a HMBC signal to a new deshielded quaternary carbon at 172.6 ppm (P-10) and a correlation 
to an amide nitrogen through a 15N-1H correlation experiment (-260.5 ppm, P-8). A COSY 
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experiment showed that this α-proton was the first of 5 proton-proton coupled 1H signals, 
with the first correlation from position 9 at 4.53 ppm to a diastereotopic methylene group 
split into two signals between 1.98-1.91 and 1.89-1.82 ppm (P-11). Both of the signals 
attributed to position 11 showed proton-proton coupling to a second methylene group at 1.76 
ppm (P-12). This signal was an overlapping multiplet with an integration of 3. Despite the 
signal overlap, the presence of the methylene group was established through HSQC and HMBC 
experiments. This penultimate methylene signal (P-12) was coupled to the final methylene 
group (P-13) at 2.99 ppm. This final methylene group was shown through a 15N-1H experiment 
to correlate to a primary amine 15N signal at -348.8 ppm (P-14).  
In summary for fragment 2, we identified a spin system consisting of an α-proton at 4.53 ppm 
(P-9) and 3 methylene groups at 1.98-1.91 and 1.89-1.82, 1.80-1.71 and 2.99 ppm (P’s 11, to 
13). We observed HMBC correlations between the proton at position 9 and two suspected 
amide carbonyl carbons at 169.8 ppm (P-7) and 172.6 ppm (P-10). In addition, we also 
observed correlations to two nitrogen atoms corresponding to the amide nitrogen at position 
8 and the primary amine nitrogen at position 14.  
 
 
Figure 60. Proposed structural assignment for fragment 2 of DEM30616/A (COSY = red, selected HMBC = blue). 
 
Table 12. 1H, 13C and 15N signals associated with fragment 2.  
*Unknown due to signal overlap 
Position δ1H multiplicity, (J  in Hz) δ13C δ15N HMBC  
8 - - -260.5 - 
9 4.53 (dd, J = 7.8, 6.4 Hz, 1H) 53.2 - H to C1, 7, 10, 11, 12 
10 - 172.6 - - 
11 1.98 – 1.91 (m, 1H) 
1.89 – 1.82 (m, 1H) 
27.8 - H to C9, 10, 12, 13 
12 1.80 – 1.71 (m, 3H) (a = 2H) 23.1 - * 
13 2.99 (ddd, J = 8.6, 6.9, 2.1 Hz, 2H) 38.8 - H to C11, 12 
14 - - -348.8 - 
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4.6.4 Fragment 3 
For the final fragment, a similar approach was employed as for fragment 2. We noted an 
apparent α-proton multiplet between 4.21 and 4.13 ppm in the 1H NMR spectrum (P-16). This 
showed a HMBC signal to a new deshielded quaternary carbon at 178.1 ppm (P-17) which, due 
to its chemical shift, we assigned as a carboxylic acid. The α-proton at position 16 also showed 
a correlation to an amide nitrogen through a 15N-1H correlation experiment (-252.9 ppm, P-
15). A COSY experiment showed that this α-proton was the first of 5 proton-proton coupled 
1H signals, with the first correlation from the α-proton (P-16) to a diastereotopic methylene 
group split into two signals between 1.80-1.71 and 1.69-1.60 ppm (P-18). The peak between 
1.80-1.71 ppm was part of the overlapping signal used for the assignment of position 12. 
Similarly, the peak found between 1.69-1.60 ppm was an overlapping multiplet, with an 
integration of 3. The two extra hydrogen signals attributed to this multiplet formed the 
penultimate methylene group at position 19. The final methylene group (P-20) was 
represented by a multiplet between 3.56-3.44 ppm. And showed HMBC coupling to a 
deshielded carbon atom at 159.5 ppm. This was shown to be a formyl carbonyl via a HSQC 
signal to a highly deshielded singlet in the 1H NMR. This highly deshielded singlet had been 
split into two signals, a major peak at 7.83 ppm and a minor one at 8.18 ppm, that when taken 
together gave an integration of one. Both the methylene group at position 20 and the formyl 
proton at position 20 showed correlations in the 15N-1H spectrum to a deshielded nitrogen 
atom at -199.3 ppm. We assigned this nitrogen as a hydroxamic acid.   
 
In summary for fragment 3, we identified a spin system consisting of an α-proton between 
4.21-4.13 ppm (P-16) and 3 methylene groups at 1.80-1.71 and 1.69-1.60, 1.69-1.60 and finally 
3.56-3.44 (P’s 18 to 20). We observed HMBC correlations between the proton at position 16 
and an amide carbonyl carbon at 172.6 ppm (P-10) and a carboxylic acid carbonyl carbon at 
178.1 ppm (P-17). In addition, we also observed correlations from the methylene group at 
position 20 and the formyl proton at position 22 to a nitrogen atom corresponding to a 
hydroxamic acid at position 21.  
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Figure 61. Proposed structural assignment for fragment 3 of DEM30616/A (COSY = red, selected HMBC = blue). 
 
Table 13. 1H, 13C and 15N signals associated with fragment 2.  
*Unknown due to signal overlap 
 
With the assignment of the final fragment accomplished, we completed the full assignment of 
the chemical structure of DEM30616/A (77). This is a di-peptide which contains a catecholate 
aromatic ring and a hydroxamic acid group. Our assignment is in keeping with that previously 
provided by Fundación Medina.  
 
 
Figure 62 Structural assignment of DEM30616/A (77) (COSY = red, selected HMBC = blue). 
 
 
 
Position δ1H multiplicity, (J  in Hz) δ13C δ15N HMBC  
15 - - -252.9 - 
16 4.21 – 4.13 (m, 1H) 54.6 - H to C10, 17 18, 19 
17 - 178.1 - - 
18 1.80 – 1.71 (m, 3H) (b = 1H)  
1.69 – 1.60 (m, 3H) (b = 1H) 
28.2 - * 
19 1.69 – 1.60 (m, 3H) (a = 2H) 22.7 - * 
20 3.56 – 3.44 (m, 2H) 50.0 - H to C16, 18, 19, 22 
21 - - -199.3 - 
22 7.83 and 8.18 (s, 1H) 159.4  H to C20 
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4.7 Advanced Marfey’s Analysis of DEM30616/A 
With the chemical structure of 79 now completed, we next wished to assign the absolute 
stereochemistry of the two ornithine residues found within DEM30616/A. Amino acid 
standards were prepared via functionalisation of L-ornithine with both Nα-(5-Fluoro-2,4-
dinitrophenyl)-L-leucinamide and Nα-(5-Fluoro-2,4-dinitrophenyl)-D-leucinamide and the 
retention times recorded (Table 14). With the synthesis and HPLC retention times of the 
ornithine amino acid standards completed, hydrolysis and functionalisation of DEM30616/A 
was carried out. DEM30616/A was hydrolysed using hydroiodic acid, followed by 
functionalisation with Nα-(5-fluoro-2,4-dinitrophenyl)-L-leucinamide. Comparison of the 
retention times of the Marfey’s functionalised amino acid standards against Marfey’s 
functionalised DEM30616/A revealed the presence of solely D-ornithine, which is consistent 
with the assigned absolute stereochemistry of the related siderophores chlorocatechelin A 
(79) and B (80) and mirubactin (81). 
 
Table 14. Retention times of Marfeys functionalised amino acid standards and hydrolysed DEM30616/A. 
Amino acid 
 
Marfey’s  
Chirality 
Retention Time 
(mins) 
Separation 
(mins) 
L-Ornithine α L 10.8 
0.6 
L-Ornithine α D 10.2 
L-Ornithine δ L 11.2 
0.0 
L-Ornithine δ D 11.2 
L-Ornithine α+δ L 16.8 
0.3 
L-Ornithine α+δ D 16.5 
DEM30616/A Ornithine α L 10.2 - 
DEM30616/A Ornithine δ L 11.2 - 
DEM30616/A Ornithine α+δ L 16.5 - 
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Figure 63. HPLC chromatogram showing the products of Nα-(5-fluoro-2,4-dinitrophenyl)-L-leucinamide 
derivitized DEM30616/A (top), L-derivitized L-ornithine (middle) and D-derivitized L-ornithine (bottom). 
 
4.8 Conclusions on structural assignment of DEM30616/A 
We have completed a de novo structural assignment of DEM30616/A (77) through a 
combination of high-resolution mass spectrometry, NMR studies and Marfey’s analysis. 
Through this work we have assigned the chemical structure of DME30616/A, a potential LtaS 
inhibitor, and its absolute stereochemistry (Figure 64). Now we sought to complete the total 
synthesis of (77) to generate synthetic material for use in bioassays to determine the efficacy 
of (77) as an LtaS inhibitor 
 
 
Figure 64. Structure of DEM30616/A including absolute stereochemistry. 
hydrolysed DEM30616/A 
functionalised with 
Marfey’s reagent 
D -ornithine standard 
 
 
L -ornithine standard 
 
 
92 
 
4.9 Total synthesis of DEM30616/A (79) 
4.9.1 Introduction 
Since DEM30616/A may indeed be a LtaS inhibitor, and having confirmed its chemical 
structure, we elected to complete the total synthesis of DEM30616/A. This would allow for a 
repeat of bioassays utilising synthetic material and subsequently prove the efficacy of isolated 
DEM30616/A. Throughout the remainder of this chapter in a bid to avoid confusion, the 
isolated, bacterially derived natural product will be referred to exclusively as DEM30616/A 
and any material produced in the laboratory will be referred to exclusively as syn.30616/A. 
 
4.9.2 Reterosynthesis of DEM30616/A (79) 
Similarly to the retrosynthesis of madurastatin C1 (25), we envisaged disconnections at the 
amide bonds of DEM30616/A (79) to be most appropriate to generate our synthetic targets. 
This would generate a 2,3-dihydroxybenzoic acid which is commercially available and can be 
easily protected. The central ornithine in DEM30616/A is unmodified and so can be inserted 
easily via amide bond coupling, with a suitable protecting group being employed for the free 
amine at the α position. For the synthesis of the final ornithine-hydroxamate we envisaged 
two different synthetic routes. The first route was influenced by our previous work outlined 
for the synthesis of madurasatin C1, through the use of Miller’s ornithine oxidation chemistry, 
we hoped to generate the required hydroxamic acid group. The second synthetic route was 
inspired by the total synthesis of the aforementioned chlorocatechelins and mirubactin see 
Scheme 22 
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Scheme 22. Retrosynthetic analysis of DEM30616/A with two routes to generate intermediate 83. 
 
4.9.3 Synthesis of amide 83 
To begin the total synthesis of DEM30616/A, we looked to protect the hydroxyl groups in 2,3-
dihydroxybenzoic acid (87). To this end, 87 was reacted with benzyl bromide in the presence 
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of potassium carbonate to generate the corresponding benzyl ester (94). Benzyl ester 94 was 
then refluxed in the presence of aqueous NaOH to generate the desired carboxylic acid (86). 
 
 
Scheme 23. Synthetic route to aromatic carboxylic acid 86 via benzylic protection and ester hydrolysis. 
 
With carboxylic acid 86 now available, we next needed to incorporate a Cbz protected D-
ornithine in order to generate amide 83. We began with the removal of the Boc group in Nα-
Boc-Nδ-Cbz-L-ornithine 95, via reaction with TFA in DCM, giving near quantitative conversion 
to the TFA salt (85).  
 
 
Scheme 24. Synthetic route to deprotected ornithine 85 via TFA mediated Boc removal. 
 
The final step for the synthesis of amide 83 was therefore to use a HATU mediated peptide 
coupling of carboxylic acid (86) with our newly prepared ornithine 85. Due to the presence of 
both a free amine and an unprotected carboxylic acid in ornithine 85, we planned to pre-treat 
carboxylic acid 86 with HATU generating intermediate 96. This, followed by the addition of 
ornithine 85, would generate the desired amide (83) and prevent self-polymerisation of 
ornithine 85. As such, carboxylic acid 86 was reacted with HATU in DMF for 10 minutes 
followed by the addition of ornithine 85 and DIPEA (Scheme 25). 1H NMR of the crude reaction 
mix showed signals corresponding to our desired product, with no signals indicating that 
polymerisation had occurred. Due to the presence of a highly polar carboxylic acid group, 
purification of 78 via silica gel column chromatography proved to be non-trivial, with much of 
the crude product lost during this purification step resulting in a relatively low yield of 32%. 
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With our desired amide 83 completed, we could then look to synthesising formylated 
ornithine 84. 
 
 
Scheme 25. Synthetic route to dipeptide 78 via HATU mediated coupling of 81 to 80. 
 
4.9.4 Synthesis of the nitrone 92 Route 1. 
As discussed in our retrosynthetic analysis, we envisaged two separate routes to generate 
formylated ornithine 84. Drawing on our experience in hydroxamic synthesis used in the total 
synthesis of madurastatin C1, we elected to begin with the method of oxidation and acid 
catalysed rearrangement (Route 1). Starting from the same protected ornithine (95) used for 
the synthesis of amide 83, we envisaged that removal of the Cbz protecting group would yield 
the free amine (93) required to generate imine 97. We could then carry out the subsequent 
oxidation and acid catalysed rearrangement to give nitrone 92.  
 
 
Scheme 26. Synthetic route to nitrone 92 via removal of the Cbz group, imine formation and oxidation/acid 
catalysed rearrangement of 95. 
 
Starting from the protected ornithine 95, hydrogenation gave the corresponding free amine 
93 in a quantitative conversion, highlighted by a complete loss of aromatic signals in the 1H 
NMR. From here imine 97 was generated via stirring 95 in the presence of benzaldehyde, KOH 
and 3 Å molecular sieves. The final step was the indirect oxidation of imine 97 using mCPBA 
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to generate the corresponding oxaziridine, immediately followed by acid catalysed 
rearrangement with TFA to generate nitrone 92. Unfortunately, nitrone 92 was isolated in low 
yields and with rapid degradation of the product observed. 
In addition to the problems in isolating nitrone 92, we had foreseen that the acid catalysed 
rearrangement to make nitrone 92 would also result in the loss of the N-Boc group. Whilst this 
initially seemed advantageous as it would allow incorporation of nitrone 92 into our previously 
synthesised peptide 83. We later realised that we would need to re-protect this amine to 
ensure the selective formylation of the hydroxylamine. The additional synthetic steps required 
in this already low yielding synthetic route coupled with the expensive nature of the ornithine 
starting material 95 lead us to conclude that this synthetic route was not viable. We therefore 
elected to use our second proposed approach (Route 2) taken from the synthesis of the 
chlocatechelins.118  
 
4.9.5 Synthesis of ornithine 88 via Route 2. 
As discussed in our retrosynthetic analysis, the second route to formylated ornithine 84 was 
based on the total synthesis of the chlocatechelin’s.118 This involved the reduction of D-
glutamic acid 91 to alcohol 90, followed by a mitzunobu type reaction between alcohol 90 and 
sulphonamide 89 to generate ornithine 88 (Scheme 27). 
 
 
Scheme 27. Synthetic route to fully protected ornithine 88 via reduction of glutamic acid and subsequent 
Mitsunobu type reaction. 
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We began with the reduction of protected D-glutamic acid 91 to alcohol 90. This was 
completed by activating the carboxylic acid with ethyl chloroformate to generate the 
corresponding anhydride. This was then reduced via reaction with sodium borohydride to 
generate alcohol 90 with an average yield of 75%. Due to the inexpensive nature of the starting 
material and the simplicity of the reaction, we were able to generate hundreds of milligrams 
of alcohol 90. In parallel to the preparation of alcohol 90, we completed the synthesis of 
sulphonamide 89. This was achieved by stirring 2-nitrobenzenesulfonyl chloride (99) with O-
benzylhydroxylamine (98) using pyridine as both solvent and base. Sulphonamide 89 was 
purified via crystallisation and the structure confirmed via NMR and X-ay crystallography. With 
the preparation of alcohol 90 and sulphonamide 89 completed, a mitsunobu type coupling 
was carried out, substituting the alcohol for the nosylated hydroxylamine, generating fully 
protected ornithine 88 in 88% yield. 
 
4.9.6 Synthesis of formylated ornithine 84 
With the synthesis of fully protected ornithine 88 completed, we could next move on to the 
removal of the nosyl group followed by formylation and removal of the Boc group to generate 
formylated ornithine 84.  
 
 
Scheme 28. Synthetic route to formylated ornithine 84 via de-nosylation, formylation and deprotection of 88. 
 
To this end we reacted the fully protected ornithine 88 with thiophenol in the presence of 
base, leading to complete loss of starting material via TLC. After purification via column 
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chromatography we obtained both our desired ornithine derived hydroxylamine 100 and by-
product 102, which is consistent with the proposed mechanism for this reaction. Formylation 
was carried out via a mixed anhydride approach. A mixture of formic acid and acetic anhydride 
was prepared and added to ornithine 100 yielding formylated ornithine 101 in 95% yield. 
Finally, the Boc protecting group was removed from the amine at the α-position via stirring a 
solution of 101 in DCM with TFA to yield 84 as the TFA salt. 
 
4.9.7 Synthesis of syn.30616/A79 
With the synthesis of formylated ornithine 84 and carboxylic acid 83 completed, the coupling 
together of these two intermediates could now be carried out to generate fully protected 
DEM30616/A 103. This, followed by a global hydrogenation/deprotection would give 
syn.30616/A 79. 
 
 
Scheme 29 Synthetic route to syn.30616/A (79) via HATU mediated peptide coupling followed by global 
hydrogenation/deprotection. 
 
To accomplish this we mixed carboxylic acid 83 with HATU, and subsequently added 
formylated ornithine 84 and DIEPEA as base. This afforded our desired di-peptide (103) in 63% 
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yield after purification via column chromatography. The final deprotection reaction was 
carried out via hydrogenation over palladium on carbon, leading to complete removal of both 
the benzyl groups and the Cbz group to generate syn.30616/A (79). Due to our experiences 
using celite as a filtration method to remove palladium on carbon causing degradation of 
synthetic madurastatin C1 (25), we looked to find an alternative filtration method that would 
avoid using celite. As such we employed the use of C8 SPE cartridges. These reverse phase 
cartridges allowed for effective filtration of the palladium on carbon, whilst circumventing the 
problem of celite contaminating our sample.  
Syn.30616/A (79) was then isolated and purified via HPLC. The HPLC sample containing our 
synthetic material contained multiple compounds, which were all isolated. Each was then 
subjected to an analytical HPLC experiment, with the retention time of one of these isolated 
compounds matching that of DEM30616/A. The HPLC peak containing what we suspected to 
be syn.30616/A (79) was collected, and analysed via mass spectrometry and 1H NMR, all of 
which matched that of the natural product DEM30616/A. We therefore had succeeded in 
synthesising syn.30616/A. One of the additional peaks collected had the same m/z value as 
DME30616/A but had a differing retention time. We therefore assigned this compound as a 
diastereomer. 
Whilst the completion of the synthesis of syn.30616/A was satisfying, HPLC isolation did not 
give perfectly clean material, as two extra aromatic signals were observed via 1H NMR. Due to 
the small quantity of sample obtained, (c. 1mg) further analytical experiments to try and 
determine the identity of the contaminant were not carried out.  
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Figure 65. NMR comparison of DEM31376/A (top) and syn.30616/A (bottom) in D2O, 700 MHz, 298 K.  
 
4.10 Biological studies using syn.30616/A (79) 
With synthetic material in hand, repeats of the bioassay experiments that had originally used 
DEM30616/A could be carried out using syn.30616, to establish the efficacy of DEM30616/A 
as a LtaS inhibitor. We would expect the same recovery of the Δmbl mutant observed when 
the bacterial cells were grown in the presence of DEM30616/A when using syn.30616/A.  
Micobiological studies were carried out by Dr. Bernard Kepplingher at the Centre for Bacterial 
Cell Biology, the outcome of which showed that this was the indeed case. The incubation 
studies carried out using syn.30616/A caused the same recovery observed when the Δmbl 
mutant was incubated with DEM30616/A without any additional Mg2+ required.  
Although the Δmbl mutant has been used as a screening method to detect potential LtaS 
inhibitors, we do not yet have any idea on the mode of action of DEM30616/A. Due to the 
structural similarity of DEM30616/A to known siderophores (chlorocatechelins A, B and 
mirubactin) and the classical chelating groups present in DEM30616/A (a catecholate and a 
hydroxamic acid) the role of DEM30616/A as a potential metal chelator should be taken into 
account. Indeed, given the reliance of the Δmbl mutant on high concentrations of Mg2+ to 
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grow properly, a bi-dentate siderophore could act as a growth factor for the Δmbl mutant, 
chelating Mg2+ and carrying it into the bacterial cell, giving a false positive result. Further 
research on the biological role of DEM30616/A will therefore need to be carried out. One 
approach would be the synthesis of non-metal chelating mimics of DEM30616/A, which are 
now accessible due to our work on the total synthesis of syn.30616/A. If these non-metal 
chelating mimics also cause recovery of the Δmbl mutant, then we would be confident that 
we have indeed discovered a novel LtaS inhibitor.   
 
4.11 Conclusions   
Lipoteichoic acid (LTA) plays an essential role in bacterial growth and virulence, and disruption 
of the production of this molecule could prove to be an effective antibacterial treatment. In 
the search for inhibitors of LtaS enzyme responsible for the production of LTA, we have 
identified a compound of interest: DEM30616/A. Using a combination of mass spectrometry, 
NMR and Marfey’s analysis, we have determined the chemical structure and assigned the 
absolute stereochemistry of DEM30616/A. With the structure assigned, we have also 
completed the total synthesis of DEM303616/A (syn.30616/A).  
During our total synthesis of DEM30616/A, we investigated two separate approaches to 
synthesise the formyl containing ornithine amino acid 84. The first approach utilising Millers 
oxidative strategy gave poor yields and required a high number of reaction steps, making this 
synthetic route unattractive. As a result, we completed the total synthesis of syn.30616/A via 
a new synthetic route based around the synthesis of chlorocatechelin. Results from biological 
assays utilising synthetic material (syn.30616/A) showed recovery of the Δmbl mutant, 
matching the results observed when using the natural product DEM30616/A. This proved the 
efficacy of the natural product via the recovery of the Δmbl mutant. Whilst we were successful 
in the total synthesis of DEM30616/A, improvements need to be made to reduce 
diastereomer production.  
Whilst we were satisfied that DEM30616/A causes recovery of the Δmbl mutant there is some 
concern that the observed recovery may not be due to inhibition of LtaS. Due to the chemical 
structure of DEM30616/A bearing classical siderophore like chelating groups, and the 
dependency of the Δmbl mutant on high concentrations of Mg2+ one could make the argument 
that DEM30616/A may be acting as a Mg2+ siderophore, transporting Mg2+ ions into the 
bacterial cell and allowing for normal growth of the mutant, without additional Mg2+ being 
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added to the growth media. Further research will be needed to establish whether 
DEM30616/A is acting as either a LtaS inhibitor or a Mg2+ siderophore growth factor.  
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 Chapter 5. Conclusions and Future Work 
 
5.1 Conclusions  
5.1.1 Introduction 
Over the course of this project the isolation, structural determination and total synthesis of 
two bacterially derived natural products has been completed. The first of these natural 
products (DEM31376/A) being a pentapeptide siderophore and the other (DEM30616/A) a di-
peptide that was investigated as a potential LtaS inhibitor. Siderophores are secondary 
metabolites that are produced by bacteria in order to acquire iron from their natural 
environment. Iron is an essential element for bacterial cell growth and function, but is 
relatively inaccessible as a nutrient for bacteria due to the rapid oxidation of Fe2+ to Fe3+ in 
aqueous aerobic environments. This leads to the production of insoluble iron oxide salts which 
then precipitate out of aqueous environments at neutral pH’s. This low availability of iron is a 
limiting factor in the growth of bacteria. DEM31376/A is the pentapeptide siderophore 
produced by the novel bacterial strain DEM31376. 
The second siderophore investigated in this project was DEM30616/A, a compound found as 
a result of an antibiotic screening study to identify novel LtaS inhibitors. Lipotechioic acid is a 
vital component of the bacterial cell wall in Gram positive bacteria. Inhibition of one of the 
enzymes responsible for producing lipoteichoic acid, namely LtaS, could lead to the discovery 
of new antibiotic compounds.  
 
5.2 Summary of research on DEM31376/A 
A large-scale fermentation of the bacterial strain DEM30616 was carried out by us in 
collaboration with Demuris Ltd. and lead to the isolation of 283 mg of DEM31376/A. With this, 
structural determination was carried out via a wide range of analytical techniques. High 
resolution mass spectrometry was used to identify the molecular ion for DEM31376/A, and 
the resulting chemical formula and double bond equivalents were calculated. From here, 1D 
and 2D NMR experiments allowed us to assign the chemical structure of DEM31376/A, whilst 
the stereochemistry was assigned via advanced Marfey’s analysis showing that DEM31376/A 
was comprised of D-serine, and two L-ornithine amino acids.  
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Figure 66. Chemical structure of madurastatin C1 (DEM31376/A) 
 
With this completed we discovered that we had re-isolated the known natural product 
madurastatin C1. However, the structure of madurastatin C1 described in the literature was 
different to that assigned by us. This was due to differing structural assignments of the cyclised 
serine, assigned as a three-membered aziridine ring in the literature, and as a five-membered 
oxazoline ring by ourselves. Synthesis of two standards containing a five-membered oxaozline 
(32) and a three membered aziridine (47) were completed and their 13C NMR spectra 
compared to that of madurastatin C1. With this we were able to show not only that the 
assigned chemical structure of madurastatin C1 was incorrect, but the entire family of 
madurastatin siderophores (A1, B1, B3) and the related natural product MBJ-0035 should be 
re-assigned to contain a five-membered oxazoline as opposed to the currently reported three-
membered aziridine. This work culminated in a publication in the ACS Journal of Natural 
Products in 2017.  
 
 
Figure 67. Chemical structures of our synthesised oxazoline model (32) and aziridine model (34) 
 
With the structure of DEM31376/A now fully assigned, we next moved our attention to the 
total synthesis of DEM31376/A. This began with a retro-synthetic analysis of madurastatin C1, 
which allowed us to come up with a viable synthetic rout based around disconnections at the 
amide/hydroxamic acid bonds. In order to generate the required hydroxamic acids, we elected 
to use oxidation chemistry at the ornithine amino acids. Meanwhile, the amide bond coupling 
reactions carried out utilising DCC, EDC and HATU. A convergent strategy designed around 
building the two halves of madurastatin C1 separately and then joining these together in a 
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late stage peptide coupling reaction was carried out in a bid to maximise yields and reduce 
the risk of diastereomer formation (see schemes 30-32). 
 
 
Scheme 30. Synthetic route to the left-hand half (73) of madurastatin C1 (DEM31376/A) 
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Scheme 31. Synthetic route to the right-hand half (72) of madurastatin C1 (DEM31376/A) 
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Scheme 32. Synthetic route showing the coupling of the left (73) and right (72) halves of madurastatin C1 
(DEM30616/A), followed by a ring cyclisation and global deprotection to yield the final product madurastatin C1 
(DEM31376/A) (25) 
 
The synthetic route allowed us to generate the constituent amino acids in large quantities 
(100’s of milligrams) and in good overall yields. We also showed that ring cyclisation through 
the use of DAST was an appropriate step to generate the five-membered oxazoline ring 
without generating unwanted by-products as was the case with thionyl chloride. Whilst the 
total synthesis was not fully achieved as the final product degraded in the presence of celite 
and palladium on carbon after the filtration step, we do believe that this synthetic procedure 
would yield the correct natural product, provided a more efficient filtration step was used 
after the final hydrogenation step. 
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5.3 Future research on DEM31376/A (madurastatin C1) 
5.3.1 Improvements to overall yield. 
First and foremost, the total synthesis of madurastatin C1 would need to be completed. As we 
were unsuccessful in the isolation of synthetic madurastatin C1 during this project, that would 
be the primary objective of any future research. During the total synthesis of madurastatin C1 
there are several notable steps in which synthetic yields were reduced, which could be 
mitigated via new approaches. In the coupling of the left (73) and right (72) hand half’s of 
madurastatin C1, we also observed the cyclised by-product (75). In order to mitigate this in 
future, the alcohol group on serine should be protected from the outset with an easily 
removable protecting group. As there are other alcohol functionalities present in 
madurastatin C1, the protecting group used for the serine hydroxyl should be different from 
these to allow for selective removal. The use of a silicon protecting group such as a TBDMS 
group would allow for selective late stage deprotection of the serine hydroxyl group, to allow 
for the ring cyclisation reaction to occur, without causing the other benzyl and Cbz protecting 
groups to be removed. The protection of the serine-hydroxyl functionality would give 
increased yields via preventing any unwanted side reactions occurring at this position. In 
addition to the use of a serine protecting group, we would also employ a similar strategy used 
after the global deprotection of our other natural product, DEM30616/A, to remove the 
palladium on carbon after the global deprotection reaction. This would involve filtration of the 
reaction mix through a SPE C8 cartridge as opposed to filtration through celite. This was shown 
to successfully trap the palladium on carbon in the synthesis of DEM30616/A and would 
prevent the degradation observed at the end of our total synthesis of madurastatin C1. 
 
5.3.2 Alternate synthetic targets. 
As discussed in Chapter 1 section 1.4.4.3, sideromycins have been generated in the laboratory 
by coupling antibiotic compounds to known siderophores. These antibiotics can have 
extremely large surface area or molecular weight but are still taken up by some bacterial 
species. This would be an interesting avenue to explore, as the N-methyl group in 
madurastatin C1 could easily be substituted for a N-R functionality. This R group could be a 
linked antibiotic compound to generate a novel synthetic sideromycin analogue. This 
approach could be completed by ether incorporating the antibiotic molecule into the N-
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methyl ornithine amino acid (54) during a total synthesis or via coupling of an antibiotic 
molecule with bacterially derived madurastatin C1.  
 
5.4 Summary of research on DEM30616/A 
DEM30616/A was discovered during a screening study to find a novel LtaS inhibitor. After its 
discovery, we were able to solve its chemical structure via a mixture of HRMS and 1D and 2D 
NMR studies. The result of this de-novo structure determination was in keeping with the 
chemical structure preliminarily assigned by Fundación Medina. Upon determination of the 
chemical structure it was noted that DEM30616/A is very closely related to the 
chlorocatechelin’s A and B as well as mirubactin. Indeed the chemical structure is so similar 
that, following the convention of the naming of the chlorocatechelins, DEM30616/A should 
be named mirubactin B.  With the chemical structure solved, we then went on to assign the 
absolute stereochemistry of DEM30616/A through Marfey’s analysis, showing that 
DEM30616/A contained two D-ornithine amino acids.  
 
 
Scheme 33. Chemical structure of DEM30616/A. 
 
With the chemical structure and absolute stereochemistry assigned for DEM30616/A, we next 
sought to complete the total synthesis of 79. With this synthetic material (syn.30616) we 
hoped to be able to re-create the biological activity observed for the natural product, helping 
to prove the efficacy of (79) as an LtaS inhibitor. A retrosynthetic analysis was carried out, with 
disconnections being made at the amide bonds and the formyl group of the hydroxamic acid. 
We carried out the total synthesis of DEM30616/A using the approach used in the total 
synthesis of the chlorocatechelins and mirubactin.117–119 This utilised D-glutamic acid followed 
by activated reduction and mitsunobu chemistry to generate the required formylated 
hydroxylamine ornithine amino acid. In addition to this, filtration of the crude product 
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(syn.30616) after the final hydrogenation reaction was carried out through the use of C8 SPE 
cartridges, as recommended to us by Prof. Marvin Miller. 121 This prevented the degradation 
seen for synthetic madurastatin C1. 
 
 
Scheme 34. Synthesis of the left-hand side of DEM30616/A (83). 
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Scheme 35. Synthesis of the right-hand side (formylated ornithine-hydroxylaimne) of DEM30616/A (84) 
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Scheme 36. Synthetic route showing the coupling of the left (83) and right (84) halves of Syn.30616, followed by 
a global deprotection to yield the final product (79). 
 
To this end, we successfully developed a synthetic route to generate (79), ultimately 
completing the total synthesis and isolating 1 mg of (79) via HPLC. Comparison of the 1H NMR 
and HPLC retention times of syn.30616/A against those of the isolated natural product showed 
that we had successfully synthesised 79. With this competed, the material was handed over 
to our microbiology colleagues at the Centre for Bacterial Cell Biology, who re-ran their 
inhibition experiments with syn.30616, and showed that the same outcome was observed 
with the synthetic material, lending support to the theory that 79 is indeed an LtaS inhibitor. 
 
5.5 Future research on DEM30616/A (syn.30616) 
5.5.1 Improvements to overall yield. 
Whist the total synthesis of syn.30616 was successful, only 1 mg of material was isolated. In 
addition to this low mass of material, we also suspect that diasterimers have also been 
generated due to the presence of a HPLC peak with the same m/z value and UV-Vis trace as 
that of syn.30616 but with a different retention time to that of the natural product. As such, 
improvements to the overall yield should be attempted. The reaction with the lowest overall 
yield was the first amide bond forming reaction to make 83 (32%) and required multiple 
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rounds of column chromatography to isolate. Optimisation of the reaction conditions and 
isolation of (83) should improve the overall yield of this reaction. 
Another area in which we believe improvements could be made to the overall yield could be 
in the synthesis of (101). We believe that this synthetic route could be reduced from five steps 
to three. This could be achieved via generation of amide (104, scheme 37) and then use of this 
in the Mitsunobu type reaction to generate (101). If this reaction can be completed 
successfully, then it would shorten the number of steps required to complete the synthesis of 
syn30616 and therefore give higher yields overall. 
 
 
Scheme 37. Proposed alternative synthetic route to generate (101) in one step from (90). 
 
5.5.2 Alternate synthetic targets. 
Due to the role DEM30616/A as a potential LtaS inhibitor, the synthesis of structural 
derivatives is of interest. Modifications to syn30616 would allow us to probe the mode of 
action of this potential antibiotic molecule. For example, it would be interesting to discover if 
inversion of the stereochemistry of this molecule gave an active or inactive molecule. If this 
derivative with inverted stereochemistry was still active it could suggest that the role of this 
molecule is not as an enzyme inhibitor (as these are usually highly selective for a specific 
chirality of molecule). Further alterations could also be made by changing the functional 
groups, particularly the metal chelating catecholate and hydroxamic acid groups. The 
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catecholate could be modified by removing one or both hydroxyl groups, whilst the 
hydroxamic acid could be replaced with the corresponding free amine or a simple amide. 
 
5.5.3 Microbiological studies 
Due to the anticipated role as an LtaS inhibitor, several microbiological studies will need to be 
carried out in order to determine the mode of action of DEM30616/A. First of all, we need to 
account for the inherent flaw in the bioassay used to identify this potential LtaS inhibitor. This 
flaw is that the recovery of correct bacterial growth can be due to either the presence of high 
concentrations of Mg2+ or an LtaS inhibitor. If DEM30616/A is acting as a Mg2+ chelator, 
allowing transport into the bacterial cell, then this could lead to the observed bacterial growth 
without any inhibition of LtaS occurring at all. This problem could be investigated in several 
ways. Firstly, isolated DEM30616/A should be mixed with a source of Mg2+ and analysed to 
see whether DE30616/A is indeed capable of chelating Mg2+. If this is indeed the case then 
isolated DEM30616/A should be fed to several different bacterial strains including strain 
DEM30616. If DEM30616/A is indeed acting as an LtaS inhibitor then it should show antibiotic 
activity against the bacterial strains tested. Conversely, if DEM30616/A is merely acting as a 
Mg2+ shuttle, then it should not show any antibiotic activity. Modifying the metal chelating 
functional groups found in DEM30616/A to make them none-chelating and repeating the 
feeding studies against the Δmbl mutant could also prove useful, if no growth recovery is 
observed when fed with non-metal chelating DEM30616/A then it may suggest that the metal 
chelating and transport role is providing the bacterial recovery. However this result would 
need to be carefully examine as significantly changing the solubility, lipophilicity and 
molecular weight of DEM30616/A to make structural derivatives could stop its antibiotic 
activity, giving a false positive result toward a Mg2+ transport hypothesis.  
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Chapter 6 – Experimental  
 
6.1 General experimental information 
6.1.1 Analysis 
Thin-layer chromatography was conducted on TLC silica gel 60 F254 plates and visualised using 
UV light. 1H and 13C{1H} NMR spectra were recorded on a Bruker Avance III 700 MHz, Bruker 
Avance II HD 500 MHz, Bruker Avance II 400 MHz or Bruker Avance III 300 MHz spectrometer. 
Infrared spectra were recorded on a Varian 800 FT-IR Scimitar Series spectrometer. Melting 
points were obtained using a Sturart SMP3 melting point apparatus. High resolution mass 
spectra were obtained from the National Mass Spectrometry Facility (Swansea University) or 
Pinnacle (Newcastle University). LCMS was performed on an Agilent Infinity series HPLC, 
Agilent eclipse plus, using a C18 3.5 μM, 4.6 x 100 mm column with a Bruker micrOTOF II mass 
spectrometer. X-ray diffraction data were measured at 150 K on a Gemini ultra diffractometer 
equipped with an Enhance Ultra X-ray source (λCuKα = 1.54184). Through the Olex2 interface, 
the structures were solved with the XT structure solution program using intrinsic phasing and 
refined with the XL refinement package using least squares minimisation. Optical rotation 
measurements were obtained with a POLAAR 2001 polarimiter at λ = 589 nm using a 0.5 dm 
cell path length at 25 °C in spectrophotometric grade methanol. 
 
6.1.2 Chemical procedures 
Standard Schlenk techniques were used for all chemical reactions using air sensitive reagents 
under an atmosphere of nitrogen. Dry solvents were distilled under an atmosphere of 
nitrogen; THF and Et2O were distilled from sodium/benzophenone, toluene was distilled from 
sodium whilst DCM was distilled from calcium hydride, all were then used directly. Manual 
column chromatography was carried out using Geduran silicagel 60 (40 – 63 μm). Celite Filter 
aid, Super-cel was used without additional pre-treatment. Automated flash column 
chromatography was performed using a biotage isolera One using KP-Sil SNAP C18 30 g 
cartridges. mCPBA was purified by dissolving 2 g of mCPBA in 20 mL of diethyl ether. This was 
then washed (3 x 10 mL) with pH 7.5 buffered aqueous solution (20.5 mL 0.1 M NaOH, 12.5 
mL 0.2 M KH2PO4, 17 mL H2O) and the ether layer evaporated under reduced pressure to give 
high purity mCPBA. 
  
 
116 
 
Isolation of DEM31376/A/madurastatin C1 (25)  
The following isolation procedure is taken directly from the supporting information of our 
publication entitled: Structural Reassignment and Absolute Stereochemistry of Madurastatin 
C1 (MBJ-0034) and the Related Aziridine Siderophores: Madurastatins A1, B1, and MBJ-
0035.99 
Actinomadura sp. DEM31376 was cultivated on ISP2-agar plates [4 gL-1 Yeast extract, 10 gL-1 
malt extract, 4 g L-1 glucose, 1% agar, dissolved in 1 L of distilled H2O (pH 7.2) and sterilized 
by autoclaving for 30 min at 121 °C] at 30 °C for 7 days. A loopfull of vegetative cells from the 
ISP2 agar plate was taken and inoculated into 100 mL flask containing 10 mL ISP2 media and 
incubated at 30 °C for 3 days with rotatory shaking (140 rpm). This culture was used (250 µL) 
to inoculate a 500 mL flask containing 50 mL ISP2 media which was incubated at 30 °C for a 
further 3 days with orbital shaking. Finally, the seed culture of 500 mL ISP2 media (in 2.5 L 
baffled flask) was inoculated using 25 mL of the above culture and incubated at 30 °C for 3 
days with orbital shaking. This was used to inoculate 18 L of ISP2 media (supplemented with 
0.1% polypropylene glycol) in 20 L stirred tank reactor (Applikon). Actinomadura sp. 
DEM31376 was cultivated for 11 days at 30 °C. Twenty seven samples were collected over 11 
days for further analysis. The pH was set to 7 at the beginning but was not maintained 
throughout the cultivation. The dissolved oxygen was controlled at 50% via the agitation 
speed (starting speed 400 rpm). Compressed air was applied to the vessel at 1 v/v/minute. 
The phosphatase concentration of samples collected from 20 L stir tank was measured by 
addition of 1 mL of Reagent ASA (0.25% Ammonium molybdate, 0.3 M sulphuric acid, and 1% 
ascorbic acid) to 85 μl of sample and KH2PO4 standards in the range of 0.0125 to 8 mM and 
incubated for 90 minutes at 37 °C. Reactions were stopped by adding 400 μL of 2 M sulphuric 
acid and absorbance was measured at 820 nm. The concentration was calculated from the 
KH2PO4 calibration curve. Glucose concentration of samples was measured using a SD 
Codefree Blood glucose monitoring system with disposable test strips. For the isolation of 
madurastatin C1, cultivation of Actinomadura sp. DEM31376 in a 20 L stirred tank reactor was 
repeated as described above and broth was collected after 5 days. The harvested culture broth 
was stirred with 320 g resin beads (Amberlite XAD16N, Sigma) for 16 hours at room 
temperature, followed by filtration. The beads were then washed with deionized H2O (3 × 2 L) 
and extracted with MeOH (3.5 L) with stirring for three hours at room temperature. The MeOH 
extract was filtered and evaporated under reduced pressure to yield 5.48 g of crude material. 
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The crude was then dissolved in 50 mL of deionized H2O and loaded onto a pre-hydrated 10 g 
HyperSep™ C8 cartridge (Thermo Scientific™) using a Vacuum manifold (Thames Restek). The 
cartridge was then washed with water (100 mL) and the aqueous collected. The cartridge was 
then washed with 100 mL of 25, 50 and 100% H2O:MeOH. The 50 and 100% H2O:MeOH 
fractions were combined, dried under reduced pressure and dissolved in 50 mL deionized H2O. 
This was subjected to reversed phase chromatography using Biotage Isolera One system 
equipped with 30 g SNAP ultra C18 column (Biotage). Eluents A and B were 0.1% formic acid 
in water and 0.1% formic acid in MeCN respectively. The gradient consisted of wash with 
eluent A for 1 minute followed by linear gradient of 0 – 100% (B) over 10 minutes with a hold 
at 100% (B) for a final minute, with a flow rate of 25 mL/min. The major fraction, eluted 
between 40 - 60% MeCN, was dried under reduced pressure to yield 237.8 mg of madurastatin 
C1 (25).  
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NMR assignment of DEM31376/A/madurastatin C1 (25) 
 
 
Table 15. NMR data for madurastatin C1 in D6-DMSO at 298 K, 700 MHz, 1H NMR collected at 700 MHz, 13C{1H} 
NMR collected at 176 MHz, 15N shifts were measured indirectly by 1H-15N HMBC performed at both 8 and 12 Hz, 
referencing against liquid NH3 
Position δ1H multi, (J in Hz) δ13C δ15N HMBC  
1 - 159.1   
2 7.01 dd (J = 8.3, 1.1 Hz, 1H) 116.6  H to C6, 4, 1, 7 
3 7.47 ddd (J = 8.7, 7.3, 1.8 Hz, 1H) 134.1  H to C6, 5, 1 
4 6.97 – 6.93 (m, 1H) 119.1  H to C6, 2, 5, 3, 1 
5 7.65 dd (J = 7.8, 1.8 Hz, 1H) 128.1  H to C2, 3, 1, 7 
6 - 109.9   
7 - 165.9   
8 - - 208.2 N to H9, 10 
9 5.01 dd, (J = 10.4, 7.7 Hz, 1H) 67.4  H to C10, 6, 7, 11 
10 4.65 dd (J = 10.5, 8.4 Hz, 1H) 
4.52 t (J = 8.0 Hz, 1H) 
69.4  H to C9, 7, 11, 10 
H to C9, 7, 11, 10 
11 - 170.2   
12 8.52 t (J = 5.9 Hz, 1H) - 109.2 H to C13, 14, 11 
N to H13 
13 3.75 dd (J = 16.5, 6.1 Hz, 1H) 
3.67 dd (J = 16.5, 5.7 Hz, 1H) 
42.2  H to C14, 11 
H to C14, 11 
14 - 168.4   
15 7.93 t (J = 5.8 Hz, 1H), - 112.5 H to C16, 14 
N to H13, 17 
16 3.28 – 3.22 (m, 2H) 34.6  H to C17, 14, 18 
17 2.53 – 2.51 (m, 2H)  32.0  H to C16, 18 
18 - 170.9   
19 - - 175.9 N to H20, 21 
20 3.49 – 3.42 (m, 4H)(2H) 47.0  H to C21, 22, 18 
21 1.58 tt (J = 16.5, 6.7 Hz, 2H) 22.8  H to C22, 20, 23 
22 1.40 ddd (J = 15.9, 13.1, 6.8 Hz, 1H)  
1.48 ddt, (J = 11.7, 9.8, 5.9 Hz, 1H) 
30.2  H to C20, 23, 26 
H to C20, 23, 26 
23 2.87 t (J = 6.6 Hz, 1H) 63.7  H to C21, 22, 25, 26 
24 - - 29.1 N to H25, 22 
25 2.21 (s, 3H) 34.2  H to C23 
26 - 173.5   
27 8.11 d (J = 8.3 Hz, 1H) - 118.8 H to C28, 33, 26 
N to H27, 28, 23, 29 
28 4.32 ddd (J =10.9, 8.2, 5.3 Hz, 1H) 49.4  H to C30, 29, 33, 26 
29 1.96 – 1.82 (m, 3H) (1H) 
1.67 qd (J =12.5, 4.3, 1H) 
27.8  H to C30, 29, 33 
H to C30, 28, 31, 33 
30 1.96 – 1.82 (m, 3H) (2H) 20.4   
31 3.49 – 3.42 (m, 4H) (2H) 51.2  H to C30, 29, 33 
32 - - 171.8 N to H31, 29 
33 - 165.0 
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(S)-2-acetamido-3-methoxy-3-oxopropyl 2-hydroxybenzoate (43) 
 
 
 
Following a modified procedure outlined by Miller et al.89, to a stirred suspension of L-serine 
methyl ester hydrochloride (35) (0.78 g, 5.0 mmol, 1 eq) in DCM (10 mL) at 0 °C was added 
DIPEA (2.2 mL, 12.5 mmol, 2.5 eq) and the mixture stirred for 5 minutes. The resulting 
suspension was then added dropwise to a solution of 2-(chlorocarbonyl)phenyl acetate (37) 
(0.99 g, 5.0 mmol, 1 eq) in DCM (5 mL) and the resulting mixture allowed to warm to room 
temperature and stirred overnight. The solution was diluted with DCM (100 mL) and washed 
with 1 M HCl(aq) (3 x 50 mL), saturated NaHCO3(aq) (3 x 50 mL) and brine (30 mL). The organic 
layer was then dried over Na2SO3, filtered, and concentrated under reduced pressure to give 
a brown solid. This was then purified via silica gel column chromatography (EtOAc/DCM 9:1, 
Rf = 0.18, UV light) to give (S)-2-acetamido-3-methoxy-3-oxopropyl 2-hydroxybenzoate (43) 
(0.579 g, 2.06 mmol, 41%) as a white solid.  
 
Mp = 89=91 °C. [α]D = -3.63 ° (c = 1, MeOH). 1H NMR (300 MHz, Chloroform-d) δ 10.48 (d, J = 
1 Hz, 1H1), 7.73 (ddd, J = 8.0, 1.8, 0.5 Hz, 1H), 7.47 (ddd, J = 8.7, 7.2, 1.7 Hz, 1H), 6.98 (ddd, J = 
8.4, 1.1, 0.5 Hz, 1H), 6.88 (ddd, J = 8.2, 7.3, 1.1 Hz, 1H), 6.41 (d, J = 7.6 Hz, 1H), 5.00 (dt, J = 7.4, 
3.6 Hz, 1H), 4.70 (dd, J = 11.3, 3.4 Hz, 1H), 4.64 (dd, J = 11.4, 3.8 Hz, 1H), 3.81 (s, 3H), 2.06 (s, 
3H). 13C NMR (75 MHz, Chloroform-d) δ 170.09, 170.07, 169.68, 161.9, 136.4, 129.9, 119.5, 
117.9, 111.8, 64.9, 53.2, 51.8, 23.3. IR (neat): υmax/cm-1 3277.4, 3207.2, 1734.8, 1682.2. HRMS 
(pNSI) calcd for C13H16NO6 [M+H]+: 282.0972, found 282.0971. 
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2-(benzyloxy)benzoyl chloride (39) 
 
 
 
To a stirred suspension of 2-benzyloxybenzoic acid (38) (1.00 g, 4.38 mmol, 1.0 eq) in dry 
toluene (4 mL) was added thionyl chloride (0.32 ml, 4.42 mmol, 1.01  eq) and a reflux 
condenser added. The mixture was then stirred under reflux for 4 hours, after which time the 
sample was concentrated under reduced pressure to yield crude 2-(benzyloxy)benzoyl 
chloride (39) which was used without further purification.  
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Methyl (2-(benzyloxy)benzoyl)-L-serinate (41) 
 
 
Following the procedure outlined by Miller et al.89, to a stirred suspension of L-serine methyl 
ester hydrochloride (1.343 g, 8.6 mmol, 1.0 eq) in DCM (5 mL) at 0 °C was added Et3N (3.0 ml, 
21.6 mmol, 2.5 eq) and the mixture stirred for 5 minutes. The resulting suspension was then 
added dropwise to a solution of 2-(benzyloxy)benzoyl chloride (39) (2.23 g, 8.6 mmol, 1 eq) in 
DCM (5 mL) at -78 °C and the resulting mixture allowed to warm to room temperature and 
stirred overnight. The solution was diluted with DCM (20 mL) and washed with 1 M HCl(aq) (50 
mL), saturated NaHCO3(aq) (50 mL) and saturated brine (30 mL). The organic layer was then 
dried over Na2SO4, filtered, and concentrated under reduced pressure to give methyl (2-
(benzyloxy)benzoyl)-L-serinate (41) (2.798 g, 8.5 mmol, 99%) as a white powder. X-Ray grade 
crystals were grown from slow evaporation of a 3mg/mL solution in DCM.  
 
Mp = 125-127 °C [lit: 128-129 °C][89]. [α]D +29.0 ° (c = 0.2, MeOH). Rf = 0.25(DCM/EtOAc 2:1,  
UV light) 1H NMR (400 MHz, CDCl3) δ 8.76 (d, J = 7.1 Hz, 1H13), 8.20 (dd, J = 7.8, 1.8 Hz, 1HAr), 
7.54 – 7.33 (m, 6HAr), 7.17 – 7.04 (m, 2HAr), 5.30 – 5.21 (m, 2H5), 4.84 (dt, J = 7.1, 3.9 Hz, 1H14), 
3.95 – 3.85 (m, 2H15), 3.70 (s, 3H18), 2.14 (s, 1H16). 13C NMR (101 MHz, CDCl3) δ 170.917, 165.712, 
157.2Ar, 135.7Ar, 133.4Ar, 132.6Ar, 129.02, 128.81, 128.33, 121.7Ar, 121.4Ar, 113.0Ar, 71.65, 63.915, 
55.414, 52.718. IR (neat): υmax/cm-1 3325, 2930, 2851, 1736, 1625. HRMS (pNSI) calcd for 
C18H20NO5 [M+H]+: 330.1336, found 330.1337 
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Methyl (S)-2-(2-(benzyloxy)phenyl)-4,5-dihydrooxazole-4-carboxylate (32) and methyl (R)-2-(2-
(benzyloxy)benzamido)-3-chloropropanoate (44) 
 
 
 
Method 1) Following the procedure outlined by Miller et al.89, to a stirred solution of methyl 
(2-(benzyloxy)benzoyl)-L-serinate (41) (0.200 g, 0.6 mmol, 1 eq) in DCM (4 mL) under an 
atmosphere of nitrogen at room temperature was added SOCl2 (0.31 mL, 4.3 mmol, 7.0 eq). 
The resulting mixture was stirred for 1 hour and then solid potassium carbonate (1.174 g, 8.5 
mmol, 14.0 eq) was added in one portion and the mixture stirred at room temperature for 
one hour. After this time saturated NaHCO3(aq) was added (10 mL) and the emulsion extracted 
with DCM (50 mL). The organics were then washed with water (50 mL) and saturated brine 
(20 mL). The organic layer was then dried over Na2SO4, filtered and concentrated under 
reduced pressure to give a white solid. This was then purified via silica gel column 
chromatography (DCM/EtOAc 9:1) to give methyl (S)-2-(2-(benzyloxy)phenyl)-4,5-
dihydrooxazole-4-carboxylate (32) (0.064 g, 0.20 mmol, 34%) as a white solid and methyl (R)-
2-(2-(benzyloxy)benzamido)-3-chloropropanoate (44) (0.095 g, 0.27 mmol, 45%) as a white 
solid. 
 
Method 2) Following a modified procedure adapted from Williams et al.91, to a stirred solution 
of methyl (2-(benzyloxy)benzoyl)-L-serinate (41) (0.165 g, 0.5 mmol, 1 eq) in DCM (4 mL) under 
an atmosphere of nitrogen at -78 °C was added DAST (0.079 mL, 0.6 mmol, 1.2 eq). The 
resulting mixture was stirred for 2 hours and then solid potassium carbonate (0.192 g, 1.25 
mmol, 2.5 eq) was added in one portion and the mixture allowed to warm to room 
temperature over one hour. After this time saturated NaHCO3(aq) was added (10 mL) and the 
emulsion extracted with DCM (3 x 20 mL). The organics were then washed with water (2 x 20 
mL) and saturated brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure to give a white solid. This was then purified via silica gel column chromatography 
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(EtOAc/DCM 1:9 Rf = 0.38, UV light) to give methyl (S)-2-(2-(benzyloxy)phenyl)-4,5-
dihydrooxazole-4-carboxylate (32) (0.122 g, 0.39 mmol, 79%) as a white solid. 
 
Methyl (S)-2-(2-(benzyloxy)phenyl)-4,5-dihydrooxazole-4-carboxylate (32)  
 
 
 
Mp = 121-122 °C [lit: 121 – 123 °C][89]. [α]D = +71.2 ° (C = 0.5, MeOH) 1H NMR (700 MHz, DMSO-
d6) δ 7.67 (dd, J = 7.6, 1.8 Hz, 1H), 7.53 – 7.51 (m, 2H3), 7.50 (ddd, J = 8.4, 7.4, 1.9 Hz, 1H), 7.41 
– 7.35 (m, 2H2), 7.32 – 7.28 (m, 1H1), 7.22 (dd, J = 8.5, 0.9 Hz, 1H), 7.03 (td, J = 7.5, 1.0 Hz, 1H), 
5.22 (s, 2H5), 4.97 (dd, J = 10.3, 7.9 Hz, 1H13), 4.56 (dd, J = 10.3, 8.6 Hz, 1H14a), 4.53 (dd, J = 8.6, 
7.8 Hz, 1H14b), 3.71 (s, 3H16). 13C NMR (176 MHz, DMSO-d6) δ 171.515, 164.212, 157.06, 137.14, 
132.8Ar, 131.0Ar, 128.32, 127.41, 126.73, 120.5, 116.711, 114.0, 69.55, 69.014, 68.213, 52.216. 1H 
NMR (700 MHz, MeOD) δ 7.68 (dd, J = 7.7, 1.8 Hz, 1H), 7.50 – 7.44 (m, 3H), 7.38 – 7.34 (m, 
2H), 7.30 – 7.25 (m, 1H), 7.16 (d, J = 8.4 Hz, 1H), 7.02 (td, J = 7.6, 0.9 Hz, 1H), 5.21 (s, 2H), 4.97 
(dd, J = 10.5, 7.6 Hz, 1H), 4.67 (dd, J = 8.7, 7.6 Hz, 1H), 4.62 (dd, J = 10.5, 8.8 Hz, 1H), 3.79 (s, 
3H). 13C NMR (176 MHz, MeOD) δ 173.0, 168.1, 159.0, 138.4, 134.2, 132.1, 129.4, 128.7, 128.1, 
121.7, 118.1, 115.0, 71.5, 70.8, 69.3, 53.1. 1H NMR (300 MHz, CDCl3) δ 7.84 – 7.76 (m, 1H), 
7.55 – 7.46 (m, 2H), 7.44 – 7.28 (m, 4H), 7.04 – 6.93 (m, 2H), 5.19 (s, 2H), 4.98 (dd, J = 10.7, 
8.1 Hz, 1H), 4.68 (dd, J = 8.7, 8.1 Hz, 1H), 4.58 (dd, J = 10.7, 8.7 Hz, 1H), 3.81 (s, 3H). 13C NMR 
(75 MHz, CDCl3) δ 171.9, 165.8, 157.8, 137.0, 132.9, 131.8, 128.6, 127.8, 126.9, 120.9, 117.4, 
113.9, 77.2, 70.8, 69.4, 68.9, 52.8. IR (neat): υmax/cm-1 3314, 3038, 2952, 2852, 1732, 1690, 
1645. HRMS (pNSI) calcd for C18H18NO4 [M+H]+: 312.1230, found 312.1230. 
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Methyl (R)-2-(2-(benzyloxy)benzamido)-3-chloropropanoate (44) 
 
 
[α]D = +20.0 ° (C = 0.05, MeOH) 1H NMR (300 MHz, Chloroform-d) δ 8.88 (d, J = 7.6 Hz, 1H13), 
8.29 – 8.14 (m, 1HAr), 7.53 – 7.31 (m, 6HAr), 7.09 (ddd, J = 9.1, 7.8, 1.3 Hz, 2HAr), 5.26 (s, 2H5), 
5.21 (dt, J = 7.1, 3.3 Hz, 1H14), 3.97 (dd, J = 11.3, 3.3 Hz, 1H15a), 3.87 (dd, J = 11.2, 3.5 Hz, 1H15b), 
3.69 (s, 3H17). 13C NMR (75 MHz, Chloroform-d) δ 169.416, 165.112, 157.3Ar, 135.4Ar, 133.5Ar, 
132.6Ar, 128.9Ar, 128.7Ar, 128.4Ar, 121.6Ar, 120.9Ar, 112.9Ar, 71.55, 53.814, 52.917, 45.315. IR 
(neat): υmax/cm-1 3359.0, 1745.0, 1645.1, 753.6. HRMS (pNSI) calcd for C18H19ClNO4 [M+H]+: 
348.0997, found 348.1007. 
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Methyl (S)-1-tritylaziridine-2-carboxylate (47) 
 
 
 
Following a modified procedure adapted from Carlson et al.93, to a stirred solution of N-Trityl-
L-serine methyl ester (45) (9.036 g, 25.0 mmol, 1 eq) in DCM (20 mL) at room temperature was 
added Et3N (5.27 mL, 37.5 mmol, 1.5 eq). The solution was then cooled to 0 °C in an ice bath 
and methanesulphonyl chloride (2.32 mL, 60.0 mmol, 2.4 eq) was added dropwise. After 
complete addition, the ice bath was removed and the reaction stirred at room temperature 
overnight. The reaction was quenched via the addition of saturated NaHCO3(aq) and the slurry 
extracted with DCM (20 mL). The organic layer was collected, washed with water (2 x 40 mL), 
saturated brine (40 mL), dried over Na2SO3, filtered, and the organics removed under reduced 
pressure to yield the crude mesylate as a yellow oil. This oil was then taken and dissolved in 
THF (10 mL) and trimethylamine (7.02 mL, 50.0 mmol, 2 eq) was added. The reaction was then 
heated to reflux overnight, after which time the reaction mix was concentrated under reduced 
pressure. The product was then crystallised from EtOAc, filtered, washed with hexane and 
dried under vacuum to yield the product, methyl (S)-1-trityaziridine-2-carboxylate (47) as a 
pale yellow coloured powder (6.037 g, 70%).  
 
Mp = 127-129 °C [lit. 127-128 °C] 120. [α]D = –11.6 (c 0.1, MeOH). Rf = 0.10 (EtOAc:Petrol (40-
60 °C) 9:1, UV light). 1H NMR (300 MHz, CDCl3): δH 7.54 – 7.46 (m, 6H), 7.36 – 7.16 (m, 9H), 
3.77 (s, 3H), 2.26 (dd, J = 2.7, 1.6 Hz, 1H), 1.89 (dd, J = 6.2, 2.7 Hz, 1H), 1.42 (dd, J = 6.2, 1.6 Hz, 
1H). 13C NMR (75 MHz, CDCl3) δ 172.1, 143.7, 129.5, 127.8, 127.1, 77.2, 74.5, 52.3, 31.8, 28.9. 
IR (neat): υmax/cm-1 2996, 2951, 1742, 1179. HRMS (pNSI) calcd for C23H21NNaO2 [M+Na]+: 
366.1470, found 366.1467. 
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Methyl (S)-1-(2-(benzyloxy)benzoyl)aziridine-2-carboxylate (34) 
 
 
 
Following a modified procedure adapted from Weiss et al.98, to a stirred solution of methyl 1-
tritylaziridine-2-carboxylate (47) (0.515 g, 1.5 mmol, 1eq) in DCM (5 mL) at 0 °C was added 
triethylsilane (1.02 mL, 1.5 mmol, 1eq) followed by the dropwise addition of TFA (3 mL, 4.5 
mmol, 3eq). After 4 hours the mixture was cooled to -78 °C and Et3N (1.05 mL, 7.5 mmol, 5eq) 
was added and the reaction left stirring for a further 10 minutes. After this time 2-
(benzyloxy)benzoyl chloride (39) (0.407 g, 1.65 mmol, 1.1eq) in DCM (2 mL) was added. The 
mixture was left stirring at room temperature overnight, and concentrated under reduced 
pressure to give a brown solid. This was then purified via silica gel column chromatography 
(diethyl ether/petrol 1:1, Rf = 0.25, UV light) to give methyl (S)-1-(2-
(benzyloxy)benzoyl)aziridine-2-carboxylate (34) (0.164 g, 0.53 mmol, 35%) as a yellow oil. 
 
1H NMR (700 MHz, MeOD) δ 7.83 (dd, J = 7.8, 1.8 Hz, 1H), 7.52 – 7.46 (m, 3H), 7.41 – 7.35 (m, 
2H), 7.32 – 7.28 (m, 1H), 7.18 – 7.15 (m, 2H), 7.03 (ddd, J = 7.8, 7.3, 1.0 Hz, 1H), 5.23 – 5.17 
(m, 2H), 3.59 (s, 3H17), 3.23 (dd, J = 5.3, 3.1 Hz, 1H), 2.63 (dd, J = 5.3, 1.3 Hz, 1H), 2.62 (dd, J = 
3.1, 1.3 Hz, 1H). 13C NMR (176 MHz, MeOD) δ 178.1, 170.3, 159.1, 138.1, 135.1, 132.7, 129.6, 
129.0, 128.5, 123.9, 121.8, 115.1, 71.7, 52.9, 49.0, 37.5, 33.1. 1H NMR (700 MHz, DMSO-d6) δ 
7.75 (dd, J = 7.8, 1.7 Hz, 1H), 7.51 (ddd, J = 8.4, 7.3, 1.9 Hz, 1H), 7.49 – 7.47 (m, 2H), 7.41 – 7.36 
(m, 2H), 7.34 – 7.30 (m, 1H), 7.21 (dd, J = 8.6, 0.9 Hz, 1H), 7.04 (td, J = 7.5, 1.0 Hz, 1H), 5.29 – 
5.15 (m, 2H), 3.57 (s, 3H), 3.29 (dd, J = 5.5, 3.1 Hz, 1H), 2.66 (dd, J = 5.4, 1.4 Hz, 1H), 2.54 (dd, 
J = 3.1, 1.4 Hz, 1H). 13C NMR (176 MHz, DMSO-d6) δ 175.0, 168.5, 157.0, 136.7, 133.7, 131.2, 
128.4, 127.7, 127.2, 122.4, 120.5, 114.0, 69.7, 52.2, 35.8, 32.0. 1H NMR (300 MHz, CDCl3) δ 
7.94 (ddd, J = 7.7, 1.9, 0.5 Hz, 1H), 7.51 – 7.28 (m, 6H), 7.07 – 6.95 (m, 2H), 5.19 (d, J = 0.9 Hz, 
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2H), 3.61 (s, 3H), 3.20 (dd, J = 5.5, 3.1 Hz, 1H), 2.67 (dd, J = 3.1, 1.3 Hz, 1H), 2.62 (dd, J = 5.5, 
1.3 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 176.0, 169.0, 157.8, 136.6, 133.9, 132.3, 128.7, 128.1, 
127.1, 122.8, 121.1, 113.8, 70.9, 52.5, 36.3, 32.5. IR (neat): υmax/cm-1 3067, 3032, 3007, 2953, 
2876, 1740, 1660, 1200, 697. HRMS (pNSI) calcd for C18H18NO4 [M+H]+: 312.1230, found 
312.1230. 
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Methyl (2-(benzyloxy)benzoyl)-D-serinate (56) 
 
 
Following a modified procedure outlined by Miller et al.89, to a stirred suspension of D-serine 
methyl ester hydrochloride (58) (1.50 g, 9.64 mmol, 1.1 eq) in DCM (10 mL) at 0 °C was added 
Et3N (3.1 mL, 21.9 mmol, 2.5 eq) and the mixture stirred for 5 minutes. The resulting 
suspension was then added dropwise to a solution of 2-(benzyloxy)benzoyl chloride (39) (2.17 
g, 8.8 mmol, 1 eq) in DCM (5 mL) at -78 °C and the resulting mixture allowed to warm to room 
temperature and stirred overnight. The solution was diluted with DCM (100 mL) and washed 
with 1 M HCl(aq) (3 x 50 mL), saturated NaHCO3(aq) (3 x 50 mL) and brine (30 mL). The organic 
layer was then dried over Na2SO3, filtered, and concentrated under reduced pressure to give 
a brown solid. This was then purified via silica gel column chromatography (EtOAc/DCM 1:2, 
Rf = 0.25, UV light) to give methyl (2-(benzyloxy)benzoyl)-D-serinate (56) (1.94 g, 5.9 mmol, 
67%) as a white solid. X-Ray grade crystals were grown from slow evaporation of a 10mg/mL 
solution in methanol.  
 
Mp = 127-129 °C. [α]D = -21.6 ° (c = 1, MeOH). 1H NMR (300 MHz, Chloroform-d) δ 8.76 (d, J = 
7.2 Hz, 1H13), 8.19 (dd, J = 7.8, 1.8 Hz, 1HAr), 7.55 – 7.31 (m, 6HAr), 7.15 – 6.95 (m, 2HAr), 5.32 
– 5.14 (m, 2H5), 4.84 (dt, J = 7.6, 4.0 Hz, 1H14), 3.95 – 3.83 (m, 2H15), 3.69 (s, 3H18), 2.24 (s, 
1H16). 13C NMR (75 MHz, Chloroform-d) δ 170.917, 165.712, 157.1, 135.7, 133.3, 132.5, 128.92, 
128.81, 128.33, 121.7, 121.3, 112.9, 71.55, 63.815, 55.414, 52.718. IR (neat): υmax/cm-1 3370.8, 
3324.8, 1735.0, 1632.9.  
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(2-(Benzyloxy)benzoyl)-D-serine (61) 
 
 
 
To a stirred suspension of methyl (2-(benzyloxy)benzoyl)-D-serinate (56) (1.01 g, 3.06 mmol) 
in THF (6 mL) was added 2 M NaOH (1.5 mL) and the mixture stirred for 1 hour. After this time 
the mixture was diluted with EtOAc (20 mL) and extracted with saturated NaHCO3(aq) (20 mL). 
The aqueous was then taken, acidified to pH 2 with 2 M HCl and extracted with EtOAc (3 x 20 
mL). The combined organic layers were washed with water (20 mL), brine (20 mL), dried over 
sodium sulphate, filtered and evaporated under reduced pressure to give 
((benzyloxy)carbonyl)glycine (61) (0.693 g, 2.20 mmol, 72%) as a white solid.  
 
[α]D = -22.4° (c = 1, MeOH).. 1H NMR (300 MHz, Chloroform-d) δ 8.88 (d, J = 6.3 Hz, 1H13), 8.18 
(dd, J = 7.9, 1.8 Hz, 1H), 7.58 – 7.31 (m, 6H), 7.13 – 7.00 (m, 2H), 5.21 (d, J = 2.7 Hz, 2H5), 4.68 
(dt, J = 6.3, 4.1 Hz, 1H14), 3.96 (dd, J = 11.5, 3.9 Hz, 1H15a), 3.72 (dd, J = 11.5, 4.3 Hz, 1H15b). 13C 
NMR (75 MHz, Chloroform-d) δ 172.717, 167.512, 157.4, 135.3, 134.0, 132.5, 129.0, 121.8, 
120.2, 113.0, 71.75, 62.215, 55.314. 
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Methyl ((benzyloxy)carbonyl)glycinate  (63) 
 
 
 
To a stirred solution of glycine methyl ester hydrochloride (62) (3.00 g, 23.8 mmol) in water 
(10 mL) was added benzyl chloroformate (4.6 mL, 31.0 mmol 1.3 eq) and the mixture stirred 
rapidly. Sodium hydrogen carbonate (4.20 g, 50.0 mmol, 2.1 eq) suspended in water (20 mL) 
was then added to the reaction mixture and the solution stirred at room temperature for 72 
hours. After this time the mixture was diluted with water (50 mL), acidified to pH 3 with 2 M 
HCl and extracted with diethyl ether (2 x 50 mL). The combined organic layers were washed 
water (50 mL), brine (50 mL), dried over sodium sulphate, filtered and evaporated under 
reduced pressure to give crude methyl ((benzyloxy)carbonyl)glycinate as a mixture with 
residual benzyl chloroformate. The crude mixture was subjected to column chromatography 
(ethyl acetate/40-60 petrol 1:1, 40-60 Rf = 0.65) to give pure methyl 
((benzyloxy)carbonyl)glycinate (63) (5.251 g, 23.5 mmol, 99%) as a clear oil.  
 
1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.29 (m, 5H1-3), 5.28 (s br, 1H7), 5.13 (s, 2H5), 3.99 
(d, J = 5.6 Hz, 2H8), 3.76 (s, 3H10). 13C NMR (101 MHz, Chloroform-d) δ 170.49, 156.26, 136.24, 
128.52, 128.21, 128.13, 67.15, 52.310, 42.78. IR (neat): υmax/cm-1 3352.2, 1704.0, 1521.0. HRMS 
(pNSI) calcd for C11H13NO4Na [M+Na]+: 246.0737, found 246.0738. 
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((benzyloxy)carbonyl)glycine (59) 
 
 
 
To a stirred suspension of methyl ((benzyloxy)carbonyl)glycinate (63) (1.339 g, 6 mmol) in THF 
(5 mL) was added 2 M NaOH (5 mL) and the mixture stirred for 1 hour. After this time the 
mixture was diluted with EtOAc (20 mL) and extracted with NaHCO3(aq) (20 mL). The aqueous 
layer was collected, acidified to pH 2 (2 M HCl) and extracted with EtOAc (3 x 20 mL). The 
combined organic layers were washed with water (20 mL), brine (20 mL), dried over sodium 
sulphate, filtered and evaporated under reduced pressure to give 
((benzyloxy)carbonyl)glycine (59) (1.013g, 4.8 mmol, 83%) as a white solid.  
 
Mp = 116-118 °C. 1H NMR (300 MHz, DMSO-d6) δ 12.58 (s, 1H10), 7.57 (t, J = 6.2 Hz, 1H7), 7.50 
– 7.08 (m, 5H1-3), 5.04 (s, 2H5), 3.67 (d, J = 6.2 Hz, 2H8). 13C NMR (75 MHz, DMSO-d6) δ 171.69, 
156.56, 137.04, 128.42, 127.81, 127.73, 65.55, 42.18. IR (neat): υmax/cm-1 3327.1, 1724.4, 1533.1. 
HRMS (pNSI) calcd for C10H10NO3 [M-H]-: 208.0615, found 208.0616. 
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methyl 3-(2-(((benzyloxy)carbonyl)amino)acetamido)propanoate (57) 
 
 
 
To a stirred solution of ((benzyloxy)carbonyl)glycine (59) (1.00 g, 4.78 mmol) in DCM (20 mL) 
was added HATU (2.00 g, 5.26, mmol 1.1 eq) and the mixture stirred for 10 minutes. To this 
mixture was added β-alanine methyl ester hydrochloride (0.734 g, 5.26 mmol, 1.1 eq) and the 
reaction mix stirred for an additional 20 minutes. To this was added DIPEA (3.3 mL, 19.12 
mmol, 4.0 eq) and the mixture stirred at room temperature overnight. After this time the 
mixture was diluted with DCM (20 mL) and washed with saturated NH4Cl(aq) (2 x 20 mL), 
saturated NaHCO3(aq) (2 x 20 mL) and brine (50 mL). The organics were then dried over sodium 
sulphate, filtered and evaporated under reduced pressure and crude mixture subjected to 
silica gel column chromatography (ethyl acetate/40-60 petrol 2:1, Rf = 0.2) to give pure methyl 
3-(2-(((benzyloxy)carbonyl)amino)acetamido)propanoate (57) (1.175 g, 4.0 mmol, 84%) as a 
white solid.  
 
Mp = 93-95 °C. 1H NMR (300 MHz, Chloroform-d) δ 7.42 – 7.27 (m, 5H1-3), 6.78 (t, J = 6.0 Hz, 
1H10), 5.74 (t, J = 5.7 Hz, 1H7), 5.09 (s, 2H5), 3.81 (d, J = 5.7 Hz, 2H8), 3.65 (s, 3H14), 3.49 (q, J = 
6.1 Hz, 2H11), 2.50 (t, J = 6.1 Hz, 2H12). 13C NMR (75 MHz, Chloroform-d) δ 172.813, 169.29, 
156.66, 136.24, 128.51, 128.22, 128.13, 67.15, 51.814, 44.58, 34.911, 33.712. IR (neat): υmax/cm-1 
3314.4, 1732.2, 1689.5, 1534.7. HRMS (pNSI) calcd for C14H18N2O5Na [M+Na]+: 317.1108, 
found 317.1107. 
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2-((3-methoxy-3-oxopropyl)amino)-2-oxoethan-1-aminium bromide (64) 
 
 
 
To a stirred solution of methyl 3-(2-(((benzyloxy)carbonyl)amino)acetamido)propanoate (57) 
(0.500 g, 1.7 mmol) in DCM (12 mL) was added 33% HBr in acetic acid (12 mL) and the mixture 
stirred for 1 hour. After this time, the reaction mixture was evaporated using a flow of air, 
before being dissolved in CHCl3 (10 mL) and concentrated under reduced pressure. The 
residue was the dissolved in CHCl3 concentrated under reduced pressure a second time. The 
residue was triturated by dissolving in the minimum amount of MeOH followed by the 
addition of an equal volume of hexane and the stoppered solution left to stir overnight. The 
resulting solid was then collected via filtration to yield 2-((3-methoxy-3-oxopropyl)amino)-2-
oxoethan-1-aminium bromide (64) (0.340 g, 1.41 mmol, 83 %) as an orange solid.  
 
1H NMR (400 MHz, DMSO-d6) δ 8.45 (t, J = 5.8 Hz, 1H4), 7.97 (br-s, 3H1), 3.61 (s, 3H8), 3.51 (s, 
2H2), 3.35 (q, J = 6.6 Hz, 2H – overlaps with residual water peak), 2.51 (t, J = 6.2 Hz, 2H – 
overlaps with residual DMSO peak). 13C NMR (101 MHz, DMSO-d6) δ 171.57, 165.99, 51.438, 
40.12, 34.75, 33.36. HRMS (pNSI) calcd for C6H13N2O3 [M+H]+: 161.0921, found 161.0918. 
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(R)-3-(2-(2-(2-(benzyloxy)benzamido)-3-hydroxypropanamido)acetamido)propanoate (52) 
 
 
 
To a stirred solution of (2-(benzyloxy)benzoyl)-D-serine (61) (0.392 g, 1.24 mmol, 1eq)  in DMF 
(12 mL) was added HATU (0.519 g, 1.36 mmol, 1.1 eq) and the mixture stirred for 10 minutes. 
To this mixture was added methyl 3-(2-aminoacetamido)propanoate hydrobromide (64) 
(0.300 g, 1.24 mmol, 1eq) and the reaction mix stirred for an additional 20 minutes. After this 
time DIPEA (0.86 mL, 4.96 mmol, 4eq) was added dropwise and the mixture stirred at room 
temperature overnight. After this time, the mixture was diluted with brine (10 mL) and the 
resulting slurry extracted with EtOAc (3 x 50 mL). The combined organic layers were then 
washed with 0.2 M HCl (30 mL), saturated NaHCO3(aq) (30 mL) and brine (50 mL). The organics 
were then dried over sodium sulphate, filtered and evaporated under reduced pressure. The 
crude mixture was then subjected to silica gel column chromatography (EtOAc/Meoh 9:1, Rf 
= 0.43) to give methyl (R)-3-(2-(2-(2-(benzyloxy)benzamido)-3-
hydroxypropanamido)acetamido)propanoate (52) (0.381 g, 0.83 mmol, 67%) as a white solid. 
 
[α]D = -34.6 ° (c = 1, MeOH). 1H NMR (300 MHz, Chloroform-d) δ 8.69 (d, J = 6.6 Hz, 1H13), 8.13 
(dd, J = 7.8, 1.8 Hz, 1H), 7.57 – 7.31 (m, 6H), 7.15 – 7.03 (m, 3H18+Ar), 6.89 (t, J = 5.9 Hz, 1H 21), 
5.22 (s, 2H5), 4.65 – 4.49 (m, 1H14), 4.01 (dd, J = 11.1, 3.3 Hz, 1H15a), 3.84 (d, J = 5.8 Hz, 2H19), 
3.65 (s, 3H25), 3.59 (dd, J = 11.1, 5.1 Hz, 1H15b), 3.55 – 3.40 (m, 2H22), 2.72 (br-s, 1H16), 2.53 
(dd, J = 6.9, 5.5 Hz, 2H23). 13C NMR (75 MHz, Chloroform-d) δ 173.124, 171.817, 168.920, 166.412, 
157.1, 135.5, 133.6, 132.3, 129.03, 128.95, 128.4, 121.8, 121.1, 113.0, 71.65, 62.615, 55.514, 
52.025, 43.319, 35.122, 33.823. HRMS (pNSI) calcd for C23H28N3O7 [M+H]+: 458.1922, found 
458.1922. 
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(R)-3-(2-(2-(2-(benzyloxy)benzamido)-3-hydroxypropanamido)acetamido)propanoate (73) 
 
 
 
To a stirred suspension of methyl (R)-3-(2-(2-(2-(benzyloxy)benzamido)-3-
hydroxypropanamido)acetamido)propanoate (52) (0.261 g,  0.57 mmol, 1eq)  in THF (5 mL) 
was added aqueous 2 M NaOH solution (5 mL). The mixture was stirred for 30 minutes after 
which time water (50 mL) was added and the reaction mixture was washed with EtOAc (2 x 50 
mL). The aqueous layer was then acidified to pH 2 (HClaq) and extracted with EtOAc (3 x 50 mL) 
and the combined organic layers   concentrated under reduced pressure yielding (R)-3-(2-(2-
(2-(benzyloxy)benzamido)-3-hydroxypropanamido)acetamido)propanoic acid (73) (0.216 g, 
0.49 mmol, 86%) as a colourless oil. 
 
[α]D -13.2 ° (c = 1, MeOH). 1H NMR (300 MHz, Methanol-d4) δ 8.00 (dd, J = 7.9, 1.8 Hz, 1H), 
7.55 – 7.28 (m, 6H), 7.21 (dd, J = 8.5, 1.0 Hz, 1H), 7.06 (td, J = 7.6, 1.0 Hz, 1H), 5.29 (s, 2H), 4.53 
(t, J = 5.2 Hz, 1H), 3.94 – 3.76 (m, 3H), 3.76 – 3.61 (m, 1H), 3.48 – 3.39 (m, 2H), 2.52 (t, J = 6.9 
Hz, 2H). 13C NMR (75 MHz, Chloroform-d) δ 174.9, 171.9, 170.3, 166.3, 157.1, 135.6, 133.5, 
132.0, 128.9, 128.7, 128.0, 121.6, 120.9, 113.1, 71.4, 62.4, 55.9, 43.1, 35.5, 33.7.  
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(S,E)-5-(benzylideneamino)-2-(((benzyloxy)carbonyl)amino)pentanoic acid (67) 
 
 
 
To a stirred solution of KOH (1.10 g, 19.53 mmol, 1.04 eq) in methanol (42 mL) was added (S)-
5-amino-2-(((benzyloxy)carbonyl)amino)pentanoic acid (66) (5.00 g, 18.78 mmol, 1.0 eq). 
After the solids had dissolved, benzaldehyde (2 mL, 19.72 mmol, 1.05 eq) was added followed 
by 3 Å mol. sieves. The mixture was then stirred at room temperature overnight after which 
time the molecular sieves were filtered off and washed with methanol. The filtrate was then 
evaporated under reduced pressure to give (S,E)-5-(benzylideneamino)-2-
(((benzyloxy)carbonyl)amino)pentanoic acid (67) (7.254 g, 18.48 mmol, 98%) as a hygroscopic 
white foam. 
 
1H NMR (300 MHz, Methanol-d4) δ 8.35 (s, 1H5), 7.79 – 7.70 (m, 2H), 7.50 – 7.40 (m, 3H), 7.40 
– 7.22 (m, 5H), 5.08 (d, J = 3.4 Hz, 2H13), 4.09 (dd, J = 7.0, 4.3 Hz, 1H9), 3.70 – 3.58 (m, 2H6), 
2.03 – 1.86 (m, 1H8a), 1.86 – 1.63 (m, 3H8b+7). 13C NMR (75 MHz, Methanol-d4) δ 192.9, 177.9, 
163.0, 156.8, 137.0, 135.7, 134.3, 130.6, 128.3, 128.0, 127.9, 127.5, 127.4, 66.0, 60.5, 56.1, 
30.5, 26.7. 1H NMR (300 MHz, DMSO-d6) δ 8.29 (s, 1H5), 7.83 – 7.63 (m, 2H), 7.54 – 7.39 (m, 
3H), 7.39 – 7.20 (m, 5H), 6.36 (d, J = 6.2 Hz, 1H11), 4.98 (s, 2H13), 3.77 – 3.43 (m, 3H9+6), 1.81 – 
1.62 (m, 1H8a), 1.56 (t, J = 6.0 Hz, 3H8b+7). 13C NMR (75 MHz, DMSO-d6) δ 172.5, 160.2, 155.0, 
137.5, 136.2, 130.4, 128.6, 128.3, 127.8, 127.6, 127.5, 64.913, 60.96, 55.59, 30.78, 26.77. IR 
(neat): υmax/cm-1 3661.0, 1694.1. HRMS (pNSI) calcd for C20H23N2O4[M+H]+: 355.1652, found 
355.1655. 
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(S,Z)-N-(4-(((benzyloxy)carbonyl)amino)-4-carboxybutyl)-1-phenylmethanimine oxide (51) 
 
 
 
A stirred solution of (S,E)-5-(benzylideneamino)-2-(((benzyloxy)carbonyl)amino)pentanoic 
acid (67) (6.93 g, 17.65 mmol, 1 eq) in methanol (32 mL) was cooled to 0 °C in an ice bath. A 
pressure equalising dropping funnel was fitted to which was added freshly prepared mCPBA 
(3.42 g, 19.8 mmol, 1.12 eq) in methanol (13 mL) and the dropping funnel stoppered. The 
mCPBA solution was then added dropwise to the reaction mix over an hour. Upon complete 
addition of the mCPBA solution the reaction mix was allowed to stir at 0 °C for an additional 
hour. After this time the reaction mix was concentrated under reduced pressure and 
partitioned between EtOAc (50 mL) and water (50 mL) and the aqueous layer acidified to pH2 
(HClaq). The layers were then separated and the aqueous layer extracted with a EtOAc (50 mL). 
The combined organic layers were washed with brine (50 mL), dried over sodium sulphate, 
filtered and concentrated to give crude oxaziridine as a white solid that was used without 
further purification. 
To the crude oxaziridine was added TFA (8 mL) followed by DCM (8 mL) and the resulting 
solution was stirred at room temperature for 1 hour. After this time the solution was 
evaporated under reduced pressure and the resulting slurry was dissolved in EtOAc (32 mL). 
Hexane (64 mL) was then added, followed by the addition of benzaldehyde (1 mL, 9.84 mmol) 
and the mixture was then stirred at room temperature overnight, yielding a cloudy 
suspension. The solution was cooled in an ice bath for 2 h and the solid collected via filtration, 
washed with EtOAc (3 x 50 mL) and dried to give (S,Z)-N-(4-(((benzyloxy)carbonyl)amino)-4-
carboxybutyl)-1-phenylmethanimine oxide (51) (5.171 g, 14.0 mmol, 76% from Cbz-L-
Ornithine) as an off white solid. X-ray grade crystals were grown from slow evaporation in 
methanol. 
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Mp = 148 – 151 °C. [α]D = -4.4° (c = 1.0, MeOH). 1H NMR (300 MHz, DMSO-d6) δ 12.65 (s, 1H11), 
8.28 – 8.20 (m, 2H), 7.86 (s, 1H5), 7.66 (d, J = 8.1 Hz, 1H12), 7.49 – 7.25 (m, 8H), 5.03 (s, 2H14), 
4.07 – 3.95 (m, 1H9), 3.91 (t, J = 6.7 Hz, 2H6), 1.96 – 1.85 (m, 2H7), 1.82 – 1.68 (m, 1H8), 1.68 – 
1.55 (m, 1H8). 13C NMR (75 MHz, DMSO-d6) δ 173.610, 156.113, 137.0, 133.35, 131.0, 129.8, 
128.3, 127.9, 127.8, 127.714, 65.56, 65.4, 59.8, 53.59, 27.88, 24.17. IR (neat): υmax/cm-1 2952.7, 
1710.0, 1660.2, 1200.1, 697.1. HRMS (pNSI) calcd for C20H23N2O5 [M+H]+: 371.1607, found 
371.1601. 
 
  
 
139 
 
(S,Z)-N-(4-(((benzyloxy)carbonyl)(methyl)amino)-4-carboxybutyl)-1-phenylmethanimine oxide (54) 
 
 
 
To a stirred suspension of (S,Z)-N-(4-(((benzyloxy)carbonyl)amino)-4-carboxybutyl)-1-
phenylmethanimine oxide (51) (1.00 g, 2.70 mmol, 1.0 eq) in THF (40 mL) under nitrogen at 0 
°C was added methyl iodide (1.3 mL, 21.6 mmol) followed by sodium hydride (0.324 g, 8.1 
mmol, 60 % weight dispersion in mineral oil). The solution was then stirred at room 
temperature for 24 h. After this time the reaction was quenched via the addition of methanol. 
The reaction mix was concentrated under a flow on nitrogen until a yellow residue resulted. 
The residue was partitioned between Et2O (75 mL) and H2O (40 mL). After separation of the 
layers, the aqueous layer was acidified with 2 M HCl and extracted with 3 x 30 mL EtOAc. The 
organic layers were combined, washed with brine, dried with sodium sulphate, filtered and 
evaporated under reduced pressure. The sample was then taken and stirred overnight in 
Et2O/hexane to give (S,Z)-N-(4-(((benzyloxy)carbonyl)(methyl)amino)-4-carboxybutyl)-1-
phenylmethanimine oxide (54) (0.644 g, 1.68 mmol, 62%) as a yellow powder 
 
[α]D = -13.2 (c = 1.0, MeOH) 1H NMR (700 MHz, DMSO-d6, 352 K) δ 8.24 (dd, J = 8.0, 1.7 Hz, 
2H), 7.96 (dd, J = 8.3, 1.4 Hz, 1H), 7.92 – 7.89 (m, 2H), 7.78 (d, J = 3.3 Hz, 1H), 7.68 (ddd, J = 
8.0, 2.1, 1.2 Hz, 1H), 7.62 (tt, J = 7.6, 1.4 Hz, 1H), 7.56 – 7.52 (m, 1H), 7.52 – 7.48 (m, 1H), 7.44 
– 7.39 (m, 3H), 7.36 (t, J = 3.8 Hz, 3H), 7.33 – 7.28 (m, 1H), 5.12 (s, 2H), 4.57 (s, 1H), 3.95 (t, J = 
6.6 Hz, 2H), 2.84 (s, 3H), 2.00 – 1.90 (m, 1H), 1.90 – 1.76 (m, 3H).13C NMR (176 MHz, DMSO-
d6, 352 K) δ 172.5, 167.7, 166.4, 156.6, 137.4, 133.9, 133.6, 133.5, 133.1, 133.0, 131.6, 131.0, 
130.0, 129.7, 129.3, 128.9, 128.8, 128.7, 128.2, 127.8, 67.0, 66.0, 58.9, 31.2, 25.8, 24.8. IR 
(neat): υmax/cm-1 1948.0, 1688.2, 1604.4 HRMS (pNSI) calcd for C21H23N2O5 [M-H]-: 383.1612, 
found 383.1606. 
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benzyl (S)-(1-(benzyloxy)-2-oxopiperidin-3-yl)carbamate (55) 
 
 
 
To a stirred solution of (S,Z)-N-(4-(((benzyloxy)carbonyl)amino)-4-carboxybutyl)-1-
phenylmethanimine oxide (51) (1.00 g, 2.70 mmol) in methanol (27 mL) was added 
hydroxylamine hydrochloride (0.20 g, 2.84 mmol, 1.05 eq) and the reaction heated to reflux 
for 20 minutes. After this time 3 Å mol. sieves were added followed by Et3N and the mixture 
stirred for an additional hour. After this time the mixture was filtered through a pad of celite 
and the filtrate evaporated under reduced pressure. This was taken and partitioned between 
EtOAc (30 mL) and water (15 mL) and the organics separated, dried (Na2SO4) and evaporated 
to give the crude hydroxamic acid as a orane/red residue. The residue was dissolved in DMF 
(4 mL) followed by the addition of K2CO3 (3.73 g, 27 mmol, 10 eq) and benzyl bromide (1.44 
mL, 13.5 mmol, 5 eq). The mixture was stirred at room temperature overnight and then 
diluted with EtOAc (50 mL). The resulting slurry was then washed with water (3 x 50 mL), brine 
(50 mL), dried over sodium sulphate, filtered and concentrated under reduced pressure. The 
crude residue was then subjected to silica gel column chromatography (EtOAc/DCM 1:8, Rf = 
0.2), to yield benzyl (S)-(1-(benzyloxy)-2-oxopiperidin-3-yl)carbamate (55) (0.546 g, 1.54 
mmol, 57%) as a white solid. X-Ray grade crystals were grown from slow evaporation of a 
10mg/mL solution in methanol.  
 
Mp = 86-89 °C. [α]D = +23.2° (c = 1.0, MeOH). 1H NMR (400 MHz, Chloroform-d) δ 7.64 – 7.14 
(m, 10H1-3, 15-18), 5.70 (Br-s, 1H12), 5.12 (s, 2H14), 4.97 (d, J = 10.6 Hz, 1H5a), 4.89 (d, J = 10.6 Hz, 
1H5b), 4.17 (dt, J = 11.6, 5.2 Hz, 1H9), 3.55 – 3.37 (m, 1H6a), 3.37 – 3.22 (m, 1H6b), 2.53 – 2.33 
(m, 1H8a), 1.94 – 1.72 (m, 2H7), 1.54 (qd, J = 12.5, 4.0 Hz, 1H8b). 13C NMR (101 MHz, Chloroform-
d) δ 167.810, 156.413, 156.3, 136.3, 135.2, 128.8, 128.1, 76.05, 66.914, 52.89, 51.46, 28.28, 20.87. 
IR (neat): υmax/cm-1 3304.1, 1688.0, 1658.5. HRMS (pNSI) calcd for C20H23N2O5 [M+Na]+: 
377.1472, found 377.1464.  
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(S)-1-(benzyloxy)-2-oxopiperidin-3-aminium bromide (71)   
 
 
 
To a 100 mL round bottomed flask fitted with a subaseal was added benzyl (S)-(1-(benzyloxy)-
2-oxopiperidin-3-yl)carbamate (55) (1.00 g, 2.82 mmol, 1.0 eq) and DCM (20 mL) and a 
nitrogen atmosphere was introduced. To this was added HBr 33% in acetic acid (20 mL) 
dropwise via syringe. The reaction mix was stirred at room temperature for 1 hour and after 
this time the reaction mix was concentrated under a flow on nitrogen until a dark orange solid 
resulted. The solid was then dissolved in chloroform (40 mL) and evaporated under reduced 
pressure and repeated twice more. The residue was then dissolved in chloroform, hexane 
added and the mixture stirred overnight, yielding the product as a triturated powder. The 
powder was filtered, washed with petrol and dried to yield pure 3-amino-1-
(benzyloxy)piperidin-2-one hydrobromide (71) (8.05 g, 2.43 mmol, 86%) as a red solid. X-Ray 
grade crystals were grown from slow evaporation in methanol. 
 
[α]D = +43.0° (c = 1, MeOH). 1H NMR (300 MHz, Deuterium Oxide) δ 7.61 – 7.37 (m, 5H), 5.00 
(s, 2H), 4.10 (dd, J = 11.7, 5.7 Hz, 1H), 3.75 – 3.53 (m, 2H), 2.38 – 2.22 (m, 1H), 2.18 – 2.06 (m, 
1H), 2.04 – 1.70 (m, 2H). 13C NMR (75 MHz, Deuterium Oxide) δ 164.8, 134.0, 130.0, 129.4, 
128.8, 75.8, 50.3, 49.7, 24.6, 19.7. IR (neat): υmax/cm-1 3080.5, 1676.8. HRMS (pNSI) calcd for 
C12H17N2O2 [M-Br]+: 221.1285, found 221.1288 
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(Z)-N-((S)-5-(((S)-1-(benzyloxy)-2-oxopiperidin-3-yl)amino)-4-(((benzyloxy)carbonyl)(methyl)amino)-
5-oxopentyl)-1-phenylmethanimine oxide (53) 
 
 
To a stirred suspension of benzyl (S)-(1-(benzyloxy)-2-oxopiperidin-3-yl)carbamate (54) (0.313 
g, 1.04 mmol, 1.0 eq) in DMF (5 mL) under nitrogen at room temperature was added HATU 
(0.435 g, 1.14 mmol, 1.1 eq) and the yellow coloured solution stirred for 5 minutes. After this 
time 3-amino-1-(benzyloxy)piperidin-2-one hydrobromide (71) (0.400 g, 1.04 mmol, 1.0 eq) 
was added and the reaction took on a darker colouration. The reaction was stirred for an 
additional 20 minutes at room temperature followed by the injection of DIPEA (0.53 mL, 3.02 
mmol, 2.9 eq) and the resulting dark orange reaction mix stirred at room temperature 
overnight. After this time, the reaction mix was diluted with water (20 mL) and extracted with 
DCM (2 x 50 mL). The organic layers were combined, washed with sat. NaHCO3(aq) (50 mL), 
hydrochloric acid (50 mL) and then washed a further three times with water (3 x 50 mL). The 
organic later was then washed with brine, dried over sodium sulphate, filtered and 
concentrated under reduced pressure to yield the crude product.  The crude material was then 
taken and purified via column chromatography (DCM/MeOH 9.5:0.5) and gave pure (Z)-N-((S)-
5-(((S)-1-(benzyloxy)-2-oxopiperidin-3-yl)amino)-4-(((benzyloxy)carbonyl)(methyl)amino)-5-
oxopentyl)-1-phenylmethanimine oxide (53) as an off white foam. (0.426 g, 0.727 mmol) 70%.  
 
1H NMR (700 MHz, DMSO-d6, 348 K) δ 8.32 – 8.15 (m, 2H), 8.00 (d, J = 8.2 Hz, 1H), 7.80 (d, J = 
6.4 Hz, 1H), 7.50 – 7.20 (m, 14H), 5.20 – 5.09 (m, 2H), 4.90 – 4.82 (m, 2H), 4.63 (s, 1H), 4.40 – 
4.26 (m, 1H), 3.95 (t, J = 7.1 Hz, 2H), 3.52 – 3.42 (m, 2H), 2.85 (d, J = 1.0 Hz, 3H), 2.02 – 1.91 
(m, 1H), 1.91 – 1.76 (m, 4H), 1.76 – 1.64 (m, 2H).13C NMR (176 MHz, DMSO-d6) δ 170.4, 166.5, 
137.4, 136.2, 133.5, 131.6, 130.0, 129.5, 128.8, 128.7, 128.7, 128.6, 128.4, 128.1, 127.8, 75.2, 
67.0, 66.1, 50.9, 50.5, 30.4, 27.9, 26.1, 24.7, 21.1. HRMS (pNSI) calcd for C33H39N4O6 [M+H]+: 
587.2864, found 587.2869.  
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N-((S)-5-(((S)-1-(benzyloxy)-2-oxopiperidin-3-yl)amino)-4-(((benzyloxy)carbonyl)(methyl)amino)-5-
oxopentyl)hydroxylammonium chloride (72) 
 
 
 
To a stirred suspension of (Z)-N-((S)-5-(((S)-1-(benzyloxy)-2-oxopiperidin-3-yl)amino)-4-
(((benzyloxy)carbonyl)(methyl)amino)-5-oxopentyl)-1-phenylmethanimine oxide (53) (0.193 
g, 0.329 mmol, 1.0 eq) in methanol (5 mL) under nitrogen at room temperature was added 
hydroxylamine hydrochloride (0.024 g, 0.345 mmol, 1.05 eq) and reaction mix refluxed for 20 
minutes. After this time, the reaction mix was concentrated under reduced pressure and the 
residue triturated with MeOH/Et2O (1:3) and the solid collected by vacuum filtration. This solid 
was then dissolved again in methanol and evaporated under reduced pressure give crude N-
((S)-5-(((S)-1-(benzyloxy)-2-oxopiperidin-3-yl)amino)-4-(((benzyloxy)carbonyl)(methyl)amino) 
-5-oxopentyl)hydroxylammonium chloride (72) which was used without further purification.  
 
HRMS (pNSI) calcd for C26H35N4O6 [M+H]+: 499.2551, found 499.2535 
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benzyl ((3R,16S)-17-(((S)-1-(benzyloxy)-2-oxopiperidin-3-yl)amino)-1-(2-(benzyloxy)phenyl)-12-
hydroxy-3-(hydroxymethyl)-1,4,7,11,17-pentaoxo-2,5,8,12-tetraazaheptadecan-16-
yl)(methyl)carbamate (74) 
 
 
 
To a solution of (R)-3-(2-(2-(2-(benzyloxy)benzamido)-3-hydroxypropanamido)acetamido) 
propanoic acid (73) (0.155 g, 0.35 mmol, 1.0eq) in DMF (3 mL) under nitrogen at room 
temperature was added HATU (0.146 g, 0.384 mmol, 1.1eq) and the solution stirred for 10 
minutes. After this time N-((S)-5-(((S)-1-(benzyloxy)-2-oxopiperidin-3-yl)amino)-4-
(((benzyloxy)carbonyl) (methyl)amino)-5-oxopentyl)hydroxylammonium chloride (72) (0.176 
g, 0.363 mmol, 1.4eq) was added and the reaction was stirred for an additional 20 minutes. 
After this time DIPEA (0.24 mL, 1.36 mmol, 3.9 eq) was added and the reaction mix stirred at 
room temperature overnight. After this time, the reaction mix was diluted with water (20 mL) 
and extracted with DCM (2 x 50 mL). The organic layers were combined, washed with sat. 
NaHCO3(aq) (50 mL), 0.2 M hydrochloric acid (50 mL) and then washed a further three times 
with water (3 x 50 mL). The organic later was then washed with brine, dried over sodium 
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sulphate, filtered and concentrated under reduced pressure. The crude material was then 
subjected to silica gel column chromatography (DCM/MeOH 9:1 Rf = 0.1) to give pure benzyl 
((3R,16S)-17-(((S)-1-(benzyloxy)-2-oxopiperidin-3-yl)amino)-1-(2-(benzyloxy)phenyl)-12-
hydroxy-3-(hydroxymethyl)-1,4,7,11,17-pentaoxo-2,5,8,12-tetraazaheptadecan-16-
yl)(methyl)carbamate (74) (0.120 g, 0.13 mmol 38%)  as a yellow tinted oil.  
 
1H NMR (300 MHz, Chloroform-d) δ 9.39 – 9.08 (m, 1H), 8.72 – 8.49 (m, 1H), 8.17 – 7.96 (m, 
1H), 7.76 – 7.58 (m, 1H), 7.56 – 7.19 (m, 17H), 7.12 – 6.95 (m, 2H), 5.20 (s, 2H), 5.11 (s, 2H), 
4.91 (d, J = 10.5 Hz, 1H), 4.83 (d, J = 10.5 Hz, 1H), 4.69 – 4.51 (m, 1H), 4.53 – 4.39 (m, 1H), 4.35 
– 4.13 (m, 1H), 3.97 – 3.74 (m, 3H), 3.67 – 3.54 (m, 3H), 3.45 – 3.36 (m, 2H), 3.35 – 3.21 (m, 
1H), 2.93 (s, 3H), 2.90 – 2.78 (m, 1H), 2.63 – 2.46 (m, 1H), 2.36 – 2.17 (m, 1H), 2.15 – 1.97 (m, 
1H), 1.97 – 1.27 (m, 8H). 13C NMR (75 MHz, Chloroform-d) δ 172.8, 172.0, 171.9, 169.9, 167.9, 
166.1, 157.0, 136.6, 135.6, 135.0, 133.4, 131.9, 129.5, 129.0, 128.9, 128.7, 128.67, 128.6, 
128.1, 128.0, 127.9, 127.8, 121.6, 121.3, 113.1, 76.0, 71.4, 67.7, 62.8, 57.7, 56.0, 53.6, 51.0, 
50.7, 48.4, 46.7, 43.4, 35.7, 32.2, 29.8, 27.6, 25.5, 22.6, 22.6, 21.0. HRMS (pNSI) calcd for 
C40H58N7O12 [M+H]+: 924.4138, found 924.4143. 
 
In addition to (74), compound (75) was also isolated as a co-eluting mixture of by-products 
and as such does not have an accurate isolated yield or NMR. However the structure was 
solved via X-ray crystallography (see appendix) 
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benzyl ((S)-1-(((S)-1-(benzyloxy)-2-oxopiperidin-3-yl)amino)-5-(3-(2-((R)-2-(2-(benzyloxy)phenyl)-4,5-
dihydrooxazole-4-carboxamido)acetamido)-N-hydroxypropanamido)-1-oxopentan-2-yl)(methyl) 
carbamate (76) 
 
 
 
To a solution of benzyl ((3R,16S)-17-(((S)-1-(benzyloxy)-2-oxopiperidin-3-yl)amino)-1-(2-
(benzyloxy)phenyl)-12-hydroxy-3-(hydroxymethyl)-1,4,7,11,17-pentaoxo-2,5,8,12-tetraazah-
eptadecan-16-yl)(methyl)carbamate (74) (30 mg, 0.033 mmol, 1.0eq) in dry DCM (1 mL) under 
nitrogen at -78 °C was added DAST (5.2 μL, 0.039 mmol, 1.2eq). After addition the reaction 
was removed from the acetone/dry ice bath  and the solution stirred for a further 2 hours. 
After this time K2CO3 (11 mg, 0.08 mmol, 2.5eq) was added in one portion and the solution 
stirred for an additional 30 minutes. The reaction mix was then diluted with DCM (10 mL) and 
washed with water (20 mL), brine (20 mL), dried over sodium sulphate and concentrated 
under reduced pressure to yield benzyl ((S)-1-(((S)-1-(benzyloxy)-2-oxopiperidin-3-yl)amino)-
5-(3-(2-(2-(((R)-2-(2-(benzyloxy)phenyl)-4,5-dihydrooxazol-4-yl)amino)acetamido)acetamido) 
-N-hydroxypropanamido)-1-oxopentan-2-yl)(methyl)carbamate (76) (7 mg, 0.008 mmol, 23%) 
as a yellow oil.  
HRMS (pNSI) calcd for C48H56N7O11 [M+H]+: 906.4032, found 906.4036. 
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NMR assignment of DEM30616/A (79) 
 
 
 
Table 16. NMR data for DEM30616/A in D2O at 298 K, 700 MHz, 1H NMR collected at 700 MHz, 13C{1H} NMR 
collected at 176 MHz, 15N shifts were measured indirectly by 1H-15N HMBC performed at both 8 and 12 Hz, 
referencing against nitromethane 
Position δ1H multi, (J in Hz) δ13C δ15N HMBC  
1 - 116.4   
2 - 146.3 or 
144.4 
  
3 -   
4 6.98 (dd, J = 7.9, 1.5 Hz, 1H) 119.5  H to C1, 2, 3, 5, 6 
5 6.76 (t, J = 8.0 Hz, 1H) 119.6  H to C1, 2, 3, 4, 6, 7 
6 7.18 (dd, J = 8.1, 1.6 Hz, 1H) 119.2  H to C 1, 2, 3, 4, 5, 7 
7 - 169.8   
8 - - -260.5  
9 4.53 (dd, J = 7.8, 6.4 Hz, 1H) 53.2  H to C1, 7, 10, 11, 12 
10 - 172.6  - 
11 1.98 – 1.91 (m, 1H) 
1.89 – 1.82 (m, 1H) 
27.8  H to C9, 10, 12, 13 
12 a) 1.80 – 1.71 (m, 3H) (2H) 23.1  * 
13 2.99 (ddd, J = 8.6, 6.9, 2.1 Hz, 2H) 38.8  H to C11, 12 
14 - - -348.8  
15 - - -252.9  
16 4.21 – 4.13 (m, 1H) 54.6  H to C10, 17 18, 19 
17 - 178.1   
18 b) 1.80 – 1.71 (m, 3H) (1H) 
b) 1.69 – 1.60 (m, 3H) (1H) 
28.2  * 
19 a) 1.69 – 1.60 (m, 3H) (2H) 22.7  * 
20 3.56 – 3.44 (m, 2H) 50.0  H to C16, 18, 19, 22 
21 - - -199.3  
22 7.83 and 8.18 (2 x s, 1H) 159.4  H to C20 
*Unknown due to signal overlap 
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2,3-bis(benzyloxy)benzoic acid (86) 
 
 
 
To a schlenk flask under nitrogen was added K2CO3 (2.142 g, 15.5 mmol, 3.1 eq) and 2,3-
dihydroxybenzoic acid (87) (0.771 g, 5.0 mmol, 1 eq) and the mixture suspended in dry DMF 
(5 mL). Benzyl bromide (1.84 mL, 15.5 mmol, 3.1 eq) was added dropwise and the reaction 
stirred for 72 hours at room temperature. After this time the reaction mixture was diluted 
with water (75 mL) and the aqueous extracted with EtOAc (3 x 25 mL) to obtain the benzyl 
ester. The combined organic layers were then washed with water (3 x 25 mL), brine (50 mL), 
dried (Na2SO4), filtered and then evaporated under reduced pressure to yield the crude benzyl 
ester. The crude benzyl ester was then dissolved in methanol (8.33 mL) and 2 M NaOH (8.33 
mL) was added and. The reaction mixture was then stirred and heated to reflux for 8 hours. 
After this time the mixture was allowed to cool to room temperature, diluted with water (20 
mL) and the aqueous layer washed with diethyl ether (2 x 20 mL). The aqueous layer was then 
acidified to pH 2 (2 M HCl) and extracted with ethyl acetate (3 x 25 mL). The combined organic 
layers were then washed with brine (50 mL), dried (Na2SO4), filtered and evaporated under 
reduced pressure to yield 2,3-bis(benzyloxy)benzoic acid (86) (1.271 g, 1.80 mmol, 76%) as a 
white solid. 
 
1H NMR (300 MHz, Chloroform-d) δ 11.38 (br-s, 1H), 7.80 (dd, J = 7.8, 1.7 Hz, 1H), 7.59 – 7.17 
(m, 12H), 5.32 (s, 2H), 5.25 (s, 2H). 13C NMR (75 MHz, Chloroform-d) δ 165.2, 151.4, 147.2, 
136.0, 134.7, 129.5, 129.5, 129.0, 129.0, 128.7, 127.9, 125.2, 124.6, 123.1, 119.1, 77.3, 71.7. 
IR (neat): υmax/cm-1 3325, 2930, 2851, 1736, 1625, 1216, 736 HRMS (pNSI) calcd for C18H20NO5 
[M+H]+: 330.1336, found 330.1337 
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4-(((benzyloxy)carbonyl)amino)-1-carboxybutan-1-aminium 2,2,2-trifluoroacetate (85) 
 
 
 
To a solution of ((R)-5-(((benzyloxy)carbonyl)amino)-2-((tert-butoxycarbonyl)amino) 
pentanoic acid (95) (1.415 g, 4.1 mmol) in dry DCM (22 mL) was added TFA (22 mL). The 
mixture was stirred at RT for 1 h after which time the solvent was removed under reduced 
pressure. The residue was then triturated with Et2O to yield 4-(((benzyloxy)carbonyl)amino)-
1-carboxybutan-1-aminium 2,2,2-trifluoroacetate (85) (0.974 g) as a pink solid that was used 
without further purification. 
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(R)-5-(((benzyloxy)carbonyl)amino)-2-(2,3-bis(benzyloxy)benzamido)pentanoic acid (83) 
 
 
 
In a RBF 2,3-bis(benzyloxy)benzoic acid (86) (1.00g, 2.99 mmol, 1eq) was added dry DMF (25 
mL). HATU (1.14 g, 2.99 mmol, 1eq) and the reaction mix stirred at room temperature for 10 
mins. 2-amino-5-(((benzyloxy)carbonyl)amino)pentanoic acid (85) (0.679 g, 2.99 mmol, 1eq) 
was dissolved in 5 mL dry DMF and added followed by the addition of DIPEA (1.70 mL, 9.87 
mmol) and the reaction mix stirred for 16 h at room temperature. The reaction was quenched 
with H2O before being diluted with EtOAc (30 mL). This was then washed with 0.2M NaOH (3 
x 30 mL), 0.4M HCl (3 x 30 mL) and then and brine (30 mL). The organics were then dried over 
sodium sulphate, filtered and evaporated under reduced pressure to give a yellow oil. The 
crude mixture was then purified via silica gel column chromatography (MeOH/DCM/Acetic 
acid 0.5:9.5:0.1 Rf = 0.30) to give (R)-5-(((benzyloxy)carbonyl)amino)-2-(2,3-bis(benzyloxy) 
benzamido)pentanoic acid (83) (0.550 g, 0.94 mmol, 32%) as a yellow foam. 
 
1H NMR (700 MHz, DMSO-d6) δ 8.52 (d, J = 7.5 Hz, 1H), 7.55 – 7.46 (m, 2H), 7.45 – 7.22 (m, 
18H), 7.16 (t, J = 8.0 Hz, 2H), 5.21 (s, 2H), 5.09 (d, J = 10.4 Hz, 1H), 5.01 (d, J = 10.4 Hz, 1H), 
4.99 (s, 2H), 4.34 (q, J = 6.8 Hz, 1H), 2.94 (dq, J = 13.5, 6.7 Hz, 2H), 1.81 – 1.73 (m, 1H), 1.56 
(dq, J = 15.0, 7.9 Hz, 1H), 1.42 (p, J = 7.3 Hz, 2H).13C NMR (176 MHz, DMSO-d6) δ 174.2, 165.1, 
156.5, 152.1, 146.1, 137.7, 137.1, 129.5, 129.1, 128.9, 128.8, 128.5, 128.5, 128.5, 128.2, 124.6, 
121.9, 116.9, 75.6, 70.8, 65.6, 53.1, 38.7, 29.4, 26.4. HRMS (pNSI) calcd for C34H33N2O7 [M-H]-
: 581.2293, found 581.2284 
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benzyl (R)-2-((tert-butoxycarbonyl)amino)-5-hydroxypentanoate (90)  
 
 
 
To a 100 mL round bottomed flask under an atmosphere of nitrogen was added (R)-5-
(benzyloxy)-4-((tert-butoxycarbonyl)amino)-5-oxopentanoic acid (91) (0.765 g, 2.27 mmol, 1 
eq) and dry THF (11 mL) was added. The mixture was cooled to -10 °C and stirred for 20 
minutes. After this time, DIPEA (2.35 mmol, 0.41 mL, 1.04 eq) and ethyl chloroformate (2.58 
mmol, 0.25 mL, 1.14 eq) were added dropwise from two separate syringes at the same time 
over 10 minutes. Upon complete addition the reaction mix was stirred for a further 30 
minutes, after which time sodium borohydride (6.75 mmol, 0.255 g, 3 eq) was added in one 
portion. The reaction mix then removed from the cold bath and allowed to warm to room 
temperature, after which point, H2O (5 mL) was added dropwise over 10 minutes. Upon 
complete addition the mixture was left to stir for 30 minutes before brine (5 mL) was added. 
The mixture was then extracted with EtOAc (3 x 50 mL) and the combined organic layers were 
washed with saturated sodium bicarbonate (20 mL), saturated ammonium chloride (20 mL) 
and finally brine (20 mL). The organics were then dried over sodium sulphate, filtered and 
evaporated under reduced pressure to give a clear colourless oil. The crude mixture was then 
purified via column chromatography (ethyl acetate/petrol 40-60 1:2, Rf = 0.12) to give benzyl 
(R)-2-((tert-butoxycarbonyl)amino)-5-hydroxypentanoate (90) (0.550 g, 1.70 mmol, 75%) as a 
clear colourless oil. 
 
[α]D = +21.2° 1H NMR (300 MHz, Chloroform-d) δ 7.32 (d, J = 3.1 Hz, 5H9-11), 5.29 (d, J = 8.4 Hz, 
1H4), 5.21 – 5.09 (m, 2H7), 4.44 – 4.24 (m, 1H5), 3.58 (t, J = 6.1 Hz, 2H14), 2.37 (s, 1H15), 2.01 – 
1.80 (m, 1H12), 1.80 – 1.65 (m, 1H12), 1.65 – 1.48 (m, 2H13), 1.41 (s, 9H1). 13C NMR (75 MHz, 
Chloroform-d) δ 172.76, 155.63, 135.4, 128.6, 128.5, 128.3, 80.02, 67.17, 61.914, 53.35, 29.312, 
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28.413, 28.31. IR (neat): υmax/cm-1 3373.8 (OH), 1737.7 (C=O ester), 1693.4 (C=O amide). HRMS 
(pNSI) calcd for C17H26N1O5 [M+H]+: 324.1805, found 324.1809.   
 
153 
 
N-(benzyloxy)benzenesulfonamide (89) 
 
 
 
A stirred solution of O-benzylhydroxylamine hydrochloride (98) (2.400 g, 15.0 mmol, 1eq) in 
dry pyridine (20 mL) (0.2 mL) was cooled to 0 °C in an ice bath. To this solution was added 
dropwise a solution of 2-nitrobenzenesulfonyl chloride (99) (3.37 g, 15.2 mmol, 1.1eq) in dry 
pyridine (20 mL) over 20 minutes. The reaction mixture was stirred at 0 °C for an additional 
hour after which the ice bath was removed, and the reaction mix left to stir for an additional 
4 hours. After this time, the reaction mix was quenched with the addition of water (40 mL) 
and the mixture extracted with DCM (2 x 20 mL). The organic layers were combined, washed 
with 0.2 M HCl (3 x 10 mL), dried over sodium sulphate and concentrated under reduced 
pressure. The resulting solids were then dissolved in the minimum amount of CHCl3 and 
methanol added to promote crystallisation. The crystals were collected via filtration and 
washed with cold methanol (30 mL) to give N-(benzyloxy)benzenesulfonamide (89) (2.26 g, 
7.4 mmol, 49%) as colourless crystals. X-Ray grade crystals were generated at the interface of 
a mixture of 1:1:1 CHCl3, MeOH and H2O. 
 
Mp = 151-152 °C. 1H NMR (300 MHz, Chloroform-d) δ 8.32 – 8.19 (m, 1H), 8.12 (s, 1H6), 7.95 – 
7.85 (m, 1H), 7.84 – 7.72 (m, 2H), 7.42 – 7.32 (m, 3H1-3), 5.07 (s, 2H5). 13C NMR (75 MHz, 
Chloroform-d) δ 148.6, 134.9, 134.8, 133.8, 133.0, 130.5, 129.6, 129.0, 128.8, 125.7, 80.0. 
HRMS (pNSI) calcd for C13H13N2O5S [M+H]+: 309.0540, found 309.0543. 
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benzyl (R)-5-((N-(benzyloxy)-2-nitrophenyl)sulfonamido)-2-((tert-butoxycarbonyl)amino)pentanoate 
(88) 
 
To a 50 mL round bottomed flask under an atmosphere of nitrogen was added benzyl (R)-2-
((tert-butoxycarbonyl)amino)-5-hydroxypentanoate (90) (0.225 g, 0.700 mmol, 1 eq), 
triphenylphosphine (89) (0.193 g, 0.735 mmol, 1.05 eq) and N-(benzyloxy)-2-
nitrobenzenesulfonamide (0.223 g, 0.735 mmol, 1.05 eq). The solids were then dissolved in 
dry THF (7 mL) and the reaction mixture cooled to 0 °C. To the reaction mix was added DEAD 
(0.120 mL, 0.756 mmol, 1.08 eq) dropwise over 30 minutes. After this time the reaction mix 
was allowed to warm to room temperature, stirred for one hour and then quenched with the 
addition of saturated ammonium chloride (15 mL). The resulting mixture was then extracted 
with ethyl acetate (3 x 5 mL) and the combined organic layers were washed with saturated 
ammonium chloride (30 mL), brine (20 mL) dried over sodium sulphate, filtered and 
concentrated under reduced pressure to give a colourless oil. The crude mixture was then 
purified via column chromatography (ethyl acetate/petrol 40-60, 1:2) Rf: 0.38 to give benzyl 
(R)-5-((N-(benzyloxy)-2-nitrophenyl)sulfonamido)-2-((tert-butoxycarbonyl)amino)pentanoate 
(88) (0.380 g, 0.619 mmol, 88%) as a colourless oil. 
 
[α]D = +21.2° 1H NMR (400 MHz, Chloroform-d) δ 7.99 (dd, J = 8.0, 1.4 Hz, 1H), 7.74 (td, J = 7.7, 
1.5 Hz, 1H), 7.63 (td, J = 7.8, 1.3 Hz, 1H), 7.53 (dd, J = 7.9, 1.3 Hz, 1H), 7.42 – 7.28 (m, 10H9-11 + 
17-19), 5.15 (s, 2H7), 5.06 – 4.97 (m, 3H15+4), 4.29 (q, J = 7.2 Hz, 1H5), 3.07 (br-s, 2H14), 1.99 – 
1.76 (m, 1H12), 1.71 – 1.57 (m, 1H12), 1.56 – 1.46 (m, 2H13), 1.43 (s, 9H1). 13C NMR (101 MHz, 
Chloroform-d) δ 172.1, 155.3, 149.7, 135.3, 134.9, 134.7, 132.6, 131.0, 130.0, 129.1, 128.7, 
128.7, 128.5, 128.3, 125.9, 123.7, 80.3, 80.0, 67.2, 53.2, 52.9, 29.9, 28.3, 22.8. IR (neat): 
υmax/cm-1 3373.8 (OH), 1737.7 (C=O ester), 1693.4 (C=O amide). HRMS (pNSI) calcd for 
C30H36N3O9S [M+H]+: 614.2167, found 614.2167   
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benzyl (R)-5-((benzyloxy)amino)-2-((tert-butoxycarbonyl)amino)pentanoate (100) 
 
 
To a 50 mL schlenk flask under an atmosphere of nitrogen was added benzyl (R)-5-((N-
(benzyloxy)-2-nitrophenyl)sulfonamido)-2-((tert-butoxycarbonyl)amino)pentanoate (88) 
(0.220 g, 0.358 mmol, 1 eq), K2CO3 (0.054 g, 0.387 mmol, 1.08 eq) and DMF (2 mL). The 
reaction was stirred for 5 minutes and then thiophenol (45 µL, 1.437 mmol, 1.22 eq) was 
added via syringe. The reaction mix was then stirred for an additional 50 minutes, after which 
time the reaction was quenched with saturated ammonium chloride (10 mL). The reaction 
mixture was then extracted with EtOAc (3 x 5 mL) and the combined organic layers were 
washed with saturated ammonium chloride (30 mL), brine (20 mL) dried over sodium 
sulphate, filtered and concentrated under reduced pressure to give a colourless oil. The crude 
mixture was then purified via column chromatography (ethyl acetate/ petrol 40-60, 1:2 Rf = 
0.2) to give benzyl (R)-5-((benzyloxy)amino)-2-((tert-butoxycarbonyl)amino)pentanoate (100) 
(0.135 g, 0.315 mmol, 88%) as a colourless oil.  
 
1H NMR (300 MHz, Chloroform-d) δ 7.79 – 7.19 (m, 10H9-11+18-20), 5.36 – 5.06 (m, 3H7+4), 4.67 
(s, 2H16), 4.35 (q, J = 7.3 Hz, 1H5), 2.90 (t, J = 6.8 Hz, 2H14), 2.01 – 1.80 (m, 1H12a), 1.77 – 1.63 
(m, 1H12b), 1.59 – 1.49 (m, 2H13), 1.44 (s, 9H1). 13C NMR (75 MHz, Chloroform-d) δ 172.76, 
155.53, 138.0, 135.5, 128.7, 128.5, 128.5, 128.4, 127.9, 79.92, 76.416, 67.17, 53.55, 51.514, 
30.412, 28.41, 23.313.  
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Benzyl (R)-5-(N-(benzyloxy)formamido)-2-((tert-butoxycarbonyl)amino)pentanoate (101) 
 
 
 
A mixed anhydride solution was prepared by mixing of acetic anhydride (41 μL, 0.44 mmol, 
2eq) and formic acid (33 μL, 0.88 mmol, 4eq) for one hour. After this time the mixture was 
poured into a solution of benzyl (R)-5-((benzyloxy)amino)-2-((tert-butoxycarbonyl) 
amino)pentanoate (100) (93 mg, 0.22 mmol) in dry DCM (1 mL). The reaction mix was then 
left to stir at room temperature for 1.5 hours after which time the mixture was diluted with 
DCM (10 mL) and washed with saturated NaHCO3 (20 mL), dried over sodium sulphate and 
concentrated under reduced pressure to give benzyl (R)-5-(N-(benzyloxy)formamido)-2-((tert-
butoxycarbonyl)amino)pentanoate (101) (97 mg, 0.21 mmol, 95%) as a colourless oil.  
 
1H NMR (300 MHz, Chloroform-d) δ 8.16 (s, 1H), 7.48 – 7.22 (m, 17H), 5.19 – 5.02 (m, 5H), 4.78 
(s, 2H), 4.47 – 4.24 (m, 1H), 3.55 (s, 2H), 1.83 (d, J = 10.5 Hz, 2H), 1.65 (d, J = 7.8 Hz, 4H), 1.42 
(s, 12H). 13C NMR (75 MHz, Chloroform-d) δ 172.3, 163.2, 155.4, 135.3, 134.3, 129.5, 129.1, 
128.8, 128.6, 128.5, 128.3, 78.0, 77.7, 67.1, 53.2, 43.6, 29.9, 28.3, 23.0. HRMS (pNSI) calcd for 
C25H33N2O6 [M+H]+: 457.2333, observed 457.2331. 
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(R)-1-(benzyloxy)-5-(N-(benzyloxy)formamido)-1-oxopentan-2-aminium trifluoroacetate (84) 
 
 
 
To a 5 mL Schlenk flask under an atmosphere of nitrogen at room temperature containing 
benzyl (R)-5-(N-(benzyloxy)formamido)-2-((tert-butoxycarbonyl)amino)pentanoate (101) (50 
mg, 0.110 mmol) was added dry DCM (0.2 mL) followed by TFA (0.2 mL). The reaction mix was 
stirred at room temperature for 2 hours after which time the reaction mix was concentrated 
under reduced pressure to yield (R)-1-(benzyloxy)-5-(N-(benzyloxy)formamido)-1-oxopentan-
2-aminium trifluoroacetate (84) (51 mg) as a pale pink solid which was used without further 
purification.  
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Benzyl (R)-2-((R)-5-(((benzyloxy)carbonyl)amino)-2-(2,3-bis(benzyloxy)benzamido)pentanamido)-5-
(N-(benzyloxy)formamido)pentanoate (103) 
 
 
 
To a stirred solution of (R)-5-(((benzyloxy)carbonyl)amino)-2-(2,3-bis(benzyloxy)benzamido) 
pentanoic acid (83) (64 mg, 0.11 mmol, 1 eq) under an atmosphere of nitrogen in DMF (0.2 
mL) was added HATU (36 mg, 0.12 mmol, 1.1 eq) and the mixture left to stir for 10 minutes. 
To this mixture was added (R)-1-(benzyloxy)-5-(N-(benzyloxy)formamido)-1-oxopentan-2-
aminium trifluoroacetate (84) (51 mg, 0.11 mmol, 1.0 eq) and the reaction mix stirred for an 
additional 20 minutes. After this time DIPEA (77 μL, 0.44 mmol, 4.0 eq) was added and the 
mixture stirred at room temperature for 2.5 h. After this time the mixture was diluted with 
saturated ammonium chloride (4 mL) and water (2 mL) and the resulting slurry extracted with 
EtOAc (3 x 10 mL). The combined organic layers were then washed with saturated ammonium 
chloride (40 mL), brine (40 mL) dried over sodium sulphate, filtered and evaporated under 
reduced pressure. The crude mixture was then subjected to silica gel column chromatography 
(chloroform/acetone/methanol 50:10:1, Rf = 0.68) to give benzyl (R)-2-((R)-5-
(((benzyloxy)carbonyl)amino)-2-(2,3-bis(benzyloxy)benzamido)pentanamido)-5-(N-
(benzyloxy)formamido)pentanoate (103) (64 mg, 0.069 mmol, 63 %) as a colourless solid. It is 
noted that many of the 13C signals are duplicated leading to a higher than expected number 
of signals. 
 
1H NMR (700 MHz, DMSO-d6) δ 8.54 (dd, J = 44.9, 7.5 Hz, 1H), 8.47 (dd, J = 20.1, 8.1 Hz, 1H), 
7.54 – 7.46 (m, 2H), 7.45 – 7.11 (m, 24H), δ 5.23 – 5.19 (m, 2H), 5.15 – 5.05 (m, 3H), 4.97 (d, J 
= 7.0 Hz, 3H), 4.88 – 4.83 (m, 2H), 4.64 – 4.49 (m, 1H), 4.40 – 4.25 (m, 1H), 3.59 – 3.41 (m, 2H), 
2.99 – 2.76 (m, 2H), 1.78 – 1.68 (m, 1H), 1.67 – 1.53 (m, 4H), 1.51 – 1.31 (m, 3H). 13C NMR (176 
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MHz, DMSO-d6) δ 171.7, 171.6, 171.5, 171.5, 164.6, 164.3, 162.6, 156.1, 156.1, 151.6, 151.6, 
145.6, 145.5, 137.2, 137.2, 136.7, 136.6, 136.6, 136.4, 135.8, 135.8, 134.7, 129.6, 129.2, 129.1, 
128.7, 128.6, 128.5, 128.4, 128.3, 128.3, 128.1, 128.0, 128.0, 128.0, 127.8, 127.7, 127.7, 124.2, 
121.6, 121.5, 116.6, 116.5, 79.2, 79.0, 76.6, 75.1, 75.1, 70.3, 70.3, 66.0, 66.0, 65.1, 52.2, 51.7, 
42.4, 30.3, 29.9, 28.1, 25.8, 23.0, 22.8 (pNSI) calcd for C54H56N4O10 [M+H]+: 921.4069, found 
921.4074. 
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Syn.30616/A  (79) 
 
 
 
To a stirred solution of benzyl (R)-2-((R)-5-(((benzyloxy)carbonyl)amino)-2-(2,3-
bis(benzyloxy)benzamido)pentanamido)-5-(N-(benzyloxy)formamido)pentanoate (103) (12 
mg, 0.011 mmol) in THF (0.2 mL) was added 10% Pd/C (5 mg) and the resulting suspension 
stirred vigorously under an atmosphere of hydrogen gas for 2 hours. After this time, the 
catalyst was removed via filtration through a SPE C8 cartridge and the solids washed with 
methanol (2 mL). The filtrate was then concentrated under reduced pressure to give 
approximately 3 mg of crude material. This was then subjected to HPLC chromatography and 
a peak at 32.9 minutes was collected as it matched that of the natural product DME30616/A 
(33.3 minutes) (Injection vol 100 μL, 1.25 mL/min, MeCN:H2O 95%:5%, to 85%:15% over 50 
min, to 0%:100% over 10 min, C18, column diameter = 4.6 mm, column length 100 mm, 
scanning at 254 nm) to give 1 mg of purified syn.DEM30616/A (79) as a pale brown solid.  
1H NMR (700 MHz, Deuterium Oxide) δ 8.24 (s, 0.5H), 7.90 (s, 0.7H), 7.34 – 7.29 (m, 1H), 7.08 
(d, J = 7.7 Hz, 1H), 6.83 (d, J = 7.7 Hz, 1H), 4.62 (dd, J = 7.9, 6.2 Hz, 1H), 4.23 (q, J = 7.3 Hz, 1H), 
3.62 – 3.49 (m, 2H), 3.06 (t, J = 7.6 Hz, 2H), 2.06 – 1.97 (m, 1H), 1.97 – 1.90 (m, 1H), 1.87 – 1.79 
(m, 3H), 1.76 – 1.63 (m, 3H). 
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1H NMR of DEM31376/A (madurastatin C1)  
D6-DMSO, 298K, 700 MHz 
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13C NMR of DEM31376/A (madurastatin C1)  
D6-DMSO, 298K, 176 MHz 
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COSY NMR of DEM31376/A (madurastatin C1)  
D6-DMSO, 298K, 700 MHz 
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HSQC NMR of DEM31376/A (madurastatin C1)  
D6-DMSO, 298K, 700 MHz 
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HMBC_10Hz NMR of DEM31376/A (madurastatin C1)  
D6-DMSO, 298K, 700 MHz 
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NH long range correlation 3Hz, NMR of DEM31376/A (madurastatin C1)  
D6-DMSO, 298K, 700 MHz, N = 236 
 
173 
 
1H NMR of DEM30616/A   
D2O, 298K, 700 MHz 
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13C NMR of DEM30616/A   
D2O, 298K, 176 MHz 
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COSY NMR of DEM30616/A   
D2O, 298K, 700 MHz 
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HSQC NMR of DEM30616/A   
D2O, 298K, 700 MHz 
 
  
 
177 
 
HMBC NMR of DEM30616/A   
D2O, 298K, 700 MHz 
 
  
 
178 
 
NH long range correlation 8Hz, NMR of DEM30616/A  
D2O, 298K, 700 MHz, N = 236 
 
  
 
179 
 
HPLC chromatogram of crude syn.30626/A. HPLC 1260 Infinity II. Injection volume 100 µL, Flow rate 1.25 mL/min, 
Solvent A: MeCN, Solvent B: H2O. Time 0-50 minutes, 95% A:5% B to 85% A: 15% B. Time  50-60 minutes 85% A: 
15% B to 0% A: to 100% B. DAD at 254 nM. Column conditions Eclipse Plus C18, 3.5 µM, column length 4.6 x 100 
mm, 40°C.  
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HPLC chromatogram of Isolated syn.30616/A. HPLC 1260 Infinity II. Injection volume 100 µL, Flow rate 0.5 
mL/min, Solvent A: MeCN, Solvent B: H2O. Time 0-15 minutes, 100% A:0% B to 0% A: 100% B. Time  15-20 minutes 
0% A: 100% B. DAD at 254 nM. Column conditions Eclipse Plus C18, 3.5 µM, column length 4.6 x 100 mm, 40°C. 
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HPLC chromatogram of Isolated DEM30616/A. HPLC 1260 Infinity II. Injection volume 100 µL, Flow rate 0.5 
mL/min, Solvent A: MeCN, Solvent B: H2O. Time 0-15 minutes, 100% A:0% B to 0% A: 100% B. Time  15-20 minutes 
0% A: 100% B. DAD at 254 nM. Column conditions Eclipse Plus C18, 3.5 µM, column length 4.6 x 100 mm, 40°C. 
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1H NMR of DEM30616/A   
D2O, 298K, 700 MHz 
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13C NMR of DEM30616/A   
D2O, 298K, 176 MHz 
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COSY NMR of DEM30616/A   
D2O, 298K, 700 MHz 
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HSQC NMR of DEM30616/A   
D2O, 298K, 700 MHz 
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HMBC NMR of DEM30616/A   
D2O, 298K, 700 MHz 
 
  
 
187 
 
NH long range correlation 8Hz, NMR of DEM31376/A (madurastatin C1)  
D2O, 298K, 700 MHz, N = 236 
 
  
 
188 
 
Methyl (S)-2-(2-(benzyloxy)phenyl)-4,5-dihydrooxazole-4-carboxylate (32) 
 
Table 1. Crystal data and structure refinement for mjh150026. 
Identification code mjh150026 
Empirical formula C18H17NO4 
Formula weight 311.32 
Temperature/K 150.0(2) 
Crystal system orthorhombic 
Space group P212121 
a/Å 7.10991(7) 
b/Å 9.99847(11) 
c/Å 21.2273(2) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 1509.01(3) 
Z 4 
ρcalcg/cm3 1.370 
μ/mm-1 0.800 
F(000) 656.0 
Crystal size/mm3 0.4 × 0.34 × 0.18 
Radiation CuKα (λ = 1.54184) 
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2Θ range for data collection/° 9.778 to 133.674 
Index ranges -5 ≤ h ≤ 8, -11 ≤ k ≤ 11, -25 ≤ l ≤ 25 
Reflections collected 9614 
Independent reflections 2672 [Rint = 0.0249, Rsigma = 0.0205] 
Data/restraints/parameters 2672/0/209 
Goodness-of-fit on F2 1.085 
Final R indexes [I>=2σ (I)] R1 = 0.0270, wR2 = 0.0680 
Final R indexes [all data] R1 = 0.0277, wR2 = 0.0684 
Largest diff. peak/hole / e Å-3 0.17/-0.23 
Flack parameter -0.06(7) 
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Methyl (2-(benzyloxy)benzoyl)-L-serinate (41) 
 
Table 1. Crystal data and structure refinement for mjh150018. 
Identification code mjh150018 
Empirical formula C18H19NO5 
Formula weight 329.34 
Temperature/K 150.0(2) 
Crystal system orthorhombic 
Space group P212121 
a/Å 8.31571(8) 
b/Å 12.57373(12) 
c/Å 15.66923(15) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 1638.37(3) 
Z 4 
ρcalcg/cm3 1.335 
μ/mm-1 0.811 
F(000) 696.0 
Crystal size/mm3 0.43 × 0.25 × 0.22 
Radiation CuKα (λ = 1.54184) 
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2Θ range for data collection/° 9.018 to 134.53 
Index ranges -9 ≤ h ≤ 7, -15 ≤ k ≤ 14, -18 ≤ l ≤ 18 
Reflections collected 11667 
Independent reflections 2898 [Rint = 0.0234, Rsigma = 0.0177] 
Data/restraints/parameters 2898/0/224 
Goodness-of-fit on F2 1.113 
Final R indexes [I>=2σ (I)] R1 = 0.0273, wR2 = 0.0676 
Final R indexes [all data] R1 = 0.0285, wR2 = 0.0688 
Largest diff. peak/hole / e Å-3 0.14/-0.23 
Flack parameter 0.00(6) 
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Methyl (R)-2-(2-(benzyloxy)benzamido)-3-chloropropanoate(44) 
 
Table 1 : Crystal data and structure refinement for mjh150038. 
Identification code mjh150038 
Empirical formula C18H18ClNO4 
Formula weight 347.78 
Temperature/K 150.0(2) 
Crystal system orthorhombic 
Space group P212121 
a/Å 6.34313(11) 
b/Å 11.79295(19) 
c/Å 22.2052(4) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 1661.04(5) 
Z 4 
ρcalcg/cm3 1.391 
μ/mm-1 2.230 
F(000) 728.0 
Crystal size/mm3 0.38 × 0.1 × 0.07 
Radiation CuKα (λ = 1.54184) 
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2Θ range for data collection/° 7.964 to 133.896 
Index ranges -7 ≤ h ≤ 7, -14 ≤ k ≤ 13, -26 ≤ l ≤ 25 
Reflections collected 11687 
Independent reflections 2954 [Rint = 0.0488, Rsigma = 0.0391] 
Data/restraints/parameters 2954/0/221 
Goodness-of-fit on F2 1.060 
Final R indexes [I>=2σ (I)] R1 = 0.0321, wR2 = 0.0750 
Final R indexes [all data] R1 = 0.0381, wR2 = 0.0792 
Largest diff. peak/hole / e Å-3 0.18/-0.23 
Flack parameter -0.004(10) 
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Methyl (S)-1-tritylaziridine-2-carboxylate (47) 
 
Table 1. Crystal data and structure refinement for mjh150004. 
Identification code mjh150004 
Empirical formula C23H21NO2 
Formula weight 343.41 
Temperature/K 150.0(2) 
Crystal system orthorhombic 
Space group P212121 
a/Å 9.85701(14) 
b/Å 10.71346(15) 
c/Å 17.4921(2) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 1847.21(4) 
Z 4 
ρcalcg/cm3 1.235 
μ/mm-1 0.620 
F(000) 728.0 
Crystal size/mm3 0.26 × 0.14 × 0.08 
Radiation CuKα (λ = 1.54184) 
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2Θ range for data collection/° 9.68 to 133.976 
Index ranges -11 ≤ h ≤ 11, -12 ≤ k ≤ 11, -20 ≤ l ≤ 20 
Reflections collected 13238 
Independent reflections 3270 [Rint = 0.0302, Rsigma = 0.0223] 
Data/restraints/parameters 3270/0/236 
Goodness-of-fit on F2 1.061 
Final R indexes [I>=2σ (I)] R1 = 0.0288, wR2 = 0.0684 
Final R indexes [all data] R1 = 0.0318, wR2 = 0.0705 
Largest diff. peak/hole / e Å-3 0.10/-0.17 
Flack parameter 0.06(11) 
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 (S,Z)-N-(4-(((benzyloxy)carbonyl)amino)-4-carboxybutyl)-1-phenylmethanimine oxide (51) 
 
Table 1. Crystal data and structure refinement for mjh180049. 
Identification code mjh180049 
Empirical formula C20H22N2O5 
Formula weight 370.39 
Temperature/K 150.0(2) 
Crystal system monoclinic 
Space group P21 
a/Å 14.4192(5) 
b/Å 5.18265(16) 
c/Å 15.1106(5) 
α/° 90 
β/° 116.713(5) 
γ/° 90 
Volume/Å3 1008.69(7) 
Z 2 
ρcalcg/cm3 1.220 
μ/mm-1 0.729 
F(000) 392.0 
Crystal size/mm3 0.48 × 0.07 × 0.05 
Radiation CuKα (λ = 1.54184) 
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2Θ range for data collection/° 11.43 to 133.844 
Index ranges -16 ≤ h ≤ 17, -5 ≤ k ≤ 6, -17 ≤ l ≤ 14 
Reflections collected 13813 
Independent reflections 3466 [Rint = 0.0335, Rsigma = 0.0278] 
Data/restraints/parameters 3466/2/250 
Goodness-of-fit on F2 1.061 
Final R indexes [I>=2σ (I)] R1 = 0.0307, wR2 = 0.0776 
Final R indexes [all data] R1 = 0.0339, wR2 = 0.0797 
Largest diff. peak/hole / e Å-3 0.12/-0.14 
Flack parameter -0.05(10) 
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Benzyl (S)-(1-(benzyloxy)-2-oxopiperidin-3-yl)carbamate (55) 
 
Table 1. Crystal data and structure refinement for mjh150031_fa. 
Identification code mjh150031_fa 
Empirical formula C20H22N2O4 
Formula weight 354.39 
Temperature/K 150.0(2) 
Crystal system monoclinic 
Space group P21 
a/Å 5.8565(2) 
b/Å 4.74886(17) 
c/Å 32.8637(12) 
α/° 90 
β/° 90.461(3) 
γ/° 90 
Volume/Å3 913.96(6) 
Z 2 
ρcalcg/cm3 1.288 
μ/mm-1 0.738 
F(000) 376.0 
Crystal size/mm3 0.19 × 0.13 × 0.04 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 5.378 to 135.358 
Index ranges -6 ≤ h ≤ 6, -5 ≤ k ≤ 5, -39 ≤ l ≤ 38 
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Reflections collected 11002 
Independent reflections 3239 [Rint = 0.0323, Rsigma = 0.0297] 
Data/restraints/parameters 3239/92/305 
Goodness-of-fit on F2 1.087 
Final R indexes [I>=2σ (I)] R1 = 0.0328, wR2 = 0.0730 
Final R indexes [all data] R1 = 0.0379, wR2 = 0.0759 
Largest diff. peak/hole / e Å-3 0.12/-0.13 
Flack parameter 0.35(12) 
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Methyl (2-(benzyloxy)benzoyl)-D-serinate (56) 
 
Table 1. Crystal data and structure refinement for mjh170005_fa. 
Identification code mjh170005_fa 
Empirical formula C18H19NO5 
Formula weight 329.34 
Temperature/K 150.0(2) 
Crystal system orthorhombic 
Space group P212121 
a/Å 8.31712(6) 
b/Å 12.57172(10) 
c/Å 15.66621(14) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 1638.07(2) 
Z 4 
ρcalcg/cm3 1.335 
μ/mm-1 0.812 
F(000) 696.0 
Crystal size/mm3 0.28 × 0.16 × 0.13 
Radiation CuKα (λ = 1.54184) 
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2Θ range for data collection/° 9.02 to 133.508 
Index ranges -8 ≤ h ≤ 9, -14 ≤ k ≤ 15, -18 ≤ l ≤ 18 
Reflections collected 14353 
Independent reflections 2889 [Rint = 0.0228, Rsigma = 0.0159] 
Data/restraints/parameters 2889/0/225 
Goodness-of-fit on F2 1.077 
Final R indexes [I>=2σ (I)] R1 = 0.0233, wR2 = 0.0581 
Final R indexes [all data] R1 = 0.0241, wR2 = 0.0588 
Largest diff. peak/hole / e Å-3 0.14/-0.13 
Flack parameter 0.08(5) 
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(S)-1-(benzyloxy)-2-oxopiperidin-3-aminium bromide (71) 
 
Table 1. Crystal data and structure refinement for mjh180048. 
Identification code mjh180048 
Empirical formula C12H19BrN2O3 
Formula weight 319.20 
Temperature/K 150.0(2) 
Crystal system orthorhombic 
Space group P212121 
a/Å 6.27186(7) 
b/Å 13.02097(16) 
c/Å 16.9228(2) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 1382.02(3) 
Z 4 
ρcalcg/cm3 1.534 
μ/mm-1 4.095 
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F(000) 656.0 
Crystal size/mm3 0.39 × 0.1 × 0.05 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.568 to 133.83 
Index ranges -7 ≤ h ≤ 7, -15 ≤ k ≤ 15, -19 ≤ l ≤ 20 
Reflections collected 19643 
Independent reflections 2461 [Rint = 0.0385, Rsigma = 0.0192] 
Data/restraints/parameters 2461/0/178 
Goodness-of-fit on F2 1.045 
Final R indexes [I>=2σ (I)] R1 = 0.0172, wR2 = 0.0422 
Final R indexes [all data] R1 = 0.0183, wR2 = 0.0430 
Largest diff. peak/hole / e Å-3 0.17/-0.22 
Flack parameter -0.030(9) 
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(R)-2-(benzyloxy)-N-(4,7,11-trioxo-1-oxa-5,8-diazacycloundecan-3-yl)benzamide (75) 
 
Table 1. Crystal data and structure refinement for mjh180034_2_fa. 
Identification code mjh180034_2_fa 
Empirical formula C22H23N3O6 
Formula weight 425.43 
Temperature/K 150.0(2) 
Crystal system monoclinic 
Space group P21 
a/Å 9.3116(7) 
b/Å 18.9840(13) 
c/Å 11.8019(9) 
α/° 90 
β/° 94.865(8) 
γ/° 90 
Volume/Å3 2078.7(3) 
Z 4 
ρcalcg/cm3 1.359 
μ/mm-1 0.834 
F(000) 896.0 
Crystal size/mm3 0.09 × 0.08 × 0.02 
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Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 7.518 to 133.862 
Index ranges -8 ≤ h ≤ 11, -22 ≤ k ≤ 21, -14 ≤ l ≤ 14 
Reflections collected 14785 
Independent reflections 6517 [Rint = 0.0748, Rsigma = 0.0943] 
Data/restraints/parameters 6517/16/577 
Goodness-of-fit on F2 1.014 
Final R indexes [I>=2σ (I)] R1 = 0.0607, wR2 = 0.1271 
Final R indexes [all data] R1 = 0.0954, wR2 = 0.1488 
Largest diff. peak/hole / e Å-3 0.24/-0.22 
Flack parameter -0.1(3) 
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N-(benzyloxy)-2-nitrobenzenesulfonamide (89) 
 
Table 1. Crystal data and structure refinement for mjh170033. 
Identification code mjh170033 
Empirical formula C13H12N2O5S 
Formula weight 308.31 
Temperature/K 150.0(2) 
Crystal system monoclinic 
Space group P21/n 
a/Å 13.35590(9) 
b/Å 7.85194(5) 
c/Å 13.94732(12) 
α/° 90 
β/° 104.5616(7) 
γ/° 90 
Volume/Å3 1415.668(18) 
Z 4 
ρcalcg/cm3 1.447 
μ/mm-1 2.264 
F(000) 640.0 
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Crystal size/mm3 0.33 × 0.18 × 0.15 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.194 to 133.866 
Index ranges -15 ≤ h ≤ 15, -9 ≤ k ≤ 9, -15 ≤ l ≤ 16 
Reflections collected 51635 
Independent reflections 2507 [Rint = 0.0272, Rsigma = 0.0079] 
Data/restraints/parameters 2507/0/194 
Goodness-of-fit on F2 1.047 
Final R indexes [I>=2σ (I)] R1 = 0.0254, wR2 = 0.0647 
Final R indexes [all data] R1 = 0.0265, wR2 = 0.0655 
Largest diff. peak/hole / e Å-3 0.28/-0.29 
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